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1.1. ATHEROSCLEROSIS DISEASE 
Atherosclerosis is a slow and progressive disease that belongs to arteriosclerosis diseases which 
consist of hardening of large and medium-size arteries [1]. Atherosclerosis is a degenerative 
disease that may start in childhood and is characterized by thickening of the inner lining of the 
arterial wall, caused by deposits of fatty material in the subendothelial space (intima) at regions 
of disturbed blood flow. It is usually triggered by an interplay between endothelial dysfunction 
and subendothelial lipoprotein retention [2], that eventually forms an atheromatous plaque 
composed of infiltrating inflammatory cells (e.g. monocytes/macrophages, T cells and dendritic 
cells), smooth muscle cells (SMCs), endothelial cells (ECs) and lipids [3]. This plaque gradually 
narrows the arteries and reduces the blood flow to the tissues, resulting in pain or limited 
function of the arteries. As well, rupture of the plaque can suddenly occur and produce distal 
thrombus propagation, and hence, vessel occlusion causing an ischemic event [4]. 
 Atherosclerosis can affect arteries anywhere in the body, however, it often develops in 
blood vessels supplying heart, brain, pelvis, legs, arms and kidneys [1]. Thus, atherosclerotic 
vascular disease can be the underlying cause of myocardial infarction (coronary heart disease), 
stroke (carotid artery disease), peripheral artery disease (legs and arms) and chronic kidney 
disease [1,3], which together are responsible for approximately half of the deaths in developed 
nations [4]. 
1.1.1. Epidemiology 
Cardiovascular diseases (CV) are one of the most important causes of disability and premature 
death worldwide. One of the underlying causes of CVs is atherosclerosis, which is considered as 
chronic progressive disease that clinically appears at middle age [5] as ischemic heart disease, 
cerebrovascular disease or peripheral arterial disease [6]. Cerebrovascular disease remains a 
leading cause of death from the 1990s. In 2016, the World Health Organization estimated that 
cerebrovascular disease (i.e. stroke) accounted for 6.7 million deaths worldwide [7]. There are 
two types of stroke, hemorrhagic ones which account for about 13% of stroke cases and 
ischemic strokes covering the remaining 87%. Approximately 20% to 30% of ischemic strokes 
are caused by a carotid atherosclerotic plaque [8–10]. In fact, the most common extra-cranial 
cause of ischemic stroke is the thromboembolism from unstable atherosclerotic plaque in the 
carotid bifurcation [11]. Thereby, stroke is one of the main cerebrovascular events related to 
atheroma plaques [12]. Patients with cerebrovascular symptoms of carotid origin are at high risk 
of a subsequent imminent life-threatening stroke [13]. The population at risk for atherosclerosis 
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is extremely large, and it continues to grow in response to the epidemic of obesity and metabolic 
disease [2]. 
1.1.2.  Carotid atherosclerosis 
Carotid artery wall configuration at bends and bifurcations is associated to and altered by local 
modifications in blood flow pattern and velocity [14]. Blood flow generates a physical force on 
the vessel wall that can be divided into wall shear stress and wall tensile stress (Figure 1). Shear 
stress is the stress exerted parallel to vessel wall producing frictional force on the endothelial 
surface, whereas tensile stress is defined as the stress produced by forces perpendicular to the 
vessel wall causing dilatation force by blood flow over the vessel wall. The absolute shear stress 
has temporal and spatial variations because cardiac cycle is pulsatile, and therefore, endothelium 
is able to discriminate these variations and respond differently through mechanochemical 
transduction pathways [15]. In this way, chronic exposure to high levels of shear stress with 
little temporal oscillations promotes athero-protective mechanisms involving ECs from carotid 
wall [16,17]. In these regions, ECs show ellipsoidal morphology and coaxial alignment in the 
flow direction [2]. 
 
 
Figure 1. Wall stresses in healthy artery vessel. ρ, is tensile stress exerting perpendicular forces to the 
vessel wall. τ, is shear stress and produced forces parallel to the vessel wall. Endothelial cells and smooth 
muscle cells are aligned longitudinally and circumferentially, respectively [4]. 
However, as common carotid flow enters the bifurcation, changes appear in flow direction, and 
thus, laminar flow is localized to the inner wall of the internal carotid artery while the outer wall 
is a zone of stasis and recirculation of blood flow with relatively low wall shear stress (Figure 2) 
[14]. In this region of recirculating flow usually also temporal and spatial gradients of shear 
stress exist [18]. Thus, regions of low flow, flow separation, gradients and reversal flow are 
often grouped under the term ‘disturbed flow’ [19]. 
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Under conditions of flow disturbances ECs fail to align in the direction of flow and display 
cuboidal morphology [2], and also, are associated with high rates of both EC proliferation and 
apoptosis as well as higher permeability to solutes, increased production of reactive oxygen 
species (ROS) and extracellular matrix (ECM) proteins, in addition to increased expression of 
inflammatory mediators such as cytokines and chemokines [2,20,21]. These atherogenic flow 
patterns, in consequence, impair endothelial barrier formation, initiating a local proatherogenic 
environment [2]. 
 
Figure 2. Blood flow pattern in human carotid bifurcation. Early lesions of atherosclerosis develop in 
carotid sinus where artery wall is exposed to low shear stress, high oscillatory shear index, and temporal 
and spatial gradients. Endothelial cells at this site (in orange) display an athero-prone phenotype, which 
promotes a proinflammatory milieu. Blood-borne monocytes (in blue) enter into the intima and 
differentiate into macrophages (in red) due to lipoproteins (LP) retained in the endothelium. In contrast, 
atherosclerosis-resistant region maintains an athero-protective endothelium with a decrease in LP 
retention, promoting antiinflammatory and anti-thrombotic environment [2]. 
The mechanisms underlying this process remain unclear [22]. It has suggested that low shear 
stress could interfere with turnover of essential substances at the endothelial surface for optimal 
endothelial metabolic function whereas has also been proposed that a retarded transport of 
circulating particles away from the wall may results in lipids accumulation in the intima [14]. 
More recent studies have suggested that global DNA methylation [23]and mRNA splicing [24] 
happening in the endothelium may also be affected by the athero-prone flow. 
Therefore, atherosclerotic plaques are localized mainly in the outer wall of the bifurcation of the 
carotid artery where laminar flow is absent and stasis is predominant[15]. Furthermore, it is 
suggested that atherosclerosis develops in such static zones which have been noted at the outer 
wall of the carotid sinus in patients with cerebrovascular symptoms [14]. 
1.1.3. Biology of atherosclerotic plaque 
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The arterial wall is composed of three layers. The innermost layer is the intima, is in contact 
with the lumen of the arteries and consist of ECs, fibronectin and type IV collagen. In the media 
are mainly vascular SMCs (SMCs) embedded in collagen (types I, III, V and XVIII), fibronectin 
and proteoglycans, whereas adventitia composes the outer layer of the arterial wall and is rich in 
fibroblasts, collagen (types I and III) and elastin [25]. 
The American Heart Association Committee on Vascular Lesions suggested the following 
international histological atherosclerotic plaque classification system [26]: 
- Type I lesion: it is the initial lesion and consist of isolated foam cells. Sufficient amount 
of lipoprotein can be found here to promote the conversion of macrophages to foam 
cells. Intimal thickening will be present during every stage of atheroma plaque 
development as everyone can develop it from birth as adaptive thickening in order to 
adapt to local mechanical forces. 
- Type II lesion: the main characteristic of this stage is multifocal accumulation of lipid-
laden macrophages and smooth muscle cells. In this lesions begin to appear fatty 
streaks. 
- Type III lesion: it corresponds to the preatheroma stage. In addition to lipid-laden cells 
there are present extracellular lipid droplets and some smooth muscle cells lack their 
characteristic contractile morphology. 
- Type IV lesion: extracellular lipids droplets become in a large and confluent lipid core 
of atheroma. 
- Type V lesion: or fibroatheroma, consist of a lipid core below thick layers of fibrous 
connective tissue. 
- Type VI lesion: it is a complex plaque with possible surface defects as fissure or appear 
hemorrhage and/or thrombus. 
- Type VII lesion: it is a plaque that is predominantly calcified. 
- Type VIII lesion: fibrotic plaque consisting in collagen and smooth muscle cell 
accumulation without lipid core. 
Although the exact mechanism underlying atherosclerosis remains unknown, plaque 
development process has been tried to describe precisely for a better understanding. 
1- Initiation of atheroma plaque formation: 
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Atherosclerosis starts in the endothelium of the intimal layer at the site of artery bifurcations, 
arteries and regions of high curvature that result in complex blood flow patterns [4]. At these 
susceptible sites, the endothelium supports greater hemodynamic stress as compensatory 
response in order to maintain normal homeostatic properties [27]. Thus, when endothelial 
dysfunction occurs, endothelium increases its permeability through expression of adhesion 
receptors such as intracellular adhesion-molecule-1 (ICAM-1) and vascular cell 
adhesionmolecule- 1 (VCAM-1), and chemokines such as monocyte chemoattractant protein-1 
(MCP-1/CCL2) [28]. Therefore, endothelium allows blood low density lipoproteins (LDL) to 
enter and accumulate within the arterial wall reinforcing susceptible sites of rupture [29]. 
However, there may be an excess of LDL accumulation within the intima that is retained by 
proteoglycans and glycosaminoglycans [30] and which will be oxidized (oxLDL) by 
surrounding cells and molecules that are trying to digest it [29]. This oxLDL will act as 
chemotaxis/chemoattractant agent for monocytes, that acquire highly activated inflammatory 
phenotype and produce additional inflammatory mediators [3]. In addition, injured endothelium 
forms vasoactive molecules, cytokines and growth factors, and also modifies its properties 
toward procoagulant rather than anticoagulant processes [27], with the consequent adhesion of 
leukocytes and platelets to the intima and hence, the reaction of the innate inflammatory system 
[31]. 
2- Fatty streaks:  
During atheroma plaque formation complex interactions are taken place between resident 
(arterial wall cells) and attracted cells (mostly immune cells) to the injury as well as between all 
of these cells with platelets and lipoproteins found in the damaged area. At this stage, cells in 
the subendothelial space are involved in the vascular remodeling process [32]. ECs are able to 
bind to and activate antithrombin III due to expression of heparan sulfate in their membranes, 
and thus thrombin (coagulation factor II) remains inactivated. However, when endothelium 
becomes dysfunctional heparan sulfate expression is reduced and hence, thrombin is activated 
with subsequent platelet adhesion to the endothelium. As aforementioned, ECs also express 
specific adhesion receptors for monocytes and T lymphocytes. The latter ones produce 
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), activating monocytes and stimulating 
macrophage proliferation [30]. Monocytes within the intima take up lipids and differentiate first 
into macrophages and then are transformed into specialized cells, called foam cells. These foam 
cells express the main enzymes involved in LDL oxidation, myeloperoxidase and lipoxygenase. 
Additionally, macrophages can take up aggregated LDL by phagocytosis and oxLDL by 
scavenger receptors, both processes regulated independently of intracellular cholesterol levels. 
Thus, LDL will accumulate within the cells [30]. 
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Clearing of the oxLDL excess is carried out by high density lipoprotein (HDL) particles [29] 
that are responsible for cholesterol reverse transport, and thus, oppose the effects of LDL since 
HDL carry lipids away from these cells [4]. 
Platelets are also attracted to the site of the lesion and release molecules such as platelet-derived 
growth factor (PDGF) and endothelial growth factor (EGF) [30] that initiate SMC migration 
from the tunica layer to the intima. Once SMCs reach the intimal layer, they proliferate and 
produce connective tissue accumulation, and hence, develop the intimal hyperplasia and 
consequent thickening of the arterial wall [29]. This newly formed intima layer is called 
neointima. In order to compensate arterial wall thickening, there is a gradual dilation of the 
vessel while the lumen remains unaltered, a phenomenon termed “positive remodeling” (Figure 
3) [27]. These intimal SMCs may also accumulate fat droplets in the cytoplasm such as 
macrophages do and become also foam cells [33,34], and therefore, promote further lesion [31]. 
Thus, foam cell population within atherosclerotic plaques may be originated by SMCs or by 
macrophages. The excess of oxLDL phagocytized by foam cells and extracellular lipids retained 
in the vessel wall produce macroscopic changes called fatty streaks [29]. 
 
Figure 3. Artery remodeling when atherosclerotic plaque is formed [29]. 
3- Early fibroatheroma: 
Fatty streaks can progress to larger, more inflamed lesions called atherosclerotic plaques [4]. At 
this stage of development of the atherosclerotic plaque, foam cells, activated inflammatory cells 
(mainly T lymphocytes) and resident cells of arteries are accumulated within the intima [31] in a 
highly focal way [4]. 
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LDL uptake by macrophages/SMCs and HDL cholesterol reverse transport are the main 
cleaning system for removal of cholesterol excess. Both cleaning systems are ultimately 
exceeded because LDL accumulation is excessive and foam cell ability to accumulate 
cholesterol is limited [30]. Lipid loaded cells are finally induced to enter in apoptosis and 
consequently, multinucleated cells appear in order to phagocytose apoptotic cells in an attempt 
not to worsen the lesion [29]. However, at this point, the inflammation within the plaque 
becomes uncrontollable due to the accumulation of oxLDL, apoptotic cells and immune cells. 
Lipid filled apoptotic cells (mostly foam cells), multinucleated cells, cell debris and 
extracellular lipids pools form the lipid-rich necrotic core, which is encapsulated by a fibrous 
tissue called “fibrous cap”. SMCs secreting collagen, elastic fibers and proteoglycans are 
responsible for producing fibrous cap, which is formed over the lipid-rich necrotic core and 
under the endothelium. Once atheroma plaque has been developed, normal architecture of the 
artery wall is already disrupted [31]. 
4- Advanced atheroma/Complicated lesion: 
OxLDL regulates the production of nuclear factor (NF)-κβ molecule by macrophages that 
activates gene expression of TNF-α, interleukin (IL)-1, -6 and -8, colony-stimulating factors (G-
CSF, M-CSF, GM-CSF), MCP-1/CCL2, the tissue factor, adhesion molecules (ICAM-1, 
VACM-1) and c-myc [30] among others, increasing inflammatory response within the atheroma 
plaque. In this context, ECs are unable to adapt to these events, resulting in sustained activation 
of pathways associated with inflammation, tissue remodeling and increased production of 
reactive oxygen species (ROS) [4]. Vascular SMC-derived ECM exacerbates oxLDL effects 
because facilitates the retention of LDL lipoproteins within subendothelial space, increasing 
their susceptibility to modification toward oxLDL as well as their uptake by intimal cells [35]. 
In advanced atheroma plaques, local O2 diffusion from the arterial lumen may be insufficient 
because of intimal thickening and inflammation. Hypoxia promotes vascular endothelial growth 
factor (VEGF) expression, mainly secreted by phagocytic cells and cholesterol loaded SMCs, 
promoting angiogenesis through EC proliferation and migration within the lesion [36,37]. This 
neoangiogenesis decreases ischemic situation within plaque protecting tissue for hypoxia, 
however, is also a source of leukocyte infiltration and atherogenic lipid entry, resulting in 
plaque worsening [38]. 
Then, new vessels are formed from vasa vasorum within the intima (Figure 4) [30], but due to 
their thin wall and discontinuities in the endothelial lining, they are fragile and are prone to 




Figure 4. Neovascularization in the arterial wall. A. Healthy artery with reduced neovasculartization. 
B. Atherosclerotic artery with extended neovascularization from adventitia to inside intima [36]. 
If the fibrous cap is ruptured because any new formed vessel is broken, there is an activation of 
coagulation factors and platelet that eventually leads to a thrombus formation in the lumen of 
the vessel [29]. Furthermore, lipid-rich necrotic core has important thrombogenic ability due to 
a high tissue factor and plasmin content produced by apoptotic cells [29] and activated by ECs 
[30]. This thrombus that can be formed, will block vascular flow [29]. In consequence, plaque 
continues growing and artery could no longer compensate intimal thickening by dilation [27]. 
Any further plaque enlargement will reduce the arterial lumen and vascular hemodynamic 
(blood flow) may be affected [31]. 
Plaque´s morphology or characteristics can vary substantially among individuals and within any 
given individual [31]. For instance, plaque composition can vary considerable in the size of 
lipid-rich necrotic core, foam cell accumulation or fibrous cap thickness  [4]. The latter is one of 
the most conditioning factors to promote plaque rupture since a thin fibrotic cap is more 
susceptible to rupture than a thicker one [31]. The mechanisms responsible for plaque rupture 
are not known yet. However, the reason why the areas in which fibrous cap is attached to the 
vascular wall are prone to rupture is related with the fact that this region of the plaque contains 
few SMC and is abundant in macrophages and T lymphocytes secreting TNF-α and IL-1β. 
These factors induce increased metalloproteinase expression by SMCs and macrophages [30]. 
To date, the excessive activity of matrix metalloproteinases is one of the most supported 
mechanisms associated to plaque rupture [39–42] due to fibrous cap disruption, which causes 
atheroma plaque destabilization [43], and for that, this lesion usually is classified as vulnerable 
plaque [31]. 
5- Fibrotic plaque: 
30% of the plaques are usually totally fibrotic plaques with thick fibrous cap and low risk to be 
ruptured [29]. This kind of plaques is formed because some ruptures of thin fibrous cap are 
healed by plaque itself forming fibrous tissue over the thrombus. The repeated cycles of rupture 
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and healing result in multiple layers of healed tissue increasing the whole mass of the plaque 
[31]. Fibrotic plaques are more stable plaques because do not tend to rupture [31]; however, 
they also enhance the risk to develop a cerebrovascular event depending on the degree of 
stenosis they cause [29]. Thus, this type of plaque alone may be sufficient to cause ischemic 
stroke simply through flow restriction [31], and if they rupture, given that the thrombus is a 
reservoir of thrombin [30], its release can trigger a new thrombus formation [44]. 
Fibrotic plaques usually become calcified due to calcium deposits accumulation that occurs 
during all stages of atherosclerotic plaque development [29]. They accumulate first in small 
aggregates and then in large nodules [31]. It is believed to be originated from apoptotic cells or 
from released molecules by their matrix vesicles [45]. When plaque is ruptured, calcium 
nodules are released from lipid-rich necrotic core, which are also a source of thrombosis [31]. 
Therefore, any stable plaque can become in an unstable plaque [46]. 
1.1.4.  Unstable vs Stable plaque – Symptomatic vs. Asymptomatic patients 
Carotid artery stenosis is considered severe when lumen stenosis exceeds 70%. Stenosis degree 
is associated with a significant risk of stroke [47]; however, in the general population 0% to 3% 
of carotid atherosclerotic lesions [48]  have >70% of stenosis and remain asymptomatic, while 
only among 1%-3% culminate with stroke [49,50] . Hence, many strokes occur even with 
carotid plaques not displaying high degrees of narrowing [47]. 
The appearance of symptoms depends on multiple characteristics such as severity of the carotid 
stenosis, but also atherosclerotic plaque morphology/composition and the presence of other risk 
factors [51]. Patients with similar characteristics such as hypertension, smoking, diabetes, 
hypercholesterolemia and with carotid stenosis caused by atherosclerotic plaques have been 
found to have different risk of stroke, which has led to suggest that the degree of artery stenosis 
alone would not be the best estimation of stroke risk [52]. 
Asymptomatic plaques have relatively stable features with low risk for rupture and consequent 
event [53]; however, clinical stability does not always indicate biologic stability [54]. In 
advanced atherosclerosis, where is a complex interplay of variables in and outside the plaque 
[54], minor alterations in plaque biology may disrupt the clinically asymptomatic and stable 
condition to unstable and symptomatic disease [55]. Clinically asymptomatic carotid plaques 
frequently progress over time to produce symptoms [56] because a conversion of stable plaques 
to unstable ones may occur [46]. However, not all plaques become symptomatic and some may 
remain asymptomatic for life [57]. 
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Although the mechanism underlying plaque rupture and subsequent symptomatology is largely 
unknown there are some histological characteristics that are widely used to classify plaques as 
stable or unstable. Unstable atherosclerotic plaques are those that are vulnerable to rupture and 
usually contain large lipid pools, infiltration of inflammatory cells (lymphocytes and 
macrophages), hemorrhage and a thin or virtually absent fibrous cap with low vascular SMC 
density [44]. The size of the lipid core has been associated with rupture events by van der Wal 
& Becker [54]. It was estimated that necrotic core occupying more than 30% of the total plaque 
may be a risk factor to produce an ischemic event [44]. Moreover, lipid-rich lesions have shown 
high content of inflammatory cells in the attenuated cap and shoulders of the lesion, and for this 
reason, active plaque inflammation has also been associated with the initiation of plaque rupture 
[54]. Local differences in macrophage and SMC densities have been found along the plaque and 
its distal side. Thus, carotid plaques show large SMC-rich areas in the downstream areas of the 
stenosis which are under low flow. In contrast, in upstream shoulder that is under high flow, 
macrophage-rich areas are predominant (Figure 5) [58]. Furthermore, the upstream area is 
associated with cap rupture, intra-plaque hemorrhage and a thin fibrous cap [59]. Actually, 70% 
of ruptured plaques experience a rupture at the site of the upstream shoulder [54]. 
  
Figure 5. Diagram of carotid atherosclerotic plaque sites [58]. 
Several studies have demonstrated that smaller amounts of collagen and calcium, and more 
neoformed vessels (neovascularization) are also determinants of plaque instability and are 
characteristic of rupture-prone plaques (Figure 5) [52,60,61]. Indeed, asymptomatic patients 
usually show increased prevalence of collagen-rich stable plaques [62], composed of solid 
fibrous or fibrocellular tissue and only small amounts of extracellular lipid [54]. However, 
fissures also appear in fibrotic and calcified plaques that can make them vulnerable to rupture 
[60]. Fissures can vary in depth, but they may be limited to the plaque surface or may reach up 
to the intimal layer and lipid core [54]. When this kind of plaque surface irregularity becomes 
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gross ulceration, an opening accompanied by disintegration of tissue occurs, and subsequently, 
this may trigger hemorrhage as consequence of intimal neovessel leakages (Figure 6) [63,64]. 
 
Figure 6. Fissures are formed from the vessel lumen inside the intima and toward lipid pool. 
Because ulceration implies exposure of highly thrombogenic plaque constituents (lipids, tissue 
factor, collagens) to the blood flow, it can result in activation of the coagulation system and 
hence, thrombus formation [54]. Recent studies suggest that intra-plaque hemorrhage could be a 
trigger of plaque instability because it activates red blood cells and iron phagocytosis [64]. 
Hemorrhage also plays a role in releasing free heme, which is a strong activator of reactive 
oxygen species, and in cholesterol crystal production and retention. Thus, it develops further 
enlargement of necrotic cores [65]. The presence of fresh thrombus exposed to the vessel lumen 
has been correlated with the production of neurological symptoms [66]; in fact, ulceration is 
present in 51% of the transiently symptomatic patients compared to 36% of the asymptomatic 
patients [63]. 
Flow dynamics may also influence plaque stability in a mechanical manner through a physical 
impact that may trigger plaque rupture as well as affect cellular composition of the plaque. Fully 
stable or unstable plaques are the minority and most patients have mixtures in varying 
proportions of characteristics concerning stable/unstable plaque types [54]. This makes it more 
difficult to identify factors determining plaque vulnerability and healing [55]. 
1.1.5.  Risk factors 
It is unknown the exact cause of atherosclerosis, however, there are certain features and habits 
that maybe provoke the development of the disease. These conditions that increase disease 
progression are known as risk factors and include: 
 Physiological characteristics 
- Hyperlipidemia 
It is among the major risk factors for atherosclerosis [4], however, whether serum cholesterol 
levels are related to stroke and carotid arterial disease incidence is not yet established. 
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Lipidemic risk factors include elevated levels of total cholesterol, very low- (VLDL) and LDL, 
triglycerides, and lipoprotein (a) [67]. These are the responsible factors for bringing cholesterol 
to the tissues [68]. When endothelium permeability is increased in athero-prone regions, the 
lipoproteins enter into the vessel wall and will be retained by matrix components involved in 
remodeling if atherosclerosis has started to develop [69]. Additionally, oxidant stress together 
with LDL presence generates oxLDL molecules [68], which act as chronic stimulators of innate 
and adaptive immune response. OxLDL also induce ECs and vascular SMCs to express 
adhesion molecules, chemoattractants and growth factors that interact with receptors on 
monocytes and stimulate their migration and differentiation into macrophages and dendritic 
cells (DCs) [70]. 
On the contrary, elevated levels of HDL and apolipoprotein A1, the major protein component of 
HDL, seem to confer a protective effect. The capacity for cholesterol efflux through HDL is 
inversely correlated with carotid stenosis and plaque instability. For instance, patients with 
fibroatheroma plaques have lower cholesterol efflux than those of calcified or fibrous plaques 
[71]. 
However, an increased blood concentration of apolipoprotein B-containing lipoproteins — of 
which LDL usually is the most prevalent form — can be a sufficient cause of atherosclerosis, 
such as in familial hypercholesterolemia and other genetic hyperlipidemias (monogenic 
diseases) [70]. 
- Hypertension 
High blood pressure leads to the deposition of cholesterol in the arteries [72] and promotes 
oxidative stress[73], which increases the risk of atherosclerotic plaque rupture and consequent 
stroke [72]. For that, hypertension has been identified as a significant risk factor for 
atherosclerotic plaque formation and/or progression [74]. Recent observational studies 
concluded that risk of death caused by ischemic stroke increases progressively and linearly as 
systolic and diastolic blood pressure levels increase from 115 and 75 mmHg, respectively 
[75,76]. Moreover, in patients with known cerebrovascular disease a direct and continuous 
relationship has been found between blood pressure and recurrent strokes (The United 
Kingdom-transient ischemic attack (TIA) trial) [76]. 
- Diabetes 
Both in human and animal models, diabetes leads to broader, more diffuse and complex lesion 
although how this accelerates the disease is largely a mystery [77]. The risk of carotid disease 
and stroke is 4 times higher in diabetics than in people without diabetes [72]. Furthermore, 
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diabetes increases post-stroke mortality [78] and it is known that hyperglycemia extends the 
ischemic penumbra and has an adverse effect on neurologic outcome[79]. 
Diabetic patients usually have high blood pressure, high cholesterol and are more likely to 
develop cholesterol blockages in the artery [72]. Pathologic processes related to diabetes can 
enhance LDL oxidation because increased levels of glucose promote glycosylation and 
accelerate oxidative activities [80]. Thus, increased ROS production and oxidative stress may 
occur in diabetes that accelerate atherosclerosis [81]. 
 Behaviors 
- Smoking 
Smoking is an independent stroke risk factor, increasing the risk of stroke by about two- to 
fourfold [82]. Smoking damages the lining of the blood vessels and makes cholesterol deposits 
more likely to be formed [72], thus, smokers have more lipids in their plaques, particularly 
oxidized lipoproteins, than non-smokers [83]. Being an ex-smoker or current smoker carries 
more than 6-fold risk of atherosclerotic carotid stenosis than in non-smokers [84]. Furthermore, 
the risk for stroke increases proportionally with the number of cigarettes smoked per day [76] 
and there is a dose-response relationship so that heavy smokers are at a higher risk of stroke 
than light smokers [85]. In consequence, stopping smoking is extremely important to keep 
carotid artery blockages from worsening and to prevent stroke [72]. 
- Obesity 
Associated risk factors such as hypertension, diabetes and hyperlipidemia are more prevalent in 
obese individuals than in healthy ones [86]. The risk of ischemic stroke also increases with 
obesity, being about three times higher for obese people than the normal population [87]. In 
addition, Suk’s study [87] suggests that distribution of fat in the body could be associated to the 
risk of stroke, particularly, abdominal fat accumulation in men. Thus, current guidelines 
recommend targeting body mass index of 18.5 to 24.9 kg/m2 and waist circumference lower 
than 90cm and 100cm for women and men, respectively [86]. 
- Physical inactivity 
Sedentary lifestyle is also a significant risk factor for cerebrovascular disease. Physical activity 
has beneficial effects on blood pressure, glucose and lipoprotein levels [88]. Increased cardiac 
output during exercise increases fluid shear stress within the arteries until athero-protective 
levels of shear [89]. Additionally, this may increase endothelial nitric oxide synthase (eNOS) 
expression and hence, reduce the inflammatory status of these regions [4]. Epidemiologic and 
case-control studies have suggested that physical activity could decrease stroke incidence with a 
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dose-dependent relationship for both intensity and duration [90–92]. It is suggested that exercise 
before ischemia induces neuroprotection, reducing cerebral infarct size to levels that are not 
symptomatic [93,94]. 
 Inherent biological traits 
- Sex 
Age specific stroke incidence rates are generally higher among men compared with women 
[85]. Multiple studies [85,95] have shown an increased incidence of stroke in men compared 
with women with moderate-severe carotid stenosis. For instance, there is a progressive increase 
in thickness equal to 0.0034mm per year in men and 0.0018mm in women[96]. The male-to-
female ratio in carotid vascular disease prevalence has the maximum peak at age of 45-49 years 
[97] but in the extremes of old age, >75 years old, gender-related prevalence differences are less 
noticeable [98]. These prevalence changes according to age have been related to events linked 
to menopause that may promote atherosclerosis in women [97]. The authors speculated that 
estrogens might act not only on risk factor reduction, but also directly on plaque morphology 
and arterial remodeling [99]. Then, sex-related differences in the type of plaque rupture may be 
the result of differences in plaque composition [54]. 
Men have softer plaques, with a necrotic core more rich in lipids [100] and more erosions with 
subsequent healing than plaques from women [99]. On the contrary, plaques in women are 
likely to be fibro-calcified with less inflammatory features such as concentration of foam cells 
and lymphocytes in the cap [99,101]. This may suggest that sex hormones related to menopause 
such as estrogens play an athero-protective role giving stabilizing properties to the plaque [99]. 
Additionally, men have also greater carotid plaque area than women; in spite of women have 
greater stenosis [102]. Several studies have shown that women have significantly smaller 
carotid arteries than men, which predisposes women to higher velocity for any given blood 
pressure, reducing therefore biological risk to develop the lesion [100]. Nevertheless, women 
have worse recovery from stroke than men [103]. 
- Age 
Although the relation between advancing age and atherosclerotic plaque composition is unclear, 
there are structural changes with aging in large arteries such as carotid and aorta arteries [104]. 
These changes include arterial dilation, arterial compliance reduction, increased stiffening, 
endothelial dysfunction and intima-media thickness (IMT), considered to reflect early stages of 
atherosclerotic disease [104]. Increased IMT is a physiological effect of aging that corresponds 
to diffuse intimal thickening, especially in very elderly people. It has found that aging is the 
primary determinant of IMT [96]; during the sixth decade of life advanced lesions began to 
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appear, thus, in the seventh and eighth decades of life IMT and plaque prevalence are closely 
associated [105]. Moreover, plaques seem to become more atheromatous with aging, containing 
less SMCs and increased macrophage content. SMC apoptosis has been reported to be increased 
with age and additionally, in an inflammatory environment, SMC apoptosis may become 
impaired worsening the lesion [104,106]. 
Other risk factors are also affected with aging such as hypertension and hypercholesterolemia 
that increase their prevalence with age. Hypertension has been associated with increased 
prevalence of preclinical atherosclerosis in the older population [107] while arterial wall of aged 
people is more susceptible to hypercholesterolemia [104]. 
Therefore, the rate of progression is determined by various risk factors such as hyperlipidemia, 
levels of oxidants from smoking or other sources, elevated blood glucose, circulating 
inflammatory mediators and exercise among the previously aforementioned [4]. For example, at 
regions of arteries where athero-protective flow patterns are lost, there is an activation of 
proinflammatory pathways through ECs. Thus, the local chronic inflammation synergizes with 
additional risk factors such as hypertension, high plasma cholesterol, diabetes, etc, leading to 
more severe inflammation and atherosclerosis [4]. In addition, medical factors including 
previous transient ischemic attack (TIA) or stroke, ischemic heart disease, atrial fibrillation, and 
glucose intolerance, all increase the risk of stroke [85]. 
1.1.6.  Biomarkers of carotid atherosclerotic plaque rupture 
There is a need to identify biomarkers with the aim to select patients with carotid plaque and to 
be associated with the degree of stenosis or with features of plaque vulnerability, with the 
purpose of distinguish patients with higher risk of developing CV accidents [108]. Although 
during last decade there has been an advance in stroke risk detection from carotid artery stenosis 
degree measurement toward characterization of biological processes occurring within plaque 
[52], to date the standard diagnostic imaging tools still focus more on arterial luminal narrowing 
and less on plaque characteristics, and hence, it makes it difficult to estimate the vulnerability of 
a plaque. Therefore, plaque rupture remains complicated to predict [109]. For instance, plaque 
echolucency —lipid-rich  necrotic core or intraplaque hemorrhage based on ultrasound 
technique—, total plaque area and plaque surface irregularities have been suggested as 
ultrasound markers of unstable plaque and risk of stroke, independent of the degree of artery 
stenosis However, the association between these variables is not fully understood [52]. 
An alternative to the use of imaging methods to identify vulnerable plaques could be the use of 
circulating or plaque in situ biomarkers such as molecules or specific cell types that may be able 
to define subjects with high-risk carotid plaques. Therefore, the identification of plaque 
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instability biomarkers has been focused on finding a molecule detectable either in serum or 
tissue. This molecule must be specific of carotid atherosclerotic plaques and be different 
expressed in unstable and stable plaques, and its increase/decrease should mean that plaque is 
prone to rupture [110]. For that reason, this biomarker must be present in atherosclerotic 
plaques and be released into circulation before rupture of the plaque to facilitate efforts to 
prevent it, or after rupture and remain increased since rupture might occur up to several days 
before the patient presents symptoms [111]. This biomarker would be intended to be used for 
risk prediction instead of just diagnosis. Thus, the biomarker may be also predictor of the risk of 
flow-limiting thrombus formation after plaque rupture and then, avoid a new event [110]. 
The following are the most widely distributed biomarkers: 
 Inflammatory markers 
Inflammation in the atherosclerotic lesion is considered to play a role in the events that lead to 
plaque rupture [104]. Changes in arterial inflammation have shown to be higher in patients with 
the highest rates of atherosclerosis progression, and could therefore be considered as a local 
marker for advanced plaque development [104]. The arterial regions where flow patterns 
develop disturbances are more susceptible to activate proinflammatory signaling pathways [4] 
and plaques prone to rupture show a high grade of inflammation [112]. In fact, arterial 
inflammation has been correlated with macrophage infiltration within the plaque [113] and it 
has been shown that inflammatory cells co-localize with plaque rupture sites [104]. 
Furthermore, there is a probable association between plaque echolucency (associated to 
vulnerable plaque) and inflammatory burden, with macrophages contributing to plaque 
destabilization in lipid-rich lesions [114]. 
- C-reactive protein (CRP) 
CRP is an acute phase protein and is considered representative of the inflammatory status of an 
individual [104]. CRP is a well-established biomarker of cardiovascular risk and specially, a 
well-known circulating marker of atherosclerosis [115]. Its circulating levels have been shown 
to correlate with carotid IMT [116] and may reflect a systemic inflammatory response coming 
from inflamed atherosclerotic plaque [115].  
CRP is probably directly involved in atherogenesis; it binds to a modified form of LDL, and 
when aggregated, CRP can also bind to native LDL [117]. However, CRP is a much less 
specific indicator of vessel wall inflammation than other inflammatory molecules such as 
interleukins (ILs). The exact role of CRP in the inflammatory process is uncertain, and in 
addition to several studies that have demonstrated elevated CRP concentration to be an 
independent prognostic factor in patients with stroke [118], there are also recent studies, which 
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have shown there is no association between plasma CRP levels and carotid plaque inflammation 
[119]. Then, the role of the CRP assay for treatment decisions has not been fully established, 
and CRP is not broadly applied as a risk marker for the prediction of plaque rupture [120]. 
- Cytokines: 
Cytokines, and especially proinflammatory cytokines, have been found in plasma of 
atherosclerosis patients as well as within carotid atheroma plaques. The abundance of these 
cytokines has been associated with plaque vulnerability. Example of these are the high plasma 
levels of macrophage inflammatory protein 1beta (MIP-1b), tumor necrosis factor alpha (TNF-
α) and C-X3-C motif chemokine ligand 1 (CX3CL1 or fractalkine), that have been found to be 
associated with high content of proinflammatory cytokines within the plaque, and hence, may 
serve to identify plaques with high inflammatory activity, and moreover, as markers predicting 
future TIA [121]. Nevertheless, the association between cytokines found into the plaques and in 
plasma appeared to be stronger in asymptomatic patients than in symptomatic ones, maybe 
because a recent event would have induced a systemic inflammatory response but unstable 
carotid plaques remodel and stabilize over time after stroke [122]. 
High levels of IL-6 have been shown to be associated with low echogenicity of carotid plaques, 
which means low content in fibrotic tissue and calcification, suggesting a link between 
inflammation and the potential risk of plaque rupture [114]. Indeed, large amounts of IL-6 have 
been found in human atherosclerotic plaque, in particular within the shoulder region of stable 
and unstable plaque[123], as well as in serum from patients with vulnerable plaques. 
Furthermore, IL-6, MIP-1b and C-C motif chemokine ligand (CCL) 2 plaque levels have been 
significantly correlated with plaque lipid staining [121]. However, increased IL-6 level is non-
specific because IL-6 is also secreted by T cells during infection, therefore, could not be used as 
a marker of plaque instability [124]. 
IL-6 modulates lipid homeostasis, vascular remodeling, and plaque inflammation in 
atherogenesis, and together with IL-18 and IL-1β has been identified to play a role in the late 
stages of atherosclerotic lesion development [125]. IL-1β and IL-18 are present predominantly 
in advanced atherosclerotic lesions of unstable plaques, located in the lipid core in macrophages 
and foam cells. They are detected at higher levels in carotid atherosclerotic patients than in 
control groups (without atherosclerotic lesions), therefore, plasma levels of IL-1β and IL-18 
might be candidates to be used as predictors for carotid atherosclerosis [126]. 
In addition, IL-18 acts directly as a proinflammatory cytokine by inducing IL-1β, IL-8 and 
expression of adhesion molecules. It is produced mainly by monocytes/macrophages and is 
involved in the induction of IFN-γ production, which greatly affects collagen content through 
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inhibition of collagen synthesis by SMCs  from plaques and enhances expression of matrix 
metalloproteinases (MMPs) [127]. As a result, plaque destabilization is encouraged. However, 
even though IFN-γ plays an important role in atherosclerosis, its use as a circulating biomarker 
has been limited by the rapid metabolization that occurs following its release [121]. 
In a health condition, legumain, a cysteine protease localized in the endolysosomal system, can 
be expressed by different antigen-presenting cells (APCs) through generation of T-cell epitopes 
on major histocompatibility complex-II (MHC-II). Legumain protein and pro-legumain mRNA 
levels are increased in symptomatic human carotid plaques, as well as in unstable regions of 
plaques compared to stable ones. Legumain is co-localized with macrophages in foam-cells rich 
areas within the plaques. On the contrary, it has not been possible to discriminate between 
symptomatic and asymptomatic patients at systemic level [108]. 
CCL19, small cytokine belonging to the CC chemokine family, is found to be significantly 
upregulated in clinically and histologically unstable plaques. Serum CCL19 levels are also 
higher in patients who were recently symptomatic compared with those who were not. CCL19 is 
involved in the chemokine signaling pathways regulating cytokine production, cellular growth 
and differentiation, and apoptosis, as well as in transendothelial migration and activation of 
leukocytes, lipid uptake of macrophages, and foam cell formation within atherosclerotic 
plaques. CCL19 is strongly expressed around the core and cap region where it is co-localized 
with CD3-positive T-cell lymphocytes of recently symptomatic plaques [128]. Moreover, 
plaque T-cell accumulation appears increased in patients with carotid plaque and ischemic 
symptoms compared to those in patients with carotid plaque but without ischemic symptoms. 
Additionally, interleukin (IL)- 17A, - 21, - 23 and vascular cell adhesion molecule-1 (VCAM-1) 
expression were also found significantly increased [129]. 
Apart from the molecules already mentioned, several other inflammatory markers have been 
associated with atherosclerosis and cardiovascular disease. Serum amyloid A [67], YKL-
40[130], CD146 [131], high white blood cell count [62], P-selectin, soluble urokinase-type 
plasminogen activator receptor (suPAR) [132], IL-23 [133], visfatin [134], granzyme B [135] 
and S100A12 [136] have been all associated with carotid plaque instability and stroke [67], as 
well as with the progression of asymptomatic to symptomatic plaques [46]. 
Measurement of circulating markers after 1–2 years after the endarterectomy surgery showed 
that the levels of most of the inflammatory markers were not significantly different compared 
with the pre-operative period [115], which may suggest that there could be influenced by other 
concomitant conditions [121]. 
 Extracellular matrix markers 
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- Metalloproteinases (MMPs) and their inhibitors (TIMPs): 
MMPs are calcium-dependent zinc-containing endopeptidases capable of degrading 
extracellular matrix proteins. They are known to be involved in the cleavage of cell surface 
receptors, release of apoptotic ligands and chemokine/cytokine inactivation. MMPs are also 
thought to play a role in cell behaviors such as cell proliferation, migration, differentiation, 
angiogenesis, apoptosis and host defense [137]. 
MMPs are detected in atherosclerotic plaques and are particularly important in plaque stability 
due to their presence in areas of plaques prone to rupture [138]. Some MMP such as MMP-2, -3 
and 9 can facilitate vascular SMC migration from the media into the developing atherosclerotic 
plaque where they participate in fibrous cap formation and maintenance, thus promoting plaque 
stability. On the contrary, MMP-1, -8, -12, -13 and -14 can degrade fibrous cap and prompt the 
recruitment and accumulation of monocytes and macrophages, resulting in thinning of the 
fibrous cap and lipid core expansion, respectively [139]. Indeed, gene expression of MMP-1, -
12, and -14 is found increased in vulnerable carotid plaques compared to stable carotid plaques 
[41]. 
MMP-8 and -9 levels were found to be increased in plaques with histological evidence of 
carotid plaque instability [140,141]. In fact, macrophage-derived MMP-9 has demonstrated to 
be a trigger of intra-plaque hemorrhage, which is considered a destabilizing factor [139]. Also, 
high levels of MMP -9, together with MMP-7, are found to be associated with symptomatic 
carotid plaques obtained from patients undergoing carotid endarterectomy [142]. MMP-7, 
secreted by macrophages, can induce vascular SMC apoptosis, and therefore, compromise also 
plaque stability [143]. The activity of these three MMPs has been detected in macrophage-rich 
carotid atherosclerotic lesions whereas increased MMP-2 activity is associated with SMC-rich 
lesions [144]. Plaques seem to become more atheromatous with the aging, containing less SMCs 
and increased macrophage content and higher MMP-9 levels [104]. In fact, stroke incidence 
(ipsilateral) is significantly increased in patients with ≥50% of carotid stenosis and elevated 
plasma MMP-9 levels compared to that in patients with carotid stenosis ≥50% but without 
elevated plasma MMP-9 levels [145]. 
- A disintegrin and metalloproteinases (ADAMs) and ADAM with 
thrombospondin motifs (ADAMTSs): 
ADAM proteases are a family of transmembrane and secreted metalloendopeptidases that are 
involved in the cleavage of cell-surface molecules such as adhesion molecules, growth factors 
and receptors for cytokines/chemokines [139]. ADAMs are found in carotid atherosclerotic 
plaques at high levels compared to health arteries. For instance, ADAM-10 is expressed in both 
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early and advanced atherosclerotic carotid lesions  and its expression is markedly increased in 
unstable plaques compared to stable lesions [9,146]. This protein possesses a proteolytic 
function and activates various inflammatory factors [147]. ADAM-10 participates in protein 
kinase C (PKC)-alpha-ADAM-10 cascade regulating N-cadherin cleavage in atherosclerotic 
plaque. Soluble form of N-cadherin provides a pro-survival signal to vascular SMCs, 
macrophages and foam cells attenuating their own apoptosis. Therefore, during apoptosis in 
atherosclerotic plaques ADAM-10 appeared to be upregulated, and its increase has been 
correlated with decreased N-cadherin expression due to its cleavage, and hence, an augmented 
apoptosis [148]. 
ADAM-9, -15 and -17 are localized to foam cell-rich regions and are found upregulated in 
advanced carotid atherosclerosis at transcriptional and protein levels. It is suggested that these 
ADAMs may play a role in monocyte homing, migration and proliferation in carotid plaque 
[146]. Similarly, ADAMTS-4 and -8, inflammatory regulated enzymes, have been detected in 
foam cell-rich areas of human carotid atherosclerotic plaques and moreover, their expression 
increases during lesion progression [149]. ADAMTS-7, also, is associated with plaque 
vulnerability due to its higher expression in plaques of symptomatic patients than asymptomatic, 
and its association with plaques rich in foam cells and lipid content [150]. ADAMTS have been 
implicated in atherosclerosis due to their ability to processing pro-collagens and von Willebrand 
factor as well as remodeling ECM. In general, ADAMTS have been related to roles such as 
coagulation, inflammation, angiogenesis and cell migration. Thus, ADAMTS1 can promote 
vascular SMC migration in culture and is found to be expressed by SMCs within human 
atherosclerotic lesions suggesting a role in plaque stability [151]. 
- Tissue inhibitor metalloproteinases (TIMPs) 
TIMPs play a homeostatic role in regulating the activity of MMPs and ADAMS. TIMPs are 
commonly increased where MMP activity is prevalent with the aim to inhibit them. TIMPs 
comprise a family of four protease inhibitors TIMP-1, -2, -3 and -4. TIMP-1 has shown 
decreased serum levels in stroke patients compared to those in asymptomatic patients [152]. 
Symptomatic patients with carotid stenosis ≥50% have demonstrated to have decreased levels of 
TIMP-1 in addition to HDL, while blood IL-6 and triglycerides were found significantly 
increased compared to asymptomatic patients with carotid stenosis ≥50% [153]. TIMP-3, 
however, is associated with stable carotid plaques due to its abundant presence in foam cells 
within the fibrous cap of human plaques [42], and additionally, it has shown the highest 
expression levels of all TIMPs in stable carotid plaques [41]. TIMP-3 is also expressed by 
medial SMCs within advanced lesions albeit at lesser amounts than foam cells [154]. 
Accordingly, TIMP-3 positive foam cells are associated with stable plaques rich in SMCs and 
21 
 
small necrotic core [42]. Macrophages can express TIMP-4 as demonstrated in human 
atherosclerotic plaque lesions, in which TIMP-4 activity has been detected in macrophages 
around the necrotic core [155]. Nevertheless, the role of TIMP-4 in atherosclerosis remains 
unclear [139]. 
- Pregnancy-associated plasma protein A (PAPP-A): 
This is a high-molecular-weight zinc-binding matrix metalloproteinase which is secreted by 
vascular EC and SMCs within atherosclerotic plaques. There is an association between the high 
level of serological PAPP-A and its detection in plaques, also between the PAPP-A expression 
and fibrous cap thickness [156], as well as with rupture-prone plaques [157]. Based on this 
correlation, it is suggested that circulating high levels of PAPP-A may reflect the risk of 
developing unstable plaque [156]. 
- Fibrinogen 
Fibrinogen blood levels are associated with a specific histological composition of carotid 
atherosclerotic plaques that predispose them to rupture and thrombosis. Thus, an increase in the 
presence of blood fibrinogen is related to macrophage cap infiltration and decrease in plaque 
cap thickness, which are characteristics of vulnerable plaque. Moreover, plaques of patients 
with the highest fibrinogen levels are usually characterized by a high incidence of thrombosis 
compared with plaques of subjects with lower levels of fibrinogen. Therefore, plaque rupture 
has been associated with hiperfibrinogemia [158]. 
 Vascular calcification markers 
The risk of vascular disease increases with increasing burden of calcified plaque [104]. The 
bone matrix proteins osteopontin (OPN) and osteoprotegerin (OPG) have emerged as novel 
markers of calcified atherosclerotic plaque. OPN has a role anchoring osteoclasts in the ECM 
facilitating bone resorption whereas OPG functions by inhibiting osteoclast differentiation. High 
levels of OPN and OPG are found in symptomatic carotid plaques with possible implications for 
plaque stability [159]. Although OPN expression, in carotid plaques and blood, has displayed to 
be predictive for athero-thrombotic events [160], it does not correlate with vulnerability features 
of the plaques [161]. An increase of OPG together with lipoprotein-associated phospholipase 
A2, however, may indicate the symptomatic transformation of the carotid atherosclerotic plaque 
[153]. 
 Lipid-related markers 
Lipid core in thickened carotid walls is strongly associated with total plasma cholesterol [162]. 
Symptomatic carotid plaques trended toward more cholesterol deposition than asymptomatic 
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plaque as immunohistochemical analysis of carotid atherosclerotic plaques have shown. A 
strong correlation between increased total cholesterol staining and characteristics of vulnerable 
carotid plaque such as high content of foam cells, calcification and low SMCs have been 
demonstrated [163]. 
Pathologic studies have showed accumulation of oxLDL in rupture-prone atherosclerotic 
plaques, suggesting that high concentrations of oxLDL in plasma and plaque could play a role 
in the transition from stable to vulnerable plaques [164]. Elevated plasma oxLDL concentrations 
are also associated with moderate ischemic damage in stroke patients and a persistent increase 
in plasma oxLDL may represent a predictor of enlargement of the ischemic lesion after [165]. 
The vascular wall can be considered as a major source of circulating oxLDL [165]. Oxysterols 
arise through enzymatic reactions of cholesterol oxidation as well as non-enzymatic reactions 
such as free radical mediated processes. They are involved in advance atherosclerotic plaque 
formation [166] as demonstrated by elevated levels of oxysterols in patients with advanced 
carotid atherosclerosis [167]. 
Myeloperoxidase is one of the main enzymes responsible for oxidizing LDL molecules. It is a 
heme protein secreted by activated macrophages that has been detected in human atherosclerotic 
lesions [168] and is associated with the progression of the disease in patients with low levels of 
HDL cholesterol [169]. In human atherosclerotic tissue, myeloperoxidase catalyzes oxidative 
modification of HDL producing dysfunctional proinflammatory and proatherogenic HDL and 
influencing ATP binding cassette subfamily A receptor 1 (ABCA1) affinity with HDL, which 
results in an impaired reverse cholesterol transport [170]. In addition, myeloperoxidase activates 
metalloproteinases and hence facilitates destabilization and rupture of the vulnerable plaque 
[169]. 
 MicroRNA deregulation 
MicroRNAs (miRNAs) are non-coding small RNAs that regulate gene expression by 
degradation or translational repression of target mRNAs. A group of miRNAs contributing to 
plaque instability development has been detected. Within atherosclerotic plaque miR-100, miR-
125a, miR-127, miR-133a, miR-145, andmiR-221 levels are found to be markedly increased in 
symptomatic plaques compared to asymptomatic plaques [171]. At serum level, a recent study 
of miRNA trafficking by exosomes has shown that miR-199b-3p, miR-24-3p, miR-221-3p, 
miR-27b-3p and miR-130a-3p were increased in patients with asymptomatic carotid artery 
stenosis with progression toward symptomatic stenosis. These miRNAs had previously been 
related with processes such as inflammation, angiogenesis, or endothelial and vascular smooth 
muscle cell differentiation, leading to atherosclerotic plaque growth, instability, rupture, and 
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possible subsequent cerebrovascular events. It is suggested that this subclinical miRNA profile 
may serve as a biomarker for stenosis progression toward ischemic event [172].  
More recently, some miRNAs have been identified which can regulate MMP and TIMP 
expression, exerting direct effects on plaque progression. MiR-181b has been involved in 
TIMP-3 expression by foam cells whereas miR-24 can regulate MMP-14 protein expression on 
macrophages [139]. 
However, thus far no single biomarker has been found to be able to reliably predict ischemic 
stroke or cardiovascular disease. There is a need to carry out additional studies for the 
identification of biomarkers since microarrays, qPCR and/or immunohistochemical techniques 
have not been able to find reliable biomarkers for use in the clinic [52]. 
1.2. VASCULAR SMOOTH MUSCLE CELLS 
One of the main cellular components in carotid atherosclerosis are vascular smooth muscle 
cells. These cells are highly specialized in their main function; contraction, which is used to 
provide support and contractility to the vascular system [173]. During vascular development, 
SMCs are in a dedifferentiated state and display a high rate of proliferation, migration and 
production of extracellular matrix components (collagen, elastin, proteoglycans, cadherins and 
integrins) that comprise a major portion of the arterial wall mass and they formed abundant gap 
junctions with ECs for the right vascular maturation [174]. At the end of the development, 
SMCs became differentiated into contractile-state cells to perform their contractile function and 
show low rates of proliferation and synthetic activity [173]. 
SMCs are highly specialized cells in adult blood vessels that have developed a complex 
contractile system and maintain a quiescent state of proliferation. Their main function is to 
maintain vessel tone and diameter, and thus control blood pressure, but they also participate in 
vessel homeostasis and development. To carry out their functions they express a unique 
repertoire of contractile proteins that give them these contractile properties that differentiate 
SMCs from other muscle cell types [175]. 
Both, ECs and SMCs, are involved in blood pressure maintenance by responding to mechanical 
forces to modulate arterial diameter. The mechanism, called the myogenic effect, makes SMCs 
responsive to acute changes in blood pressure in these vessels, as myosin activation through 
voltage-dependent calcium channels results in activation of cell contraction [176]. During 
increased blood flow ECs respond to it causing relaxation of the surrounding smooth muscle 
[177]. SMC relaxation consists in increase the arterial diameter to restore wall shear stresses to 
basal levels [178]. Thus, elasticity of large arteries, such as the aorta, softens the periodic 
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variation in blood pressure expanding and deflating as pressure increase or decrease during the 
cardiac cycle. Therefore, the resultant cyclic stretch of artery walls promotes a quiescent and 
contractile state where SMCs express a full range of differentiation markers [179]. 
1.2.1. SMC phenotypic switching 
The major characteristic in the differentiation of SMC is that this cell can exhibit a wide range 
of different phenotypes at different stages of development, and even in adult organisms the cell 
is not terminally differentiated [180]. SMCs are able to suffer phenotypic modulation to ensure 
local adaptation to chronic changes in the vessel, and consequently, SMCs provide the vessel 
with the necessary flexibility to address physiological and pathological situations [181]. 
“Phenotypic modulation” is a descriptive term coined by Julie Chamley-Campbell et al. in 1979 
[182]. This term refers to the full range of possible alterations in functional and structural 
properties that can be exhibited by the SMCs in response to changing environmental cues, 
including changes in gene expression patterns, signaling mechanisms, contractility, etc. [180]. 
 
 
Figure 7. SMC phenotypic modulation in atherosclerosis disease [183]. 
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In general, SMC phenotypic switching is characterized by markedly reduced expression of 
SMC-selective differentiation marker genes [180] originated by Krüppel-like factor 4 (KLF4)-
dependent myocardin downregulation [184]. Although KLF4 is a molecular regulator of 
phenotypic switch of SMCs towards hyperplasia [185], it is normally not expressed in SMCs 
and its activation leads to downregulation of myocardin and myocardin target genes, and hence, 
modulation of these cells [184]. The only cells in the vasculature that express myocardin are 
SMCs [183]. Myocardin is the principal regulator of smooth muscle development and is 
necessary for SMC differentiation through interactions with serum response factor (SRF) [184]. 
Myocardin activates smooth muscle gene expression [186], and thus, genes like smooth muscle 
specific α-actin, calponin, h-daldesmon, transgelin and myosin heavy chain 11, that are SMC-
selective differentiation marker genes, are regulated by SRF [187]. 
Once phenotypic switching is accomplished, the function of SMC can vary dramatically 
depending on the nature of the phenotypic transitions [183]. Several phenotypes have been 
described for SMCs (Figure 7) [180]: 
- Synthetic phenotype: 
The most studied one is the synthetic phenotype; in which cells acquire characteristics such as 
an increased rate of proliferation, migration, and synthesis of ECM [180]. Synthetic SMCs have 
a lack of myofibrils and hence they lose contractile ability [188] but in contrast, they have 
increased content of rough endoplasmic reticulum, Golgi and free ribosomes used for ECM 
components production [182]. The characteristics of these two phenotypes, contractile and 
synthetic, represent the two ends of spectrum of SMCs with intermediate phenotypes [189]. Due 
to different signals, SMCs can switch in both directions, synthetic- or contractile-state, thus, 
proliferative SMCs can reacquire some of the contractile SMC characteristics when surrounding 
signals drive the cells towards it [190]. 
- Macrophage-like phenotype 
Another phenotype that SMCs can acquire is the macrophage-like phenotype (or foam cells). 
Cells with this phenotype are able to express macrophage markers such as scavenger receptor 
CD68, and gain properties such as the uptake of cholesterol. Then, after cholesterol loading, 
SMCs are able to transform into foam cells [191]; however, gene expression patterns of these 
SMC-derived macrophage-like cells seems to be distinctly different from classical monocytes, 
macrophages, and DCs. For instance, SMC-derived macrophage-like cells have reduced 
phagocytic capacity compared with activated macrophages [192]. 
- Osteoblast-like phenotype 
26 
 
It is demonstrated that high concentration of phosphate induces KLF4 expression contributing 
to transition of SMCs to osteoblast-like cells and hence, suppressing SMC contractile genes 
[193]. Pro-osteogenic factors such as the bone morphogenetic proteins and inflammatory 
mediators increase expression of the bone-related proteins osteocalcin, sclerostin, and receptor 
activator of nuclear factor-kappa β ligand (RANKL). These cells are the main responsible for 
generating matrix vesicles that serve as a nidus for bone matrix deposition in the vessel wall and 
thus, they mediate vessel calcification [194]. 
1.2.2. SMCs in carotid atherosclerosis 
Atherosclerosis is one of the best-known example in which SMC phenotypic switching plays a 
key role in the development of the disease, a disease currently responsible for >40% of all 
deaths in Western civilization [195]. 
The role of the SMC in the pathogenesis of atherosclerosis appears to vary, depending on the 
stage of the disease. The SMC has a maladaptive role in lesion development and progression; it 
is estimated that up to 70% of the lesion mass is occupied by SMCs or is SMC-derived (e.g. 
ECM). At the same time intimal SMCs within atherosclerotic lesions are contributing to luminal 
narrowing, medial SMCs play a key role in adaptive positive remodeling, a process beneficial in 
maintaining blood flow [195].  
In the context of atherosclerosis, there is a pathological environment with mechanical forces, 
endocytosis of specific molecules, chemokines and growth factors that regulate SMC-specific 
genes [196]. These signals induce contractile SMCs to undergo transient modification of their 
phenotype toward a highly synthetic phenotype [180], and consequently, these cells proliferate 
and migrate from the media to the intima [196]. Thus, SMCs contribute to the healing of the 
damaged wall; 1) in long periods of elevated pressure, intimal thickening reinforces the arterial 
wall avoiding its rupture[4]; 2) SMCs maintain plaque stability by producing a protective 
fibrous cap overlying encapsulated lipid core to avoid proinflammatory response [191]. Upon 
resolution of the injury, the local environmental cues within the vessel return to normal, and 
SMCs reacquire their contractile phenotype/properties [180]. Thus, this ability to adapt to 
distinct functions indicates mature SMCs which are not fully differentiated and  may retain 
significant plasticity [175]. 
In the firsts stages of plaque development adaptive intimal thickening takes place, which 
implies a change in their phenotype from contractile- to synthetic-state. This phenotypic 
switching is considered a pre-requisite in the initiation of the plaque formation [189]. However, 
SMC accumulation can become aberrantly regulated leading to increased switched cells and 
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extracellular matrix formation [197], that forwards the progression of the plaque from moderate 
to advanced stage [189]. 
Exposition of SMCs to oxidized phospholipids induce SMC phenotypic switch from the 
contractile to the synthetic phenotype and increased expression of chemokines by SMCs. 
Oxidized phospholipids also increased nuclear translocation of KLF4, a known repressor of 
SMC marker genes [198]. In this way, in the process of plaque formation where there is a 
prolonged exposure to oxLDL, the retention of blood lipoproteins is facilitated by SMC-derived 
ECM, increasing the susceptibly of oxLDL modification and therefore, their uptake by SMCs 
[35]. The presence of excessive oxLDL promotes over-expression of scavenger proteins 
involved in LDL phagocytosis leading to the formation of foam cells. Nevertheless, SMC-
derived foam cells have less affinity for LDLs than cells specialized in phagocytosis and also, 
they have reduced ability to clear dying cells and necrotic debris [189]. As a result, SMC-
derived foam cells do not contribute to produce fibrous cap components but promote necrotic 
core formation and enlargement as well as neointima formation [183]. SMC-derived foam cells 
end up transforming into apoptotic cells, promoting adjacent SMC proliferation, plaque 
calcification, and increasing plaque size with reduced fibrous cap area and plaque stability 
[199]. 
Since inflammation may become unchecked and excessive, some factors can promote death of 
macrophages and SMCs, and together with the reduced phagocytosis of debris by SMC-derived 
cells and macrophages [200], the atherosclerotic plaque evolves toward an advanced stage. 
Dead cells begin to form the lipid-rich necrotic core in the central part of the intima covered by 
collagen-rich fibrous cap that is produced by migrated SMCs [31]. 
Apoptotic SMCs or matrix vesicles released by these cells originate micro-calcifications in the 
neointima of atherosclerotic plaques. These matrix vesicles are the mineral nucleation sites for 
the initial deposition of calcium and phosphate in blood vessel and are originated from de-
differentiated or calcifying SMCs as a mechanism to decrease high levels of intracellular 
calcium [201]. Oxidant stress and endoplasmic reticulum stress are implicated in vascular 
calcification and have shown to promote differentiation of SMCs to osteoblast-like cells, 
however, other mechanisms such as calcification inhibitors, DNA damage response signaling, 
lipid deposition and inflammation are also involved. The presence of these matrix vesicles 
derived from SMCs have been shown to be one of the responsible of disruption of normal vessel 
architecture [194]. 
Within the fibrous cap, SMCs may play either a beneficial adaptive role or a detrimental role in 
determining plaque stability, depending on the phenotypic state of these cells. Synthetic-state 
cells are the responsible for stabilizing fibrous cap, but on the contrary, in response to 
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environmental cues these cells may undergo apoptosis and/or activate expression of various 
matrix metalloproteinases and/or inflammatory mediators that may contribute to events such as 
plaque rupture and thrombosis, and subsequently may lead to stroke [195]. The possibility of 
the plaque to rupture increases as the cap becomes thinner, promoted by death of SMCs and 
breakdown of collagen and ECM. Thus, thickness of the fibrous cap and the degree of cap 
inflammation are factors determining the stability of the atherosclerotic plaque. However, SMCs 
can repair the rupture. For this, synthetic SMCs proliferate and synthesize ECM resulting in 
subclinical plaque rupture but with luminal narrowing produced by a thick atherosclerotic 
plaque. These SMCs properties, i.e. proliferation, migration and ECM synthesis, are affected by 
cell death in the necrotic core and cellular senescence within the plaque in advanced stage. 
Hence, the balance between both conditions is going to determine the population of SMCs 
present in the atherosclerotic plaque and its stability [183]. 
Therefore, as aforementioned, SMCs are able to show their plasticity and give rise to a 
considerable diversity of SMC responses during atherosclerosis plaque development [191]. For 
instance, intimal thickening, a hallmark of development from moderate stage to advanced 
atheroma plaque, is considered a SMC phenotypic response to cope with vascular wall damage 
[202]. 
1.2.3. SMC-specific markers 
The expression patterns of a wide range of protein markers have been characterized to describe 
the phenotypic state of SMCs. At the contractile extreme, and in healthy adult blood vessel, are 
SMCs with a fully functional contractile apparatus [203] which includes the expression of 
smooth muscle α-actin (α-SMA or ACTA2), smooth muscle myosin heavy chains (e.g. 
MYH11), h1-calponin, SM-22α or transgelin (TAGLN), h-caldesmon (CALD1), smoothelin, 
desmin and metavinculin among others.  In the other extreme it can be found synthetic, 
macrophage or osteogenic-like phenotype SMCs [180]. 
Myocardin is one of the central regulators of most, but not all, SMC-specific contractile marker 
genes that directly interacts with transcriptional cofactor SRF, which is involved in the 
regulation of cell programs such as proliferation and differentiation of SMCs and is also active 
in the promoters of muscle-specific genes during differentiation [203]. SRF binds to a CArG 
box DNA sequence of genes such as α-SMA, calponin, SM-22α and MYH11 [187] inducing 
their transcription and maintaining the contractile state [204]. 
Functional contractility is the most robust indicator of contractile SMC phenotype [203]. 
Contraction occurs through cyclic interaction between thin and thick contractile filaments, 
composed of the SMC-specific isoforms of α-SMA and myosin heavy chain, respectively [204]. 
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α-SMA is the first known protein expressed during differentiation of the SMC and is the most 
widely used SMC marker because is the most abundant protein in differentiated SMCs reaching 
the 40% of total protein content [174]. Additionally, it is highly selective for SMC or SMC-like 
cells in adult animals under normal conditions [180], however, in atherosclerosis is also 
expressed in many non-SMC cells like ECs or fibroblasts [205]. 
The following are the most used SMC markers: 
 TRANSGELIN (SM22α or TAGLN) 
SM22α is one of the earliest markers of contractile vascular SMCs and is, together with α-SMA, 
the most widely used markers for SMC identification [204]. Overexpression of SM22α inhibits 
SMC proliferation and neointima formation via blockade of the Ras-extracellular signal 
regulated kinase (ERK) 1/2 pathway [206]. SM22α co-localized with F-actin and participates in 
the organization of the cytoskeleton facilitating the assembly of actin filaments into bundles in 
differentiated vascular SMCs. Thus, SM22α facilitates the activities of migration and 
contraction in contractile vascular SMCs [207]. Its disruption is known to increase 
atherosclerotic lesions [208] due to the blockade of SM22α expression that lead to the thinning 
and dispersion of actin filaments and consequently, the cell contractility and mobility are lost 
[207]. 
 MYOSIN HEAVY CHAIN 11 (MYH11 OR SM-MHC) 
It is the most specific SM-marker known up to date and its absence or reduction is the result of 
phenotypic switching [204]. MYH11 can be expressed transiently under certain circumstances 
in other non-vascular SMCs in vivo, however, there is no conclusive evidence of this and at 
present is considered the most discriminating marker of differentiated SMCs [195]. The signal 
transduction pathways that are activated by stretch and shear stress have been shown to increase 
expression of MYH11 [181]. Cells which stain for MYH11 exhibit the elongated morphology 
and, the electrical and contractile behavior expected from SMCs [205]. 
 CALDESMON 
This protein is additional thin filament protein whose function is thought to be in regulation of 
calcium activation of the myofilaments. There are multiple isoforms of caldesmon which are 
classified as high (h) and low (l) molecular weight caldesmon proteins [209]. The expression 
ratio of h- and l-caldesmon are closely associated with phenotypic modulation of SMCs. Thus, 
mRNA and protein levels of h-form are primarily found in differentiated vascular SMCs and l-




It is a thin filament-associated protein that inhibits actin-activated myosin ATPase activity 
[209]. Calponin has the ability to stabilize actin filaments in living cells and to reduce actin 
remodeling, thus, acquiring a structural role [211]. There is some evidence for differential 
expression of three calponin isoforms (i.e. CNN1, CNN2 and CNN3) in SM and non-muscle 
tissues [209]. CNN1 is specifically expressed in SMCs and plays a role in SM contractility, 
while CNN2 is expressed in both SMCs and non-muscle cells, and CNN3 appeared to be 
expressed in embryonic development and myogenesis contributing to actin cytoskeleton-based 
functions [212]. 
 SMOOTHELIN 
Smoothelin is a structural component of the contractile apparatus. It increases the contractile 
potential of SMCs and contributes to the maintenance of the contractile phenotype. In 
atherosclerotic lesions, the neointima contains little smoothelin until the plaque stops growing 
and smoothelin appears to be expressed in SMCs present at the cap. There is a co-localization of 
smoothelin and α-SMA as demonstrated in primary SMCs. Smoothelin decreases together with 
myosin heavy chain and partly α-SMA, but smoothelin downregulation is more rapid as 
compared to these other SMC contractile proteins. The lack of smoothelin leads to a decreased 
contractile potential of SMCs [213]. 
 DESMIN 
Desmin is a muscle-specific protein that functions as subunit of intermediate filament in 
cardiac, skeletal and smooth muscle. It plays a role in cell-matrix interactions via its anchorage 
on dense bodies and membrane-associated dense bands, and thus, is involved in the correct 
transmission of contractile force to the cell surface. Desmin has been postulated to be essential 
for maintaining the structure and mechanical strength of the vascular wall [214]. The pre-
atheroma stage revealed a lack of expression of desmin by SMCs and the switch to a synthetic 
phenotype [215]. 
Although many markers of contractile phenotype can be found (Figure 8), those previously 





Figure 8. SMC phenotype markers [196] 
There are also several markers of synthetic SMC phenotype, but these have been utilized less 
widely because, generally, they display less SMC specificity [203]. Myosin heavy chain 10 
(MYH10 or SMemb) and vimentin are example of synthetic phenotype markers. The first is the 
non-muscle myosin heavy chain isoform and is expressed in SMCs undergoing growth and/or 
cell division, such as proliferating vascular SMCs in atherosclerotic neointima [216]. And the 
second is an intermediary filament that can be found in differentiated SMCs but it is co-
expressed there with MYH11, desmin and α-SMA, while SMCs of synthetic phenotype 
expressed α-SMA and vimentin [215]. 
The recognition of the synthetic phenotype mostly relies upon the reduced expression, or the 
absence, of cytoskeletal markers of the mature or differentiated phenotype [196]. Relative 
expression of these and other marker proteins can be used to localize vascular SMCs on the 
contractile-synthetic state; however, during tissue repair there is a continuum process that give 
cells diverse functions [203]. Thus, the rigorous identification of mature SMC requires 
examination of multiple marker genes and if tested in tissues, appropriate localization within the 
medial layer of blood vessels or other SMC tissues is needed [175]. 
2. OBJECTIVES 
SMCs are central players in carotid atherosclerosis plaque development. Although the precise 
mechanisms involved in plaque destabilization are not completely understood, it is known that 
SMC differentiation, proliferation and migration participate in plaque stabilization. The two 
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aims of this study are: first, to analyze expression patterns of genes involved in carotid 
atherosclerosis development (e.g., transcription factors of regulation of SMC genes) of SMCs 
located inside (PLQ: plaque) and outside (MIT: macroscopically intact tissue) the plaque lesion 
that may give clues about changes in phenotypic plasticity during atherosclerosis. And second, 
to perform a comparative transcriptomic analysis between the two groups, asymptomatic 
(Asympt) and symptomatic (Sympt), by applying RNAseq technology to understand the role of 
SMCs in symptomatology of carotid atherosclerosis. 
3. SUBJECTS & METHODS 
3.1. SMC CHARACTERIZATION 
3.1.1. Patient selection 
Patients who underwent carotid endarterectomy at Basurto University Hospital were selected to 
be included in the current study on the bases of clinical parameters (age, symptoms and no other 
clinical manifestations such as cardioembolic origin stroke). 39 patients were selected who were 
proposed for carotid endarterectomy by the committee of medical experts from Basurto 
University Hospital, who evaluated the clinical data of patients. MRI and cervical duplex was 
performed in all patients by the radiology service at the hospital. Patients with >70% stenosis 
and diagnosed cerebrovascular event were selected as Sympt patients (n=20), while patients 
with stenosis of >80% and no events were included as Asympt (n=19) in the study. 
Demographic and clinical data for the selected patients are summarized in Table 1. Carotid 
tissue sample was collected after surgery and transported immediately to the lab for cell 
isolation. 





68 ± 9 
14 male/5 female 
20 
71 ± 8 




Risk Factor (%) 
Contralateral occlusion 66 61 ns (1.0) 
Hypertension 66 69 ns (1.0) 
Diabetes mellitus 51 8 ns (0.09) 
Augmented cholesterol 83 62 ns (0.3) 
Cardiopathy 0 23 ns (0.2) 
Ischemic cardiopathy 41 46 ns (1.0) 
Atrial fibrillation 9 23 ns (0.6) 
Intermitent claudication 26 24 ns (1.0) 




Statins 100 70 ns (0.1) 
Anticoagulant 8 23 ns (0.2) 
Table 1. Demographic and clinical data from asymptomatic and symptomatic patients. Statistical 
analysis was performed with the chi-square test for all parameters except age, for which the non-
parametric Mann–Whitney U test was used. p-value ≤0.05 was considered significant. 
This study was approved by the local ethical committee (Ethical committee of clinical research, 
Basurto University Hospital) and all carotid atheroma plaques were collected from patients who 
had signed written informed consent. This research was performed in agreement with the 
principles outlined in the Declaration of Helsinki. 
3.1.2. Isolation of human vascular smooth muscle cells 
SMCs were extracted from 39 carotid arterial atherosclerotic tissue samples. SMCs from plaque 
site area (PLQ-SMCs) and tissue from neighboring area (macroscopically intact tissue (MIT)-
SMCs) were isolated for each sample. PLQ-SMCs were extracted from central site of atheroma 
plaque where maximum of the lesion is presented while MIT-SMCs come from furthest area 
from the center of the atheroma plaque. An enzymatic tissue digestion method was used to 
isolate and culture SMCs from atherosclerotic tissue samples in two consecutive digestions. 
First, tissue was digested by 3 hours incubation at 5% CO2 and 37ºC with 300U/mL of 
Collagenase type I (ColI, 17018029, Thermo Fisher Scientific, Waltham, MA, USA) followed 
by a second digestion over night with 220U/mL of ColI at 5% CO2 and 37ºC. Digested tissue 
was filtered by a 100 µm nylon Falcon™ Cell Strainer (CLS431752-50EA, Sigma-Aldrich, St 
Louis, MO, USA) to remove undigested tissue and then cells were plated in selective medium, 
which consist in: 
- 2ng/ml FGFb (130-093-839, Miltenyi Biotec, Bergisch Gladbach, Germany) 
- 20ng/ml IGF-1 (130-093-885, Miltenyi Biotec, Bergisch Gladbach, Germany) 
- 0.5ng/ml EGF (130-0997-749 Miltenyi Biotec, Bergisch Gladbach, Germany) 
- 5ng/ml Heparin (H3149, Sigma-Aldrich (St Louis, MO, USA) 
- 5% newborn calf serum (N4762, Sigma-Aldrich, St Louis, MO, USA) 
- 0.2µg/ml bovine serum albumin (BSA) (A9418, Sigma-Aldrich, St Louis, MO, USA) 
- 2mM L-glutamin (G7513, Sigma-Aldrich, St Louis, MO, USA) 
- 100µg/ml Streptomycin and 100U/ml Penicillin (P4458, Sigma-Aldrich, St Louis, MO, 
USA) 




This medium promotes selective SMC growth. All the experiments were carried out with cells 
in passage zero to reach a situation as close as possible to the real one. 
Human iliac arterial smooth muscle cells (HIASMCs) were obtained from the Coriell Cell 
Repositories (Coriell AG11545, N.J., USA). These cells were obtained by explantation of iliac 
arterial tissue. The culture was grown on flasks coated with 0.1 % gelatin (G8090, Sigma-
Aldrich, St. Louis, MO, USA) and with the medium 199 (11150059, Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with: 
- 0.02 mg/ml endothelial cell growth supplement (ECGS; 02-102, Millipore, Billerica, 
MA, USA) 
- 0.05 mg/ml heparin (H3149, Sigma-Aldrich, St Louis, MO, USA) 
- 10% fetal bovine serum (FBS) (F7524, Sigma-Aldrich, St Louis, MO, USA) 
- 2mM L-glutamin (G7513, Sigma-Aldrich, St Louis, MO, USA) 
- 100µg/ml Streptomycin and 100U/ml Penicillin (P4458, Sigma-Aldrich, St Louis, MO, 
USA). 
3.1.3. Flow cytometry 
SMC cultures were trypsinized (11581861, Thermo Fisher Scientific, Waltham, MA, USA) and 
then fixed with 4% paraformaldehyde during 10 min at room temperature. SMCs were 
permeabilized with 0.5% saponin (S7900, Sigma-Aldrich St Louis, MO, USA) in phosphate-
buffered saline (PBS) for 5 min and blocked with 1% BSA (A6003, Sigma-Aldrich St Louis, 
MO, USA) for 30 min. Primary antibodies used were anti-α SMA at 1/100 (ab66133, Abcam, 
Cambridge, UK), transgelin/SM22 monoclonal antibody at 1/100 (TAGLN) (60213-1-Ig, 
ProteinTech, Manchester, UK) and anti-CD31 (also called platelet and endothelial cell adhesion 
molecule 1, PECAM1) [EPR3094] antibody at 1/50 (ab76533, Abcam, Cambridge, UK) during 
1h in shaking at room temperature. SMCs were washed with 5mM EDTA (E7889, Sigma-
Aldrich St Louis, MO, USA) and 0.5% BSA in PBS and were incubated with secondary 
antibodies Alexa Fluor®488 goat anti-mouse IgG (H+L) (A-11001, Invitrogen, Thermofisher, 
Carlsbad, CA, USA) and Alex Fluor®647goat anti-rabbit IgG (H+L) (A-21244, Invitrogen, 
Thermofisher, Carlsbad, CA, USA) at 1/500 for 30 min in shaking and darkness. After washing 
cells, they were resuspended in 5mM EDTA and 0.5% BSA in PBS. Cells were analyzed using 
a Miltenyi MACS Quant flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). 
3.1.4. Gene expression analysis 
RNA was extracted from SMCs with PureLink® RNA mini kit (1218308A, Thermo Fisher 
Scientific, Waltham, MA, USA) followed by DNaseI treatment (12185010, Thermo Fisher 
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Scientific, Waltham, MA, USA). RNA integrity (RIN > 9) was analyzed by using RNA 6000 
Nano Chips on the Bioanalyzer Agilent 2100 (Agilent Technologies, Palo Alto, CA, USA), and 
then, RNA was retrotranscribed with High-Capacity cDNA Reverse Transcription Kit 
(4368814, Thermo Fisher Scientific, Waltham, MA, USA) using 160ng. Gene expression 
analysis was carried out using Fast SYBR® Green Master Mix (4385614, Thermo Fisher 
Scientific, Waltham, MA, USA) in ABI7500 Fast Real-Time PCR instrument (Applied 
Biosystems™, CA, USA). Primers for genes related with contractile phenotype were ACTA2, 
MYH11, caldesmon (CALD1), calponin 1 (CNN1) and TAGLN; for synthetic phenotype were 
MYH10, intercellular adhesion molecule 1 (ICAM1), secreted phosphoprotein 1 (SPP1), MMP3, 
7, 9, TIMP1 and microtubule-associated protein 1 light chain 3 B (MAP1LC3B); primers for 
transcription factors related with specific SMCs differentiation were MKL1/Myocardin like 2 
(MKL2), serum response factor (SRF), kruppel like factor (KLF) 4 and 5; primers for genes 
related with macrophage-like phenotype were CD68 molecule (CD68) and galectin 3 (LGALS3) 
(Table 2). Additionally, SYBRgreen technology was used for gene expression of C-X-C motif 
chemokine ligand 9 (CXCL9) and CXCL10, CD5 molecule like (CD5L) and bone 
morphogenetic protein 2 (BMP2) for quality control of pure SMCs used for RNAseq analysis. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ribosomal protein L41 (RPL41) and β-
actin (ACTB) were tested as housekeeping genes. The geometric mean of GAPDH and RPL41 
was used for data analysis due to their stable gene expression values across samples [217]. PCR 
amplification efficiencies were in all cases close to 100%. Results were analyzed using ΔΔCt 
method [218]. We analyzed gene expression by taking into account the localization of SMCs, 
PLQ-SMCs (n = 39), or MIT-SMCs (n = 39) using the Wilcoxon matched-pairs signed rank 
test. The Mann–Whitney U test was used to analyze gene expression patterns between plaque 
SMCs from Asympt (n = 20) and Sympt (n = 19) patients, as well as the expression levels of 15 
µM 7-ketocholesterol (7-KC)-treated HIASMCs versus not-treated HIASMCs. Statistical 
analysis was performed with GraphPad Prism 5 software. p-value < 0.05 was considered 
significant. 
Gene symbol Gene name Accesion number Assay code 
ACTA2 α-smooth muscle actin NM_001613 Hs.PT.56a.2542642 
ACTB Actin β NM_001101 QT00095431 
BMP2 Bone morphogenetic protein 2 NM_001200 Hs.PT.56a.28076895 
CALD1 H-caldesmon NM033138 QT00997899 
CD5L CD 5 molecule like NM_005894 Hs.PT.56a.2816096 
CD68 CD68 molecule NM_001040059 Hs.PT.58.2488447.g 
CNN1 Calponin 1 NM_001229 Hs.PT.58.38799164 
CXCL9 C-X-C motif chemokine ligand 9 NM_002416 Hs.PT.56a.27316119 







ICAM1 Intercellular adhesion molecule-1 NM_000201 Hs.PT.56a.4746364 
KLF4 Kruppel like factor 4 NM_004235 Hs.PT.58.45542593 
KLF5 Kruppel like factor 5 NM_001730 Hs.PT.56a.40282397 
LGALS3 Galectin 3 NM_001177388 Hs.PT.58.1435723 
MAP1LC3B 
Microtubule associated protein 1 
light chain 3 beta 
NM_022818 QT00055069 
MKL2 MKL1/myocarkin like 2 NM_002446 Hs.PT.85.19760686 
MMP3 Matrix metallopeptidase 3 NM_002422 QT00060025 
MMP7 Matrix metallopeptidase 7 NM_002423 QT00001456 
MMP9 Matrix metallopeptidase 9 NM_004994 QT00040040 





MYH11 Myosin heavy chain 11 NM_002474 Hs.PT.58.2909933 
RPL41 Ribosomal prtein L41 NM_001035267 Hs.PT.58.38804367 
SPP1 Secreted phosphoprotein 1 NM_001040058 Hs.PT.58.19252426 






Tissue inhibitor of 
metallopeptidase 1 
NM_003254 QT00084168 
Table 2. List of primers used in gene expression analysis for SMC phenotypic characterization. 
3.1.5. Western blot 
Cell lysis was performed with RIPA lysis buffer (150 mM TrisHCL, 150 mM NaCl, 0.5% 
Deoxycholate, 0.1% SDS, 1% NP-40) for 30 min at 4 °C followed by centrifugation at 20,000xg 
for 10 min. Cell lysates were quantified by Pierce™ BCA Protein Assay Kit (23225, Thermo 
Scientific) and 12µg protein were loaded into 6%- or 12% SDS-PAGE gels with reducing 
loading buffer. Then, proteins were transferred from SDS-PAGE gel to 0.45 µm-pore PVDF 
membrane, which was blocked with 2% casein solution. Inmunodetections were done by 
incubation with following primary antibodies: anti-smooth muscle MYH11 (ab82541, Abcam, 
Cambridge, UK), ACTA2 (23081-1-AP, ProteinTech, Manchester, UK), TAGLN (60213-1-Ig, 
ProteinTech, Manchester, UK) and anti-CD31 antibody [EPR3094] antibody (ab76533, Abcam, 
Cambridge, UK) and then washed 3 times with TBS-Tween. The secondary antibodies were 
anti-rabbit IgG, horseradish peroxidase linked (#7074, Cell Signaling Technology, MA, USA) 
and anti-mouse IgG, horseradish peroxidase linked and anti-ACTIN antibody (A2066, Sigma-
Aldrich, St Louis, MO, USA) as well as anti-GAPDH antibody (MAB374, Millipore, Billerica, 
MA, USA) as housekeeping were used for normalization. Proteins were detected with 
Immobilon™ Western Chemiluminescence HRP Substrate detection reagent (WBKLS0500, 
Millipore, Billerica, MA, USA) and were visualized with the ChemiDoc™XRS Imaging System 
(Bio-Rad, Richmond, CA, USA). Data analysis was done by densitometry scanning by 
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comparing MIT and PLQ cells and additionally, between A and S plaque SMCs, both using 
Image Lab™ Software (Bio-Rad, Hercules, CA, USA).  
3.1.6. Confocal microscopy 
Cells were grown on 24 well plates with 144mm round glass coverslips, fixed in ice-cold 
methanol for 10 min at room temperature and then blocked in PBS/3% w/v BSA (A6003, 
Sigma-Aldrich St Louis, MO, USA) for 30 min and stained with anti-smooth muscle myosin 
heavy chain 11 antibody (ab82541, Abcam, Cambridge, UK) for 1h at room temperature. Cells 
were washed with PBS and incubated with Alexa FluorR 488 goat anti-rabbit IgG (H + L) 
secondary antibody (A-11008, Invitrogen, Thermofisher, Carlsbad, CA, USA) for 45 min at 
room temperature in darkness and DNA was counterstained with 4′,6-diamino-2-fenilindol 
(DAPI). After three washes, coverslips were mounted in Fluoromount™ Aqueous Mounting 
Medium (F4680, Sigma-Aldrich, St Louis, MO, USA). Image acquisition was performed with 
Leica TCS STED CW SP8 super-resolution microscope with a 40x or 10x lenses and recording 
optical sections every 0.3 μm. Image analysis was done using ImageJ software (National 
Institute of Health, USA). Image analysis was done analyzing staining fluorescence of each cell 
per cell area in MIT and PLQ SMCs with ImageJ software (National Institute of Health, 
Bethesda, MD, USA). 
3.2. RNA-SEQ TECHNOLOGY 
3.2.1. Patient selection for SMCs isolation from Sympt and Asymptc carotid plaques 
Sympt patients (n=7) were identified as those with >70% stenosis and presenting symptoms of 
transient ischemic attack or ipsilateral stroke within the past 6 months, while Asympt patients 
(n=7) were those with stenosis >80% without any presence of cerebrovascular disease. Degree 
of stenosis was evaluated with carotid cervical Eco-Doppler ultrasound and tomographic 
angiography according to established criteria [219]. Brain MRI was performed in all patients 
before and after the surgery to monitor potential complications. All patients were evaluated 
before and after the operation by a specialized neuropsychologist. The analysis carried out by 
the neuropsychologist were Mini Mental State Examination (MMSE) to evaluate the general 
state of the patient; WMS-III that evaluates memory; the subtests of matrices and cubes of the 
WAIS-III to analyze executive functions; and the speed of processing was evaluated through the 
number key subsets of the WAIS-III. Neuropsychiatric disorders were evaluated through the 
Neuropsychiatric Inventory (NPI), and assessment of impairment and disability were measured 
through the Blessed Scale, The Informant's test and with the interview for the impairment of 
activities of daily living in the dementia. 
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Only patients who fulfill all the required parameters were finally included in the study (Table 3). 
Other required parameters for selection of eligible patients to be included in this study were 
defined as: (1) age (70 years±12); (2) no other medical conditions and (3) no previous 
contralateral endarterectomy and (4) no other cause of stroke, such us cardioembolic. During the 
recruitment period several patients were excluded from the study because they presented at least 
one of the following problems: (1) patients showing sign of dementia according to the 
minimental state examination test (MMSE); (2) patients with psychological alterations due to 
drugs or cerebral surgery intervention; (3) patients who presented medical or surgery 
complications that may alter the intellectual capacity and/or the neuroimaging test and (4) 
patients who were not able to perform the neuropsychological test due to difficulty of 
communication (i.e. vision impairment). 
Patient Selection All Symptomatic Asymptomatic 
Number, n 14 7 7 
Years 68 68 ± 8 68 ± 8 
Sex M/F, n 11/3 4/3 7/0 
Treatment with statins 14 7 7 
Risk factors (%) 
Diabetes Mellitus 100 43 (3) 57 (4) 
Dyslipidemia 100 100 (7) 100 (7) 
Arterial hypertension 100 100 (7) 100 (7) 
Tobacco 100 57 (4) 43 (3) 
Table 3. Demographic data of cohort of samples from Basurto University Hospital 
3.2.2. RNA library assembly 
Ribosomal RNA removal was performed with the Ribo-Zero rRNA removal kit (MRZH11124, 
Illumina Inc, San Diego, CA, USA). Generation of libraries was performed with the TruSeq 
Stranded Total RNA library Prep kit (20020596, Illumina Inc, San Diego, CA, USA) following 
manufacture’s recommendations. We started from 2 μg of total RNA (RIN > 9) libraries, which 
were sequenced using a HiSeq2000 instrument (Illumina Inc, San Diego, CA, USA). 
Sequencing readings were paired-end with a length of about 100 bp reading performed in 14 
samples. The estimated coverage was around 60 million reads per sample (3 lanes). Library 
generation and RNA sequencing was done at Sistemas Genómicos S.L. (Valencia, Spain) 
following manufacturer´s instructions. 
3.2.3. RNA transcriptomics analysis 
The quality control of the raw data was performed using the FastQC tool. Then, the raw paired-
end reads were mapped against the human genome provided by Ensembl database (version 
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GRchr37/hg19) using tophat2 algorithm [220]. Insufficient quality reads (Phred score < 10; 
quality of the identification of the nucleobases generated) were eliminated using the Picard 
Tools software (version 1.129) (http://picard.sourceforge.net). Gene predictions were estimated 
using the Cufflinks method [221] and the expression levels were calculated using the HT Seq 
software (version 0.6.0, http://www-huber.embl.de/users/anders/HTSeq/). This method employs 
unique reads for the estimation of gene expression and eliminates the multimapped reads. 
Differential expression of genes (DEG) and isoforms (DEI) analysis between Sympt and 
Asympt was done by using statistical packages designed by Python and R, i.e. DESeq2 method 
(version 3.4) [222]. Finally, we selected differentially expressed genes with a p-value adjusted 
(Padj) by false discovery rate (FDR) < 0.05 [223] to avoid identification of false positives across 
the differential expression data and, a fold change (FC) of at least 1.5.  
3.2.4. Gene Set functional enrichment analysis and network analysis 
Differentially expressed sets were processed using ClusterProfiler [224], a bioconductor 
package, to search for biological processes involved in plaque instability. This tool screens for 
genes in specific databases (i.e. Gene Ontology – GO, Kyoto Encyclopedia of Genes and 
Genomes – KEGG, DRUG, etc.) to evaluate biological annotations that rise as over-represented 
with respect to the whole genome. A p-value of 0.05 adjusted by FDR, called q-value, was used 
to determine a functional category as statistically significant or over-represented [223]. Gene 
networks were generated using GeneMANIA software (http://www.genemania.org/). 
GeneMANIA uses functional interconnections among genes from published data to generate a 
global view of interactions of genes. MCODE tool (http://apps.cytoscape.org/apps/mcode) was 
used to identify highly interconnected clusters in a network. 
3.2.5. Digital PCR on Fluidigm Biomark platform 
Assays for 41 genes identified in our RNAseq DEG analysis and 4 housekeeping genes chosen 
from our own DEG as those showing no variability between samples (G3BP stress granule 
assembly factor 2 (G3BP2), muskelin1 (MKLN1), echinoderm microtubule associated protein 
like 3 (EML3) and AarF domain containing kinase 5 (ADCK5)) were use for validation (Table 
4).  
Gene Symbol Gene name Accesion number Assay ID 
ANXA10 Annexin A10 NM_007193 Hs.PT.58.258700 
ANXA3 Annexin A3 NM_005139 Hs.PT.56a.103535 
BMP2 Bone morphogenetic protein 2 NM_001200 Hs.PT.56a.28076895 
DEPP1 DEPP1, autophagy regulator NM_007021 Hs.PT.58.40344222 
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CA12 Carbonic anhydrase 12 NM_001218 Hs.PT.56a.24934240 
DIRAS3 DIRAS family GTPase 3 NM_004675 Hs.PT.58.971668 
GULP GULP, Enguylfment adaptor PTB domain conatining 1 NM_001252668 Hs.PT.58.26109032 
ID1 Inhibitor of DNA binding 1 NM_002165 Hs.PT.58.45682625.g 
ID4 Inhibitor of DNA binding 4 NM_001546 Hs.PT.58.26292654.g 
ITGA7 Integrin subunit alpha 7 NM_001144997 Hs.PT.58.19415929 
KCNE4 
Potassium Voltage-Gated 
Channel Subfamily E 
Regulatory Subunit 4 
NM_080671 Hs.PT.58.46324308 
KLF5 Kruppel like factor 5 NM_001730 Hs.PT.56a.40282397 
MGST1 Microsomal glutathione S-transferase 1 NM_001260511 Hs.PT.58.38644776 
MOCOS Molybdenum cofactor sulfurase NM_017947 Hs.PT.58.3583296 
NPPC Natriuretic peptide C NM_024409 Hs.PT.58.40078220 
PTHLH Parathyroid hormone like hormone NM_002820 Hs.PT.58.41054442 
SMAD9 SMAD family member 9 NM_001127217 Hs.PT.58.18749479 






RGS2 Regulator of G protein signaling 2 NM_002923 Hs.PT.58.22488494 
TMEM35A Transmembrane protein 35A NM_021637 Hs.PT.58.2938658 
CHODL Chondrolectin NM_024944 Hs.PT.58.5002738 
ABCG2 ATP Binding Cassette Subfamily G Member 2 NM_001257386 Hs.PT.58.39633789 
ADAMTS7 
ADAM Metallopeptidase With 
Thrombospondin Type 1 Motif 
7 
NM_014272 Hs.PT.58.20739942 
DHRS3 Dehydrogenase/Reductase 3 NM_004753 Hs.PT.58.21163170 
EPHA4 EPH receptor A4 NM_004438 Hs.PT.58.40080791 
EPHB2 EPH receptor B2 NM_017449 Hs.PT.58.19695111 
ESM1 Endothelial cell specific molecule 1 NM_001135604 Hs.PT.58.19279572 
FRMD3 FERM Domain Containing 3 NM_001244960 Hs.PT.58.25637022 
HAPLN1 Hyaluronan And Proteoglycan Link Protein 1 NM_001884 Hs.PT.58.39802081 
IL17RD Interleukin 17 receptor D NM_017563 Hs.PT.58.15565560 
MYO18B Myosin XVIIIB NM_032608 Hs.PT.58.947408 








SOCS3 Suppressor Of Cytokine Signaling 3 NM_003955 Hs.PT.58.4303529 
SYNE3 
Spectrin Repeat Containing 
Nuclear Envelope Family 
Member 3 
NM_152592 Hs.PT.58.21438299 
TBX18 T-box 18 NM_001080508 Hs.PT.58.20293106 
TNFAIP8L3 TNF alpha induced protein 8 like 3 NM_207381 Hs.PT.58.549257 
DDR2 Discoidin Domain Receptor Tyrosine Kinase 2 NM_001014796 Hs.PT.58.26536814 
RDH10 Retinol Dehydrogenase 10 NM_172037 Hs.PT.58.4062554 
ZSCAN31 Zinc Finger And SCAN Domain Containing 31 NM_001243241 Hs.PT.58.39448911 
G3BP2 G3BP Stress Granule Assembly Factor 2 NM_012297 Hs.PT.58.1944755 
MKLN1 Muskelin 1 NM_001145354 Hs.PT.58.2002335 
EML3 Echinoderm microtubule associated protein like 3 NM_153265 Hs.PT.58.3509596 
ADCK5 AarF Domain Containing Kinase 5 NM_174922 Hs.PT.58.786984 
Table 4. List of primers used in gene expression analysis for RNAseq results validation. 
RNA was converted into cDNA using the AffinityScript Multiple Temperature cDNA Synthesis 
kit (200436, Agilent, Technologies, Santa Clara, CA, USA) following manufacturer’s 
instructions. Gene expression analysis was performed with the Fluidigm Biomark 48.48 
dynamic arrays (Fluidigm Corp., South San Francisco, CA, USA) and pre-designed PrimeTime 
qPCR assays (IDT, Leuven, Belgium) in 24 samples in duplicates; 13 samples were 
corresponding to those used in RNAseq and 11 new extra samples for RNAseq result validation. 
Patient characteristics for the additional 11 samples are giving in Table 5. Gene expression 
levels of housekeeping genes were used as endogenous control to normalize our samples. 
Relative expression was calculated using the ΔΔCt method [218]. The statistical significance of 
gene expression levels between Sympt and Asympt was analyzed with the GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA) using the non-parametric Mann-Whitney U-test (one-
tailed) and level of significance was defined at p < 0.05. All PrimeTime qPCR assays showed 
amplification efficiencies close to 100%. 
Patient Selection All Symptomatic Asymptomatic 
Number, n 11 4 7 
Years 68 68 ± 8 68 ± 8 
Sex M/F, n 7/4 1/3 6/1 
Treatment with statins 10 3 7 
Risk factors (%) 
Diabetes Mellitus 54 (6) 75 (3) 43 (3) 
Dyslipidemia 90 (10) 100 (4) 86 (6) 
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Arterial hypertension 81 (9) 75 (3) 86 (6) 
Tobacco 46 (5) 75 (3) 29 (2) 
Table 5. Demographic data of cohort of samples from Basurto University Hospital. 
4. RESULTS 
4.1. SMC ANALYSIS 
4.1.1. Selection of SMC culture method 
There are multiple isolation methods for SMC purification including enzyme-dispersed cells 
method, reaggregation, free-floating explants and substrate-attached explants. The choice of one 
technique or enzyme over another is arbitrary and based on experience rather than scientific 
theory [225]. We have chosen substrate-attached explants method because is recommended if 
large quantity of cells is required and starting material is small tissue such as carotid artery 
[226]. For that, immediately after extraction, the specimens were transported to Neurogenomiks 
lab (University of Basque Country and Achucarro Basque Center for Neuroscience). Fresh 
carotid artery tissue samples were processed on a sterile dissection board and were washed with 
Hank`s balanced salt solution (HBSS + 100μg/mL gentamycin + 0,025M HEPES + 20mM 
Bicarbonate) to clear of peripheral blood and of any thrombotic material. First, the artery was 
cut longitudinally with the luminal surface upward and endothelium was removed along the 
whole length of the artery by scraping the cell layer off with a sterile scalpel blade. Then, artery 
was cut into 2mm3 pieces and placed on the surface of a 25cm2 culture flask ensuring that the 
luminal surface was in contact with the flask wall. 12-16 cubes were distributed evenly on the 
surface of 25cm2 flask and a small drop of serum-containing medium was placed on each cube. 
To facilitate adherence of the explanted tissue to the culture plastic substrate, the flask was kept 
upright for 2-4h in the incubator at 37ºC and 5%CO2 with 5 mL serum containing medium in 
the bottom of the flask. After, the flask was carefully placed horizontal, such that the medium 
completely covered the attached explants, and was maintained in the incubator. Every 4 days, 
any unattached explants were removed and half of the medium was replaced with fresh pre-
warmed serum-containing medium. It is assumed that cells will initially migrate out from the 
explants within 1 to 2 weeks, and after 3 to 4 weeks, there should be sufficient density of SMCs 
around the explants for removal of the tissue. However, cell density was not enough to carry out 
expected gene expression analysis. 
Although the ultimate goal of cell isolation is to yield viable and functional dissociated cells 
[225], the cell density of cultures is also conditioning factor for experiments that will be carry 
out. In this context, we decided to try enzyme-dispersed cell method. For that, after wash carotid 
atherosclerotic human plaques, they were digested with collagenase type I enzyme. First, we 
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decided to cut the tissue as small as possible, instead of cut tissue into 2mm3 as in explants 
method, and then, we performed 3 hours digestion at 300 U/mL concentration of collagenase 
type I. Digested tissue was submitted to another digestion, in this case overnight, with 220 
U/mL collagenase type I and afterwards was filtered by a 100 μm nylon Falcon™ Cell Strainer 
for removing undigested material. Second digestion yielded higher amount of cells. Therefore, 
this method allowed us to obtain the number of cells necessary to carry out the designed 
experiments. 200.000 cells were plated in selective medium for human SMC growth (see 
Materials and Methods). All the experiments were carried out with cells in passage zero to reach 
a situation as close as possible to the real one. 
From here on, when processing the sample, it was separated into two parts, MIT and PLQ. 
Division in these two parts was performed as Figure 9 shows. 
 
Figure 9. (A) Illustrative photo of a carotid endarterectomy specimen. Macroscopically intact tissue and 
atherosclerotic tissue is visualized on sample. (B) SMC in culture medium attached to the culture flask. 
4.1.2. Purity control 
We have done some/several control tests with the aim to confirm the purity of our SMC cultures 
and discard any contamination with another cell type (i.e. ECs and fibroblasts). 
Human carotid atherosclerotic plaque tissues obtained by carotid endarterectomy surgery were 
enzymatically digested and once cells were totally disaggregated from tissue, we routinely 
analyzed the presence of two specific markers of SMCs i.e., ACTA2 and TAGLN, together with 
that of endothelial cell marker PECAM-1 by flow cytometry in 39 PLQ-SMCs and 39 MIT-
SMCs. SMC suspension was 90% ACTA2+ and almost 100% of SMCs isolated from carotid 
tissue were TAGLN+, whereas endothelial cell marker PECAM-1 was nearly absent with just 
2% of cells expressing it, together indicative for SMCs cultures devoid of endothelial cells 
following cultivation in SMC-selective culture medium. Figure 10 shows an illustration of flow 




Figure 10. Flow cytometry graphs indicating staining of SMC and EC markers in SMC cultures. 
(A) panel shows ACTA2+ and TAGLN+ staining in culture SMCs. (B) panel demonstrates absence of 
PECAM-1+ staining in SMC population. (C) panel shows PECAM-1+ detection in U937 cell line as 
positive control. 
In addition to flow cytometry, quality control of pure SMC culture was also performed by 
identification of the presence of SMC-specific marker MYH11 by microscopy. Additionally, 
cells were stained with DAPI with the aim to detect MYH11 not-expressing cells. Figure 11A 
shows representative images of four cultures of SMCs isolated from carotid plaques with 
positive staining for MYH11, DAPI-stained nuclei and merged. The number of MYH11-
positive cells in our cultures was identified by comparing the total number of cells (DAPI-
stained nuclei) with the MYH11 positive stained cells (Figure 11B) and this revealed absence of 










Figure 11. Immunolocalization of MYH11 in primary carotid SMCs. (A) Representative confocal 
images of MYH11-positive cells (left panel), DAPI-stained cells (central panel) and merged (right panel). 
Magnification: the horizontal bars represent a scale of 250µm. (B) Quantification of MYH11-positive 
cells versus total number of cells (DAPI-stained nuclei). Data are mean ± SD. *p< 0.05.  
Then, we analyzed intracellular expression of SMC specific protein MYH11, ACTA2 and 
TAGLN, and endothelial specific protein PECAM-1. Western blot analysis showed that isolated 
SMC cultures all expressed SMC markers, while they were negative for endothelial marker 
PECAM-1 (Figure 11). Cell lysates from different cell lines showed in Figure 12A are part of 
the purity control of our SMC cultures. SMC markers are not expressed by cells that are not 
SMCs, since they are negative controls for SMCs and/or positive controls for EC marker. 
GAPDH was used as loading control as in Figure 12B, where a set of SMC cultures expressing 
ACTA2 and TAGLN proteins are shown. Figure 12C shows protein identification by western 
blot using α-ACTIN, α-MYH11 and α-PECAM1 antibodies in cell lysates extracted from all 
SMC cultures used for RNAseq analysis. Jurkat and U937 cell lysates were used as positive 
control of PECAM1 detection. There is a positive detection of PECAM1 and negative detection 
of MYH11 in Jurkat and U937 cells. 
 
Figure 12. Western blot detection of SMC markers in SMC cultures. (A) Detection of ACTA2, 
TAGLN and EC marker PECAM-1 in different cell lines. (B) Example of ACTA2 and TAGLN detection 
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in SMC cultures. GAPDH was used as loading control. (C) MYH11 and PECAM1 in our SMCs cultures. 
ACTIN was used as loading control. A: A549 cell line, H: HEK293T cell line, U: U937 cell line, J: Jurkat 
cell line. V: HIASMCs. 
CXCL9 and CXCL10 along with CD5L specific markers for macrophages were tested in the 14 
samples used for RNAseq analysis. CXCL9 is a chemotactic molecule for lymphocytes T and 
CXCL10 stimulates migration of monocytes, natural killers and T lymphocytes, while CD5L is 
a secreted molecule involved in lipid synthesis regulation [227–229] and has been shown to be 
expressed in foam cells induced by oxLDL [230]. As positive control for CXCL9, 10 and CD5L 
we used RNA extracted from monocytic cell line U937 induced with lipopolysaccharide (LPS: 
100 ng/ml) during 6 hours and CD14+ monocyte-derived DCs treated with LPS (100 ng/ml) for 
6 hours. 
RNA extracted from SMCs of Asympt and Sympt patients showed no expression of CXCL9, 
CXCL10 and CD5L. In contrast, carotid atheroma plaques, expected to contain macrophages, 
exhibited high expression of CXCL9, CXCL10 and CD5L, similar to positive controls including 
human LPS-induced DCs and LPS-induced U937 monocytic cell line (Figure 13). For these 
quality control analyses we routinely used passage 0–2 cell cultures. 
 
Figure 13. Gene expression quantification of macrophages markers CXCL9, CXCL10 and CD5L 
performed by qPCR using RNA extracted from: (i) SMCs from asymptomatic patients (average of 7 
samples); (ii) SMCs from symptomatic patients (average of 7 samples); (iii) atheroma plaque (average of 
3 samples); (iv) Monocyte cell line U937 treated with LPS; (v) CD14+ monocyte-derived dendritic cells 
treated with LPS. The analysis was performed using the ΔCt method and expressed as 2(−ΔCt). The 
statistical significance was calculated using the non-parametric Mann-Whitney U-test (one-tailed) and 
level of significance was defined at p < 0.05.  
4.1.3. SMC characterization 
SMC-Specific Gene Expression Pattern Shows Phenotypic Modulation in SMCs Isolated from 
Human Carotid Plaques. 
Gene expression levels of contractile and synthetic phenotype markers were analyzed in SMCs 
isolated from both the lesion and MIT areas of carotid atherosclerosis plaques. Although ACTA2 
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expression did not show any differences, MYH11, CALD1, and CNN1 appeared to be 
downregulated in the lesion area compared to the MIT area (Figure 14A). MYH11 displayed 
decreased expression levels (p-value= 0.03) in PLQ-SMCs compared to MIT-SMCs with a FC 
of -30.67, and similarly, CALD1 (p-value = 0.001) was decreased with an FC value of -10.59. In 
contrast, TAGLN, MYH10, and ICAM1 expression was similar between PLQ-SMCs and MIT-
SMCs (Figure 14A). The synthetic indicator SPP1 was upregulated in PLQ-SMCs (p-value = 
0.009). Furthermore, MAP1LC3B, which is related to phenotype switching by playing a role in 
contractile protein removal, was also significantly over-expressed in PLQ-SMCs vs. MIT-SMCs 
(p-value = 0.0181) (Figure 14A). 
Human iliac arterial smooth muscle cells (HIASMCs), from a healthy donor treated with 7-
ketocholesterol (7-KC), an oxysterol which is abundant in the plaque, were used to mimic the 
physiological environment to which SMCs are exposed during atherosclerosis development. 
HIASMCs showed also a marked decrease of contractile biomarkers when treated during 24 h 






Figure 14. SMC specific marker expression analyzed by quantitative PCR. (A) Fold change 
differences of contractile and synthetic marker expression in 39 plaque SMCs (PLQ-SMCs) versus 39 
macroscopically intact tissue area SMCs (MIT-SMCs) analyzed by quantitative PCR (error bars represent 
± SEM, n = 39). Data was normalized with GAPDH and RPL41. Wilcoxon matched-pairs signed rank test 
(p < 0.05 * and p < 0.01 **); (B) Fold change differences of contractile and synthetic marker expression 
in 7-KC treated (15 µM) HIASMCs versus not treated HIASMCs analyzed by quantitative PCR (error 
bars represent ± SEM, n = 3). Non-parametric Mann–Whitney U test was used (p < 0.05 *). 
Transcriptional regulatory pathways control the expression of SMC markers and are governed 
by the transcription factors SRF, MKL2, KLF4, and KLF5. SRF and MKL2 were both 
downregulated in PLQ-SMCs (Figure 14A). KLF4, which has been reported to suppress 
expression of SMCs markers, at least in part by disrupting SRF–myocardin interaction, showed 
higher levels of expression in PLQ-SMCs [199]. On the other hand, KLF5 expression, involved 
in phenotypic modulation, did not differ significantly between PLQ-SMCs and MIT-SMCS 
(Figure 14A) [184]. HIASMCs treated with 7-KC also showed a similar pattern of transcription 
factor expression levels as SMC isolated from carotid plaques (Figure 14B) with SRF 
diminished and KLF4 enhanced upon 7-KC treatment. 
In a recent study, we have found SMCs isolated from carotid atherosclerotic plaques to express 
a series of macrophage markers [231], concomitant with a macrophage-like phenotype [232]. 
Analysis of the expression levels of CD68 and LGALS3 showed that both macrophage markers 
were significantly augmented in PLQ compared to MIT-SMCs (Figure 14A). Similarly, when 
HIASMCs were treated with 7KC, both genes were clearly upregulated (Figure 14B). Thus, 




To verify that these differences in gene expression were not due to patient symptomatology 
caused by the plaque, we analyzed the gene expression data separately using either only 
symptomatic samples (20 PLQ-SMCS vs. 20MIT-SMCs) (Figure 15A) or only asymptomatic 
samples (19 PLQ-SMCS vs. 19 MIT-SMCs) (Figure 15B). As similar patterns of expression 
were observed in both cases, the differences in gene expression found (Figure 15A) are 




Figure 15. Fold change differences of contractile and synthetic markers in plaque SMCs (PLQ-
SMCs) versus macroscopically intact area SMCs (MIT-SMCs) analyzed by quantitative PCR. (A) 
20 PLQSMCs versus MIT-SMCs. (B) 19 PLQ-SMCs versus 19 MIT-SMCs (error bars represent ± SEM, 
n=20 Sympt and n=19 Asympt). Wilcoxon matched-pairs signed rank test (p<0.05*). 
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Then, we decided to analyze the gene expression pattern in atheroma PLQ-SMCs isolated from 
both Sympt and Asympt patients and compare between them. We found MYH11 and KLF5 to 
be significantly under-expressed in SMCs from Sympt patients compared with those from 
Asympt patients (p-value= 0.045 and p = 0.01 respectively, Table 6), while SPP1 was 
upregulated (p-value = 0.05). The rest of the genes analyzed were found to be statistically 
similarly expressed in Asympt and Sympt PLQ-SMCs. 
 
Table 6. Relative gene expression analysis between 20 Sympt and 19 Asympt SMCs. Gene expression 
was normalized with the housekeeping genes GAPDH and RPL41. Differences between the two groups 
were analyzed with Mann–Whitney U Test. p-value ≤ 0.05 was considered significant. (FC: fold change). 
The balance between the matrix accumulation and degradation determines plaque stability and 
for that reason we analyzed matrix metallopeptidase (MMP) 3, 7, 9 and TIMP1 expression 
levels in our SMC samples (Figure 16). Our results did not identify any significant association 
between gene expression of MMPs and type of SMCs, both Asympt/Sympt and MIT/PLQ. 
Therefore, MMP3, 7, 9 and TIMP1 do not emerge as differentially expressed in SMCs between 





Figure 16. MMP3, 7, 9, tissue inhibitor MMP 1 mRNA expression quantified by qPCR in SMCs. 
(A) PLQ-SMCs versus MIT-SMCs. (B) Sympt-SMCs versus Asympt-SMCs. Wilcoxon matched-pairs 
signed rank test was used (p<0.05 was considered statistically significant). (n.s. no significant). 
MYH11 Protein Level in SMCs from Sympt vs. Asympt Patients and from PLQ vs. MIT Region 
Due to the high differences in gene expression of MYH11 we wanted to analyze MYH11 at 
protein level in carotid atheroma plaque-derived SMCs. For that, we choose Western blot and 
immunoflourescence techniques to carry out the analysis. 
In immunoblot analysis, MYH11 levels were under-expressed both in PLQ-SMCs compared to 
MIT-SMCs (Figure 17A, panels a and b) and in SMCs coming from Sympt versus Asympt 





Figure 17. MYH11 protein detection by western blot and immunocytofluorescence. (A) MYH11 
protein expression in carotid atherosclerotic SMCs. (a,b) Western Blot of MYH11 protein in plaque or 
adjacent MIT area SMCs, and Asympt or Sympt plaque SMCs, respectively; (c,d) graphic representation 
of A and B show the average of densitometry values of the bands respect to GAPDH protein expression. 
(MIT: macroscopically intact tissue area SMCs; PLQ: plaque SMCs; ASYMPT: SMCs from 
asymptomatic plaques; SYMPT: SMCs from symptomatic plaques) (p < 0.05 * and p < 0.01 ** were 
considered statistically significant); (B) Immunofluorescence of carotid atherosclerotic SMCs with 
MYH11 and nuclei staining. (a) MIT-SMC myofilaments extend throughout the cell forming a network 
with weaker MYH11 staining in the cell periphery; (b) with 2.00 zoom focusing on the cell periphery 
where MYH11 staining appears as spots; (c,d) show MYH11 staining in MIT-SMCs (c image shows 
elongated and spindle-shaped cell; and d, flattened and polarized cell with lamellipodia); (e) PLQ-SMCs 




Immunocytofluorescence analysis with anti-MYH11 by confocal microscopy was performed in 
carotid SMCs with the aim to describe the contractile system. PLQ-SMCs and MIT-SMCs were 
labeled with anti-MYH11 and DAPI to identify nuclei. Individual myofilaments were not found 
to be parallel to the long axis of the cell but formed a network of filaments, and they appeared 
distributed in the cytoplasm in all single planes of the Z-stacks images, from the base (at the 
cover slip) to the top of the cell. Z-stack images showed homogeneous distribution of myosin 
filaments creating a thick fiber-mesh in the base of the cell; myosin-containing stress fibers 
extended as a network towards the periphery of the cell (Figure 17B, panel a), whereas fibers 
usually end in extending lamellae, and MYH11 appeared as continuous spots (Figure 17B, panel 
b) [233]. In the upper planes of Z-stacks there was predominant staining of MYH11 in the 
central region of the cytoplasm with weaker staining in the cell periphery, which could be 
observed in MIT-SMCs (Figure 18, upper panels), whereas there was lack of this pattern in 
PLQ-SMCs cells (Figure 18, lower panels). Additionally, in this study, we found that MIT cells 
showed a higher volume of myofilaments per cell area (Figure 17B, panels c and d) than those 
SMCs from the center of atheroma plaque (Figure 17B, panel e), which exhibit less 
fluorescence intensity of myosin staining. 
 
Figure 18. MYH11 staining in SMCs. A, B, C and D SMCs from adjacent site. 0,9 μm z-stacks from the 
base o the top of the cells. MYH11 staining appear in perinuclear region in the upper planes of the cell 
foring thick myofilaments. A’, B’, C’ and D’ SMCs from atheroma plaque. 0,9 μm z-stacks from the base 
to the top of the cells, where there is almost lack of MYH11staining and myofilaments appear as thin 
fibers. Scale bar 50μm. 
4.2. RNA-SEQ STUDY DESIGN 
The study was designed with maximum power to detect DEG and DEI, as well as to perform 
complementary functional enrichment and network analysis. The two main factors to take into 
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account in RNAseq transcriptomics studies are the number of replicates and the sequencing 
depth. Thus, RNA sequencing was performed with a depth to obtain around 60 millions reads 
per sample, which allowed us to reach reliable detection power of differential expression [234]. 
Sequencing at this depth would allow identifying differential expression with maximum power 
in 5 replicates, even of those genes with low expression [235]. Also, variability in RNAseq 
analysis is reduced when studying a specific cell type (i.e. SMC) compared with studying the 
full atheroma plaque, which is heterogeneous and composed of varying numbers of ECs, SMCs 
and macrophages. Accordingly, to study the role of SMCs in the development of unstable 
carotid atherosclerosis, we selected 14 plaque-derived SMCs from 7 Sympt and 7 Asympt 
patients. 
This RNA sequencing analysis was done based in the Illumina sequencing technology, which 
follows these steps (Figure 19): 
1. Cluster Generation: Sequencing templates are immobilized on a proprietary flow cell 
surface (Figure 1). RNA template molecules amplification (Figures 2–7). On the order 
of ten million single-molecule clusters per square centimeter are achieved. 
2. Sequencing by synthesis (SBS): This technology uses four fluorescently-labeled 
nucleotides to sequence the millions of clusters (Figures 8-12). Base calls are made 
directly from signal intensity measurements during each cycle. 
3. Data collection, processing, and analysis: Illumina data collection software enables to 

















Figure 19. Illumina Sequencing Technology 
4.2.1. Primary analysis 
Quality Control of produced sequences: 
The FASTQ file is the standard method recognized by the bioinformatic tools and any 
bioinformatic analysis should begin with it. A FASTQ file is a plain text file that contains the 
biological sequence and the qualities associated with each of the nucleotides of the sequence. 
Then, FastQC software is responsible to analyze the quality of raw data of the generated 
sequences. 
The quality control of FastQC includes de following tests: 
 Per base sequence quality: 
The quality per base is a statistic of the quality estimated in that base/position for all the 
sequences contained in the file FASTQ. Nucleotide sequences are inferring during sequencing 
reactions by fluorescently labeled terminators.  The fluorescence is captured by a camera that 
will process images into signals that are used to infer the order of nucleotides. Accuracy is 
typically measured by a Q score (Phred quality score), a common metric to assess the accuracy 
of a sequencing run. Q scores are defined as logarithmically related to base calling error 
probability: 




Q Score 10 - Base calling accuracy 1 in 10 - Probability of incorrect base 90% 
Q Score 20 - Base calling accuracy 1 in 100 - Probability of incorrect base 99% 
Q Score 30 - Base calling accuracy 1 in 1,000 - Probability of incorrect base 99.9% 
Q Score 40 - Base calling accuracy 1 in 10,000 - Probability of incorrect base 99.99% 
Q Score 50 - Base calling accuracy 1 in 100,000 - Probability of incorrect base 99.999% 
 
Figure 20. Overview of the range of quality values across all bases at each position in the FastQ file. 
The central red line is the median value. The yellow box represents the inter-quartile range (25-75%). The 
upper and lower whiskers represent the 10% and 90% points. The blue line represents the mean quality. 
The y-axis on the graph shows the quality scores. The background of the graph divides the y axis into 
very good quality calls (green), calls of reasonable quality (orange), and calls of poor quality (red). 
If a sequencing run is assigned a Q score of 40 (Figure 20), this is equal to the probability of an 
incorrect base call of 1 in 10,000 times, or 99.99% base calling accuracy. The higher is the score 
the better would be the base call. A lower Q score of 10 means, there is the probability of an 
incorrect call in 1 of 10 bases. Lower Q scores can lead to increases in false positive variant 
calls and reduces the overall confidence that an investigator has in their sequencing data. 
The quality per base on most platforms will decrease as the run progresses, so it is common to 
see quality falling at the end of a read in the 90 inter-quartile (Figure 20). 
61 
 
 Per tile sequence quality 
The graph allows you to look at the quality scores from each tile across all of your bases to see 
if there was a loss in quality associated with only one part of the flow cell. Flow cell is a surface 
to which more than 100 million strands of RNA per cm2 are adhered. 
 
Figure 21. Example of FastQC per title quality of one sample. 
The colours of this type of graph are on a cold to hot scale. Cold colours are positions where the 
quality was at or above the average for that base in the run, and hotter colours indicate that a tile 
had worse qualities than other tiles for that base. A good plot should be blue all over (Figure 
21). Therefore, in the example above, tiles show consistently high quality. 
 Per sequence quality score 
This quality control shows distribution of sequence quality. Allow seeing if any subset of 
sequences has low quality. As it can see in Figure 22 most of the sequences have a Q score of ≥ 




Figure 22. Example of per sequence quality control of one sample. X axis shows Q score while Y axis 
shows the number of reads. 
 Per base sequence content 
This quality control represents the proportion of the four bases in each position of different 
reads. Generally, it is expected that the four bases are equally represented and are seen together 
in the same line on the graph. It is assumed that up to 10% of difference between bases content 
can be found, while if the difference between A and T or G and C is above 10% will be 
necessary to filter the reads with the aim to remove these differences. A bias which is consistent 
across all bases either indicates that the original library was sequence biased, or that there was a 
systematic problem during the sequencing of the library. Strong biases which change in 
different bases usually indicates an overrepresented sequence which is contaminating the 
library.  
Figure 23 shows a homogeneous base content from position 1 4-15 over the reading, remaining 
below 10%. However, at the beginning of the reads the differences reach 20%. The reason is the 
use of random hexameric primers that induces biases in the composition of the nucleotide at the 




Figure 23. Per base sequence content of one sample. 
 Per sequence GC content 
This module measures the GC content across the whole length of each sequence in a file and 




Figure 24. Per sequence GC content quality control. Normal distribution of GC content in blue. Our 
sample GC content in red. 
In a normal random library it would expect to see a roughly normal distribution of GC content 
where the central peak corresponds to the overall GC content of the underlying genome. Since 
we do not know the GC content of the genome, the modal GC content is calculated from the 
observed data and used to build a reference distribution. Figure 24 shows GC content of one 
sample that do not match with theoretical one, with a little peak at 53% GC and another big one 
at 61% GC. 
 Per base N content 
It represents the indetermination of bases throughout the readings. During the sequencing, if a 
base is not identified, it is collected with an N in the reading, which also implies total loss of 
quality. The assemblers and aligners have to deal with this basic ambiguity problem. Some 
sequencers replace Ns with a random base, others put a fixed base; however, all this leads to 
false mapping. 
 
Figure 25. Per base N content FastQC quality control of one sample. Y axis shows read percentages 
that have Ns in their sequences. X axis shows the position of Ns into the sequences. 
If N content exceed the 5%, the sequences have to be manage with caution while if it is over 
20% an error will raise. In the case of Figure 25 no N content is demonstrated, which suggest a 
good quality sequencing for this sample. 
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 Sequence length distribution 
It represents the distribution of sequences based on their length. This high throughput sequencer 
generates sequence fragments of uniform length.  This module generates a graph showing the 
distribution of fragment sizes in the file which was analyzed. In this case, due to generated 
fragments are of uniform length, this will produce a simple graph showing a peak only at one 
size. 
In our experiments, the samples have a distribution whose length for the great majority of the 
sequences is 101 nucleotides as can be seen in the following Figure 26. 
 
Figure 26. Example of sequence length distribution graphic. 
 Sequence duplication level 
This module counts the degree of duplication for every sequence in the set and creates a plot 




Figure 27. Plot of sequence duplication level. This plot shows the proportion of reads in the library 
which arise from sequences which occur different numbers of times. The headline figure at the tops tells 
us that around 56.16% of reads would be lost if the library were to be deduplicated. Blue line indicates 
percentage of duplicates of total sequences generated in the library. The red line shows the percentage of 
duplicates would be left after deduplication. 
The big problem with identifying and removing technical duplication is that it is not possible to 
always assume that two reads falling at the same point are the result of technical duplication.  
When the overall read density in a region gets too high then it will start to see co-incidental 
duplication from different biological molecules. For regions with very high read density 
therefore a simplistic measurement of duplication will confuse high biological read depth with 
technical duplication. 
Although due to sequencing, errors, PCR amplification etc. we expected to obtain a set of 
unique fragments, we found a high percentage of duplicated sequences from >10 to 10K (Figure 
27). This can be due to in RNA-seq analysis the high expression of the transcripts appears as 
sequence duplication. In an RNA-seq sample the expected duplication level will change 
depending on whether a read comes from an exon, intron or intergenic region, and based on the 
expression level of the gene it is in.  Some regions will be enormously dense with reads, whilst 
others will be almost empty. Therefore, it is not recommended to remove duplicates 
(deduplication) if we are interested in doing a differential expression analysis since reads 
number has to be proportional to expression levels. 
 Overrepresented sequences 
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A normal high-throughput library will contain a diverse set of sequences. Finding that a single 
sequence is very overrepresented in the set either means that it is highly biologically significant, 
or indicates that the library is contaminated, or not as diverse as it was expected. 
For each overrepresented sequence the program will look for matches in a database of common 
contaminants and will report the best hit it finds. Hits must be at least 20bp in length and have 
no more than 1 mismatch. Finding a hit does not necessarily mean that this is the source of the 
contamination, but may point you in the right direction. It is also worth pointing out that many 
adapter sequences are very similar to each other so you may get a hit reported which is not 
technically correct, but which has very similar sequence to the actual match. 
This module lists all of the sequence which makes up more than 0.1% of the total reads (Table 
7). Only the first 50bp are considered. For RNA-Seq data it is possible that there may be some 
transcripts that are so abundant that they register as overrepresented sequence. 
SEQUENCE COUNT PERCENTAGE 
POSSIBLE 
SOURCE 
CCTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTGATG 160953 1.2110797852316633 No Hit 
CTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTGATGC 97509 0.7336997681196018 No Hit 
CAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCAG 80704  0.6072517007283875 No Hit 
GGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCAGCA 68878 0.5182677766005387 No Hit 
CTCAGACCGCGTTCTCTCCCTCTCACTCCCCAATACGGAGAGAAGAACGA 64058 0.4820000179081464 No Hit 
CTGGAGTCTTGGAAGCTTGACTACCCTACGTTCTCCTACAAATGGACCTT 49657 0.37364068327554445 No Hit 
CTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCAGCACG 44662 0.3360561491119553 No Hit 
GTTTCCGACCTGGGCCGGTTCACCCCTCCTTAGGCAACCTGGTGGTCCCC 44283 0.3332043896629062 No Hit 
CCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCA 43107 0.32435565849646364 No Hit 
CTCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATC 39411 0.29654536054478686 No Hit 
AGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCAGC 38389 0.2888553917929975 No Hit 
CTCCGTTTCCGACCTGGGCCGGTTCACCCCTCCTTAGGCAACCTGGTGGT 33420 0.2514664928422719 No Hit 
GCTCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGAT 32330 0.24326486276453171 No Hit 
GGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTGATGCCGAA 28181 0.21204599745027122 No Hit 
CACAAATTATGCAGTCGAGTTTCCCACATTTGGGGAAATCGCAGGGGTCA 27501 0.2069293841907636 No Hit 
CCCCACTACCACAAATTATGCAGTCGAGTTTCCCACATTTGGGGAAATCG 25441 0.1914290557869611 No Hit 
ATTCACAGGCGCGATCCCACTACTGATCAGCACGGGAGTTTTGACCTGCT 25133 0.18911153095765468 No Hit 
AGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTGATGCCGA 23267 0.17507094221906463 No Hit 
GCTATTCACAGGCGCGATCCCACTACTGATCAGCACGGGAGTTTTGACCT 23059 0.1735058605161564 No Hit 
CCCACTACCACAAATTATGCAGTCGAGTTTCCCACATTTGGGGAAATCGC 22093 0.16623725991515 No Hit 
CCCCTCCTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATAT 22068 0.16604914913355046 No Hit 
GTCTGTTCCAAGCTCCGGCAAAGGAGGCATCCGCCGGGCCCCTCCCCGAA 20066 0.1509852377430589 No Hit 
CCGTTTCCGACCTGGGCCGGTTCACCCCTCCTTAGGCAACCTGGTGGTCC 19859 0.14942768047141466 No Hit 
GCTCCGTTTCCGACCTGGGCCGGTTCACCCCTCCTTAGGCAACCTGGTGG 18866 0.1419559202262807 No Hit 
CCCTCCTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATT 18744 0.14103793961207492 No Hit 
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GCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACTGATCAGCAC 18500 0.13920197838366338 No Hit 
CCTCCTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTG 18418 0.13858497502001688 No Hit 
GTGTGGTTGGTGCGCGGACACGCACTGCCTGCGTAACTAGAGGGAGCTGA 17582 0.13229455048332808 No Hit 
GTTGCTCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCCACTACT 16695 0.12562037995217623 No Hit 
CCACAAATTATGCAGTCGAGTTTCCCACATTTGGGGAAATCGCAGGGGTC 16445 0.12373927213618077 No Hit 
CGCTATGTTGCCCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCC 15044 0.11319754393534227 No Hit 
GTCTGGAGTCTTGGAAGCTTGACTACCCTACGTTCTCCTACAAATGGACC 14212 0.1069372171237094 No Hit 
CGTTTCCGACCTGGGCCGGTTCACCCCTCCTTAGGCAACCTGGTGGTCCC 14086 0.10598913878444768 No Hit 
CTCCTTAGGCAACCTGGTGGTCCCCCGCTCCCGGGAGGTCACCATATTGA 13891 0.10452187468797125 No Hit 
GGCTATTCACAGGCGCGATCCCACTACTGATCAGCACGGGAGTTTTGACC 13795 0.10379952928662899 No Hit 
CTATTCACAGGCGCGATCCCACTACTGATCAGCACGGGAGTTTTGACCTG 13682 0.10294926855379904 No Hit 
CGCTATGTTGCTCAGGCTGGAGTGCAGTGGCTATTCACAGGCGCGATCCC 13457 0.10125627151940314 No Hit 
Table 7. Overrepresented sequences of one sample of RNA from SMCs. 
 Adapter content 
Sequencers such as Illumina use adapters for RNA organization in the flow-cell. These adapters 
are sequences of 7-9 nucleotides that must be filtered before the alignment phase. In this quality 
control only adapters specific to the library are searched. 
 
Figure 28. Graphic of adapter content of generated reads. 
As it can observe in above graphic (Figure 28), no adapters have been found in our samples. 
 Kmer content 
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Kmer content analysis is complementary to the overrepresented sequences, but in this case it 
tries to find duplicated sequences in short and poor quality reads. FastQC cut sequences in 7-
kmer fragments (7nt) and it proves their representation in all the sequences. Then, it shows the 6 






Figure 29. Kmer content. (A) Graphic representation of kmer content throught the reads. (B) 
Representative kmers found in the reads. 
4.2.2. Secondary analysis 
Mapping, identification and quantification of the reads: 
New reads were mapped to the last version of a reference genome, i.e. Homo sapiens, provided 
by Ensembl’s data base, hg19 (http://www.ensembl.org). The process was carried out by an 
algorithm from Tophat2 v2.1.0 that maps all the reads in a quickly way and aligns RNA-seq 
reads to large genomes. This program is highly recommended and widely used. 
In a complete transcriptome sequencing process, the number of mapped reads ranges from 75 to 




Table 8. Number of mapping reads (HQ reads), assembled reads per sample (properly pair) and 
splice reads. 
Normal- high values can be observed in the process of mapping the reads. Another interesting 
factor is the percentage of reads that give information about sites of "Splice Site", this type of 
information refers to the ability of the system to detect the nature of isoforms studied and 
splicing events. 
 Afterwards, poor quality reads of mapping were removed using Picard Tool 
(http://picard.sourceforge.net). This step is necessary to avoid inferences in the correct 
alignment of the reads to the reference genome. Therefore, only high quality reads were selected 
to carry out assembly and gene identification by Bayesian inference using an algorithm 
provided by Cufflinks v2.11. 
Gene quantification was done based on the method of htseq_count 0.6.1p1, while isoform 
expression and quantification was done by the method of Cufflinks. 
One important parameter that can condition the sequencing and mapping process is the GC 
content of the mappable reads. For this reason, GC content analysis as a quality control of the 
mapping process is essential. In this step, we assessed the GC distribution (i.e. the proportion of 
guanine and cytosine bp along the reads), which should have a desired distribution between 40–
60%. Second, distribution of duplicates (quality of sequencing indicator) was evaluated to 
confirm that our sequencing contained small proportion of duplicates. 
Figure 30 (left) shows expected distribution for each sample. If there is no statistical bias a 
normal distribution should be observed, centered on values of 45-55%. All samples presented 
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normal values in the distribution of GC content and the silhouette has a normal approximation 
(Gaussian distribution) (Figure 30, left). 
 
Figura 30. GC percentage distribution in mappable reads of one sample (left). Distribution of 
duplicates in a RNA-seq process of one sample (right). 
Duplication study in processes such as RNA-seq is an indicator of the quality of the sequencing 
process and is a clear indicator of degradation of biological starting material or important 
deviations in the sequencing. Figure 30 (right) shows expected distribution in a normal RNA-
seq process. It can be observed that a small number of reads has a high number of duplicates, 
while the great majority has a low or no number of duplicates, both in original and mapping 
reads. All the samples presented optimal distribution values of the duplicates. 
4.2.3. Tertiary analysis 
Gene expression analysis: 
There are numerous studies [236,237] that indicate the need to normalize the quantification data 
for the elimination of different statistical deviations that can distort the entire subsequent 
analysis. Due to the nature of RNA-seq sequencing, the deviations of greater weight are the 
length of the gene, the library size per sample and GC content among others. Normalization was 
performed using DESeq2 method to avoid such deviations [237]. Then, normalization allows 
eliminating or minimizing these effects of distortions. Figure 31 shows the distributions of 
isoform and gene quantification before and after normalization. It can observe the average 




Figure 31. (A) Distribution of gene quantification for each sample before (above) and after (below) 
normalization. X axis shows samples and Y axis number of quantification. Horizontal line into the boxes 
is the average and vertical continuous black line at the head of the graphic is deviation. C: control 
(Asympt-SMCs) and P: patient (Sympt-SMCs) (B) Distribution of isoform quantification for each sample 
after normalization. Case: Sympt-SMCs, Normal: Asympt-SMCs. 
Differentially expressed gene/isoform between two conditions requires a concordance between 
samples of the same condition and for that, a study is necessary for the acceptance of the 
different samples as biological replicates. Then, correlation and elucidation distance between 
samples study was carried out considering all the transcriptome normalized by the size of the 
library. This process was done using R statistical program [238] and can be observed in Figure 
32 in a Principal Component Analysis (PCA) graphs. PCA was performed on gene expression 
profiles using the method published before [239]. PCA identifies samples that can be considered 




Figure 32. PCA plot. Before (left) and after (right) outlier’s detection and removing. Outliers are 
enclosed by black circles. P: patient (Sympt-SMCs) and C: control (Asympt-SMCs). 
Figure 32 shows the detection of 2 outliers between our samples, one of each condition (Sympt 
and Asympt). Since PCA is based in variance values of analyzed data set and these two samples 
were far of their data set/condition, they were removed because is understand are not biological 
replicates and can distort subsequent differential expression results. 
Dispersion adjustment illustrates how much the variance deviates from the mean and this was 
used to shrink the final estimates from the gene-wise estimates towards the fitted estimates, 
which improves gene expression analysis. Figure 33B shows the dispersion adjustment of gene 
expression data, performed without the outliers. 
 
Figure 33. (A) MA plot of Asympt vs. Sympt SMCs. Log2 fold change is on the y-axis and the average 
of the counts normalized by size factor is shown on the x-axis. Each gene is represented with a dot. Genes 
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with an adjusted p-value below a threshold (0.1) are shown in red. Points which fell out of the window are 
plotted as open triangles pointing either up or down. (B) Dispersion adjustment based on the average of 
transcript expression. Empirical (black dots), fitted values representing the relationship between the 
dispersion and the normalized counts (red line), final estimates (blue) and dispersion outlier’s values with 
high gene-wise dispersion, which were not adjusted (blue circle). 
Study of differential expression of genes/isoforms between groups of samples was carried out 
with different statistical packages designed in Python and R. For the study of differential 
expression, the algorithm proposed by DESeq2 was used [240]. The package DESeq2 provides 
methods to test for differential expression using a Bayesian procedure to moderate (or “shrink”) 
log2 FC from genes with very low counts and highly variable counts. MA plot displays obtained 
gene expression levels by DESeq2 (Figure 33A) [222]. The DESeq2 package uses an MA 
plot for visual representation of genomic data. The plot visualizes the differences between 
measurements taken in two group of samples (Sympt and Asympt SMCs), by transforming the 
data onto M (log ratio) and A (mean average) scales, then plotting these values. 
A differentially expressed gene and isoform was considered to be one that has a Fold Change 
value of less than -1.5 or more than 1.5 and a p-value adjusted by FDR of 0.05 [7]. 
4.3. TRANSCRIPTOME SEQUENCING ANALYSIS 
4.3.1. DEG and DEI analysis 
In the differential expression analysis [222,240] we were able to identify 93 genes within the 
DEG analysis. A complete list of the 93 genes showing FC values ≥1.5 (over-expressed in 
Sympt vs. Asympt) and FC ≤ -1.5 (under-expressed in Sympt vs. Asympt) with p-value ≤0.05 
(67 with p-value (Padj) corrected by FDR ≤ 0.05) [223] can be found in Table 9. 
Gene ID Symbol FC Padj 
ENSG00000165507 C10orf10 1,94 0,0006 
ENSG00000152049 KCNE4 1,87 0,003 
ENSG00000117069 ST6GALNAC5 1,83 0,009 
ENSG00000135424 ITGA7 1,81 0,005 
ENSG00000128285 MCHR1 1,76 0,02 
ENSG00000174564 IL20RB 1,75 0,02 
ENSG00000163815 CLEC3B 1,75 0,02 
ENSG00000075643 MOCOS 1,75 0,001 
ENSG00000074410 CA12 1,72 0,0006 
ENSG00000174807 CD248 1,71 0,03 
ENSG00000133454 MYO18B 1,70 0,04 
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ENSG00000179542 SLITRK4 1,65 0,06* 
ENSG00000161570 CCL5 1,65 0,06* 
ENSG00000148948 LRRC4C 1,65 0,06* 
ENSG00000117289 TXNIP 1,64 0,04 
ENSG00000123689 G0S2 1,63 0,05 
ENSG00000162706 CADM3 1,63 0,07* 
ENSG00000120088 CRHR1 1,62 0,07* 
ENSG00000184557 SOCS3 1,61 0,03 
ENSG00000176438 SYNE3 1,60 0,05 
ENSG00000161958 FGF11 1,60 0,04 
ENSG00000234745 HLA-B 1,59 0,06* 
ENSG00000164236 ANKRD33B 1,59 0,09* 
ENSG00000170624 SGCD 1,57 0,08* 
ENSG00000259649 RP11-351M8.1 1,57 0,09* 
ENSG00000172201 ID4 1,55 0,09* 
ENSG00000119938 PPP1R3C 1,54 0,09* 
ENSG00000114268 PFKFB4 1,54 0,04 
ENSG00000110076 NRXN2 1,53 0,05 
ENSG00000136378 ADAMTS7 1,52 0,02 
ENSG00000152256 PDK1 1,52 0,03 
ENSG00000112837 TBX18 1,51 0,09* 
ENSG00000162733 DDR2 1,50 0,02 
ENSG00000179348 GATA2 -1,51 0,09* 
ENSG00000120693 SMAD9 -1,52 0,05 
ENSG00000164736 SOX17 -1,52 0,09* 
ENSG00000035664 DAPK2 -1,53 0,09* 
ENSG00000144730 IL17RD -1,54 0,01 
ENSG00000133216 EPHB2 -1,55 0,03 
ENSG00000166960 CCDC178 -1,55 0,09* 
ENSG00000120279 MYCT1 -1,57 0,05 
ENSG00000121039 RDH10 -1,57 0,06* 
ENSG00000183578 TNFAIP8L3 -1,58 0,09* 
ENSG00000145681 HAPLN1 -1,58 0,09* 
ENSG00000158125 XDH -1,59 0,09* 
ENSG00000139174 PRICKLE1 -1,59 0,08* 
ENSG00000182368 FAM27A -1,59 0,09* 
ENSG00000118137 APOA1 -1,60 0,07* 
ENSG00000169684 CHRNA5 -1,60 0,09* 
ENSG00000167644 C19orf33 -1,61 0,06* 
ENSG00000116106 EPHA4 -1,61 0,05 
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ENSG00000125968 ID1 -1,61 0,04 
ENSG00000123572 NRK -1,61 0,09* 
ENSG00000121361 KCNJ8 -1,63 0,07* 
ENSG00000091129 NRCAM -1,63 0,07* 
ENSG00000175746 C15orf54 -1,64 0,05 
ENSG00000172602 RND1 -1,64 0,04 
ENSG00000095752 IL11 -1,64 0,07* 
ENSG00000175866 BAIAP2 -1,65 0,01 
ENSG00000127329 PTPRB -1,65 0,06* 
ENSG00000144366 GULP1 -1,66 0,005 
ENSG00000143140 GJA5 -1,66 0,04 
ENSG00000176399 DMRTA1 -1,68 0,05 
ENSG00000168497 SDPR -1,68 0,02 
ENSG00000010319 SEMA3G -1,69 0,02 
ENSG00000254656 RTL1 -1,69 0,03 
ENSG00000178445 GLDC -1,69 0,02 
ENSG00000162496 DHRS3 -1,70 0,04 
ENSG00000102554 KLF5 -1,70 0,003 
ENSG00000172159 FRMD3 -1,70 0,04 
ENSG00000164283 ESM1 -1,71 0,03 
ENSG00000235109 ZSCAN31 -1,72 0,01 
ENSG00000132321 IQCA1 -1,72 0,02 
ENSG00000008394 MGST1 -1,72 0,002 
ENSG00000164530 PI16 -1,73 0,01 
ENSG00000150722 PPP1R1C -1,73 0,03 
ENSG00000116741 RGS2 -1,74 0,02 
ENSG00000180660 MAB21L1 -1,76 0,02 
ENSG00000155011 DKK2 -1,77 0,01 
ENSG00000126950 TMEM35 -1,81 0,02 
ENSG00000179104 TMTC2 -1,81 0,004 
ENSG00000118777 ABCG2 -1,85 0,01 
ENSG00000125848 FLRT3 -1,87 0,007 
ENSG00000108375 RNF43 -1,90 0,003 
ENSG00000125845 BMP2 -1,90 0,005 
ENSG00000138759 FRAS1 -1,90 0,005 
ENSG00000108556 CHRNE -1,91 0,005 
ENSG00000163273 NPPC -1,93 0,003 
ENSG00000162595 DIRAS3 -1,93 0,003 
ENSG00000109511 ANXA10 -1,93 0,003 
ENSG00000154645 CHODL -2,16 0,0003 
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ENSG00000138772 ANXA3 -2,23 0,0001 
ENSG00000087494 PTHLH -2,50 1,04E-07 
Table 9. Differential gene expression between S and A. Fold Change (FC) valued is obtained by 
DeSeq2 method and p adjusted value (Padj) was calculated using the FDR method. Significant Padj value 
was considered ≤0.05. *Genes showing a trend towards significance but without reaching it (Padj ≤ 0.09). 
Accurate isoform quantification remains a challenge due to high degree of overlapping between 
transcripts [241]. The variability in precision of isoform expression estimation across samples 
would be biased using traditional differential expression packages. For that reason, here we use 
the Bayesian approach Cufflink, which estimates transcript abundance based on how many 
reads support each transcript. DEI analysis identified 143 isoforms differently expressed 
between Sympt and Asympt SMCs. Table 10 illustrates the isoforms with a FC value below 
−1.5 or higher than 1.5 and with Padj ≤ 0.05. 
Isoform id Gene id Symbol FC P value Padj 
ENST00000358321 ENSG00000099994 SUSD2 11,61 5,00E-05 0,01 
ENST00000260227 ENSG00000137673 MMP7 9,25 5,00E-05 0,01 
ENST00000506608 ENSG00000185149 NPY2R 8,39 0,0002 0,04 
ENST00000264613 ENSG00000047457 CP 7,90 0,0002 0,04 
ENST00000374975 ENSG00000198502 HLA-DRB5 5,72 5,00E-05 0,01 
ENST00000477717 ENSG00000117069 ST6GALNAC5 4,84 5,00E-05 0,01 
ENST00000075322 ENSG00000136960 ENPP2 4,59 5,00E-05 0,01 
ENST00000296130 ENSG00000163815 CLEC3B 4,37 5,00E-05 0,01 
ENST00000394887 ENSG00000196616 ADH1B 4,07 5,00E-05 0,01 
ENST00000259486 ENSG00000136960 ENPP2 3,88 5,00E-05 0,01 
ENST00000013222 ENSG00000241644 INMT 3,84 5,00E-05 0,01 
ENST00000393078 ENSG00000196136 SERPINA3 3,57 5,00E-05 0,01 
ENST00000368125 ENSG00000162706 CADM3 3,53 0,00015 0,03 
ENST00000296506 ENSG00000164106 SCRG1 3,43 5,00E-05 0,01 
ENST00000256861 ENSG00000123243 ITIH5 3,42 0,00015 0,03 
ENST00000294728 ENSG00000162692 VCAM1 3,38 5,00E-05 0,01 
ENST00000274938 ENSG00000146197 SCUBE3 3,30 5,00E-05 0,01 
ENST00000167586 ENSG00000186847 KRT14 3,06 5,00E-05 0,01 
ENST00000374737 ENSG00000155659 VSIG4 3 0,00015 0,03 
ENST00000372330 ENSG00000100985 MMP9 2,82 5,00E-05 0,01 
ENST00000447544 ENSG00000135218 CD36 2,65 5,00E-05 0,01 
ENST00000298295 ENSG00000165507 C10orf10 2,50 5,00E-05 0,01 
ENST00000604125 ENSG00000152049 KCNE4 2,48 5,00E-05 0,01 
ENST00000542220 ENSG00000159403 C1R 2,42 5,00E-05 0,01 
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ENST00000553804 ENSG00000135424 ITGA7 2,38 5,00E-05 0,01 
ENST00000367662 ENSG00000116183 PAPPA2 2,34 0,00015 0,03 
ENST00000006053 ENSG00000006210 CX3CL1 2,29 5,00E-05 0,01 
ENST00000361673 ENSG00000198796 ALPK2 2,20 5,00E-05 0,01 
ENST00000437043 ENSG00000164308 ERAP2 2,18 0,0001 0,02 
ENST00000339732 ENSG00000131386 GALNT15 2,15 0,0002 0,04 
ENST00000284322 ENSG00000154175 ABI3BP 2,12 5,00E-05 0,01 
ENST00000261799 ENSG00000113721 PDGFRB 2,10 5,00E-05 0,01 
ENST00000369317 ENSG00000117289 TXNIP 2,07 5,00E-05 0,01 
ENST00000435422 ENSG00000170624 SGCD 2,06 5,00E-05 0,01 
ENST00000345517 ENSG00000163017 ACTG2 2 0,00015 0,03 
ENST00000257435 ENSG00000134986 NREP 1,99 5,00E-05 0,01 
ENST00000429713 ENSG00000172403 SYNPO2 1,99 5,00E-05 0,01 
ENST00000412585 ENSG00000234745 HLA-B 1,98 5,00E-05 0,01 
ENST00000307365 ENSG00000168209 DDIT4 1,96 5,00E-05 0,01 
ENST00000261326 ENSG00000075643 MOCOS 1,95 5,00E-05 0,01 
ENST00000178638 ENSG00000074410 CA12 1,94 5,00E-05 0,01 
ENST00000254722 ENSG00000132386 SERPINF1 1,93 5,00E-05 0,01 
ENST00000335174 ENSG00000186352 ANKRD37 1,90 0,0002 0,04 
ENST00000378700 ENSG00000172201 ID4 1,89 5,00E-05 0,01 
ENST00000294507 ENSG00000162511 LAPTM5 1,89 5,00E-05 0,01 
ENST00000540010 ENSG00000056558 TRAF1 1,89 5,00E-05 0,01 
ENST00000330871 ENSG00000184557 SOCS3 1,88 5,00E-05 0,01 
ENST00000344366 ENSG00000074410 CA12 1,87 5,00E-05 0,01 
ENST00000238994 ENSG00000119938 PPP1R3C 1,86 5,00E-05 0,01 
ENST00000217233 ENSG00000101255 TRIB3 1,84 5,00E-05 0,01 
ENST00000327299 ENSG00000162433 AK4 1,83 0,0002 0,04 
ENST00000328916 ENSG00000182326 C1S 1,79 0,0001 0,02 
ENST00000323076 ENSG00000136167 LCP1 1,76 5,00E-05 0,01 
ENST00000157600 ENSG00000071282 LMCD1 1,75 0,0001 0,02 
ENST00000297848 ENSG00000187955 COL14A1 1,73 5,00E-05 0,01 
ENST00000369663 ENSG00000112837 TBX18 1,73 5,00E-05 0,01 
ENST00000367288 ENSG00000163431 LMOD1 1,72 5,00E-05 0,01 
ENST00000338981 ENSG00000114374 USP9Y 1,70 5,00E-05 0,01 
ENST00000566620 ENSG00000140945 CDH13 1,68 5,00E-05 0,01 
ENST00000394308 ENSG00000070669 ASNS 1,65 0,0001 0,02 
ENST00000402744 ENSG00000109472 CPE 1,65 5,00E-05 0,01 
ENST00000367922 ENSG00000162733 DDR2 1,64 5,00E-05 0,01 
ENST00000220244 ENSG00000103888 KIAA1199 1,62 0,0002 0,04 
ENST00000380250 ENSG00000073910 FRY 1,58 0,00015 0,03 
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ENST00000409652 ENSG00000221963 APOL6 1,56 0,00015 0,03 
ENST00000396680 ENSG00000128272 ATF4 1,55 0,00015 0,03 
ENST00000372764 ENSG00000122861 PLAU 1,55 0,0001 0,02 
ENST00000375377 ENSG00000165757 KIAA1462 1,54 0,00015 0,03 
ENST00000263734 ENSG00000116016 EPAS1 1,53 5,00E-05 0,01 
ENST00000295992 ENSG00000163710 PCOLCE2 1,53 5,00E-05 0,01 
ENST00000376588 ENSG00000135069 PSAT1 1,53 0,0002 0,04 
ENST00000274276 ENSG00000145623 OSMR 1,50 0,0002 0,04 
ENST00000358432 ENSG00000142627 EPHA2 -1,50 5,00E-05 0,01 
ENST00000260630 ENSG00000138061 CYP1B1 -1,53 0,00015 0,03 
ENST00000229416 ENSG00000001084 GCLC -1,56 0,0002 0,04 
ENST00000367466 ENSG00000116711 PLA2G4A -1,56 0,0001 0,02 
ENST00000005257 ENSG00000006451 RALA -1,56 0,0001 0,02 
ENST00000245185 ENSG00000125148 MT2A -1,57 0,0001 0,02 
ENST00000361441 ENSG00000244509 APOBEC3C -1,58 0,0001 0,02 
ENST00000381434 ENSG00000137033 IL33 -1,62 0,0001 0,02 
ENST00000272542 ENSG00000144136 SLC20A1 -1,63 5,00E-05 0,01 
ENST00000371697 ENSG00000148677 ANKRD1 -1,64 0,00015 0,03 
ENST00000248598 ENSG00000127951 FGL2 -1,67 5,00E-05 0,01 
ENST00000315711 ENSG00000091972 CD200 -1,68 0,0002 0,04 
ENST00000222543 ENSG00000105825 TFPI2 -1,69 5,00E-05 0,01 
ENST00000237305 ENSG00000118515 SGK1 -1,72 5,00E-05 0,01 
ENST00000367468 ENSG00000073756 PTGS2 -1,77 5,00E-05 0,01 
ENST00000258888 ENSG00000136383 ALPK3 -1,78 5,00E-05 0,01 
ENST00000426693 ENSG00000164619 BMPER -1,81 0,0002 0,04 
ENST00000379375 ENSG00000078401 EDN1 -1,86 5,00E-05 0,01 
ENST00000276925 ENSG00000147883 CDKN2B -1,91 5,00E-05 0,01 
ENST00000377861 ENSG00000184226 PCDH9 -1,91 5,00E-05 0,01 
ENST00000265080 ENSG00000113319 RASGRF2 -1,91 5,00E-05 0,01 
ENST00000377103 ENSG00000178726 THBD -1,93 5,00E-05 0,01 
ENST00000376112 ENSG00000125968 ID1 -1,99 5,00E-05 0,01 
ENST00000252593 ENSG00000130303 BST2 -2,03 5,00E-05 0,01 
ENST00000396210 ENSG00000008394 MGST1 -2,04 5,00E-05 0,01 
ENST00000330688 ENSG00000077092 RARB -2,04 5,00E-05 0,01 
ENST00000310613 ENSG00000173597 SULT1B1 -2,09 0,0001 0,02 
ENST00000327536 ENSG00000183578 TNFAIP8L3 -2,09 5,00E-05 0,01 
ENST00000274341 ENSG00000145681 HAPLN1 -2,10 5,00E-05 0,01 
ENST00000304141 ENSG00000168497 SDPR -2,10 5,00E-05 0,01 
ENST00000262259 ENSG00000105497 ZNF175 -2,15 5,00E-05 0,01 
ENST00000306773 ENSG00000171246 NPTX1 -2,21 5,00E-05 0,01 
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ENST00000222482 ENSG00000128510 CPA4 -2,27 5,00E-05 0,01 
ENST00000377474 ENSG00000178695 KCTD12 -2,35 5,00E-05 0,01 
ENST00000321196 ENSG00000179104 TMTC2 -2,35 5,00E-05 0,01 
ENST00000315274 ENSG00000196611 MMP1 -2,40 0,00015 0,03 
ENST00000444842 ENSG00000082482 KCNK2 -2,43 5,00E-05 0,01 
ENST00000286614 ENSG00000156103 MMP16 -2,43 5,00E-05 0,01 
ENST00000376468 ENSG00000120937 NPPB -2,43 5,00E-05 0,01 
ENST00000235382 ENSG00000116741 RGS2 -2,45 5,00E-05 0,01 
ENST00000546561 ENSG00000127324 TSPAN8 -2,54 5,00E-05 0,01 
ENST00000541194 ENSG00000128567 PODXL -2,59 5,00E-05 0,01 
ENST00000247829 ENSG00000127324 TSPAN8 -2,59 5,00E-05 0,01 
ENST00000232892 ENSG00000114771 AADAC -2,69 5,00E-05 0,01 
ENST00000297785 ENSG00000165092 ALDH1A1 -2,72 5,00E-05 0,01 
ENST00000591504 ENSG00000166510 CCDC68 -2,74 5,00E-05 0,01 
ENST00000307407 ENSG00000169429 IL8 -2,82 5,00E-05 0,01 
ENST00000284136 ENSG00000153993 SEMA3D -2,85 5,00E-05 0,01 
ENST00000537928 ENSG00000128567 PODXL -2,86 0,0002 0,04 
ENST00000376223 ENSG00000162496 DHRS3 -2,87 5,00E-05 0,01 
ENST00000304195 ENSG00000172159 FRMD3 -3 0,00015 0,03 
ENST00000359299 ENSG00000109511 ANXA10 -3,13 5,00E-05 0,01 
ENST00000355754 ENSG00000162654 GBP4 -3,13 5,00E-05 0,01 
ENST00000372930 ENSG00000126950 TMEM35 -3,22 5,00E-05 0,01 
ENST00000296575 ENSG00000164161 HHIP -3,48 5,00E-05 0,01 
ENST00000326245 ENSG00000179914 ITLN1 -3,49 0,0001 0,02 
ENST00000299502 ENSG00000197632 SERPINB2 -3,50 5,00E-05 0,01 
ENST00000261292 ENSG00000101670 LIPG -3,65 5,00E-05 0,01 
ENST00000237612 ENSG00000118777 ABCG2 -3,81 5,00E-05 0,01 
ENST00000397463 ENSG00000150551 LYPD1 -3,98 5,00E-05 0,01 
ENST00000381405 ENSG00000164283 ESM1 -4,14 5,00E-05 0,01 
ENST00000295461 ENSG00000163293 NIPAL1 -4,22 5,00E-05 0,01 
ENST00000261405 ENSG00000110799 VWF -4,25 5,00E-05 0,01 
ENST00000378827 ENSG00000125845 BMP2 -4,27 5,00E-05 0,01 
ENST00000263174 ENSG00000099260 PALMD -4,36 5,00E-05 0,01 
ENST00000395201 ENSG00000162595 DIRAS3 -4,39 5,00E-05 0,01 
ENST00000271348 ENSG00000143140 GJA5 -4,86 5,00E-05 0,01 
ENST00000409852 ENSG00000163273 NPPC -4,93 5,00E-05 0,01 
ENST00000282849 ENSG00000140873 ADAMTS18 -6,48 5,00E-05 0,01 
ENST00000297316 ENSG00000164736 SOX17 -6,48 5,00E-05 0,01 
ENST00000373674 ENSG00000164530 PI16 -8,28 5,00E-05 0,01 
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Table 10. Analysis of differential isoform expression between S and A using Cufflinks method. FC 
values are obtained by DeSeq2 method and p adjusted value (Padj) was calculated applying the FDR. 
Significant Padj value was considered ≤0.05. 
Identified gene expression differences were also evaluated for gender differences since we had 
in our cohort only 2 women in Asympt and none in Sympt, and no effect of gender was found 
within the genes listed in Tables 9 and 10. 
4.3.2. Functional enrichment and network analysis 
Next, we performed functional and gene network analysis. Enrichment analysis allowing 
identification of combinations of significant annotations associated with the generated DEG and 
DEI lists was performed to identify functional relationships between the Sympt and Asympt 
samples. Bioconductor-based enrichment analysis using as databases GO, KEGG, reactome, 
DO (disease ontology), OMIM (Online Mendelian Inheritance in Man), and Cincinnati 
Children’s Hospital Medical centre [242–245], generated a list of annotation groups which are 
significantly different between Sympt and Asympt. Among genes included in Tables 8 and 9, 
genes are associated with: cell growth and senescence, bone metabolism, retinol metabolism, 
vascular disease, autophagy, immune system, muscle development/ contraction. Table 11 
illustrates all annotations that included between 2 and 27 genes per group and that showed a q-
value ≤ 0.05 generated from the DEG list, and Table 12 illustrates the most significant 
annotations generated from DEI list. 
While Bioconductor-based analysis allowed us to identify common functional categories for a 
cluster of genes, we next compared these categories between the gene clusters by 
implementation of the algorithm proposed by the tool ClusterProfiler [224]. This tool, which is 
used for gene cluster comparison (i.e. downregulated and upregulated genes in Sympt versus 
Asympt), allowed us to visualize biological categories compared between gene clusters. The 
identified functional profiles based on KEGG, GO, Reactome and DO are illustrated in Figure 
34A-B and Figure 35A-B. KEGG-based comparison (Figure 34A) is used to map RNAseq data 
for biological interpretation of higher-level systemic functions and identified TGF-β signalling 
pathway, axon guidance and cell adhesion molecules (CAMs) as those categories with higher 
GeneRatio number and lower Padj value. Retinol dehydrogenase activity was identified in GO-
based comparison, which defines functional gene classes and their relationships, as the category 
with the lowest Padj (Figure 34B). 
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Category ID Name q-value Hit Count Hit in Query List 




















































GO: Biological Process GO:2000726 Negative regulation of 
cardiac muscle cell 
differentiation 
1,18E-03 3 BMP2,PRICKLE1,PI16 




Drug D010100 Oxygen 1,76E-03 23 CA12,PPP1R3C,IL11,KCNE4,RND1,PTPRB,MCHR1,MGST
1,DHRS3,PDK1,NRK,G0S2,SOCS3,XDH,TMTC2,APOA1,F
GF11,CLEC3B,ABCG2,FLRT3,PFKFB4,FRMD3,HAPLN1 















GO: Biological Process GO:0007507 Heart development 2,23E-03 12 TBX18,BMP2,DHRS3,PRICKLE1,PI16,SGCD,KCNJ8,GAT
A2,SOX17,ID1,FLRT3,MYO18B 
Drug C024746 Tobacco tar 2,69E-03 8 FRAS1,NRCAM,PRICKLE1,GLDC,ANXA10,ESM1,DMRT
A1,RGS2 





GO: Biological Process GO:0048585 Negative regulation of 















Drug CID005282222 Xanthoxin 6,22E-03 3 DHRS3,SDPR,MOCOS 
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Drug C089730 Rosiglitazone 6,22E-03 20 PPP1R3C,BMP2,RND1,MGST1,DHRS3,PDK1,KLF5,ANXA
3,KCNJ8,G0S2,C10orf10,SLITRK4,SOCS3,ANXA10,RDH10
,ID1,ID4,XDH,CLEC3B,RGS2 




Gene Family ANXA Annexins 8,94E-03 2 ANXA3,ANXA10 
Gene Family IL Interleukins and 
interleukin receptors 
8,94E-03 3 IL11,IL20RB,IL17RD 




Drug CID000093003 6-chloropurine riboside 1,08E-02 3 ID1,XDH,MOCOS 














1,15E-02 2 DHRS3,RDH10 
GO: Molecular 
Function 
GO:0004745 Retinol dehydrogenase 
activity 
1,15E-02 3 BMP2,DHRS3,RDH10 
GO: Molecular 
Function 









GO:0005102 Receptor binding 1,15E-02 19 EPHB2,IL11,CADM3,BMP2,NPPC,RND1,MCHR1,HLA-
B,NRXN2,KCNJ8,ESM1,APOA1,FGF11,FLRT3,SEMA3G,IT
GA7,RNF43,PTHLH,EPHA4 
GO: Biological Process GO:0007413 Axonal fasciculation 1,21E-02 3 EPHB2,NRCAM,EPHA4 








GO: Biological Process GO:0055026 Negative regulation of 
cardiac muscle tissue 
development 
1,31E-02 3 BMP2,PRICKLE1,PI16 










GO:0030151 Molybdenum ion 
binding 
1,49E-02 2 XDH,MOCOS 
GO: Molecular 
Function 
GO:0045499 Chemorepellent activity 1,49E-02 3 APOA1,FLRT3,SEMA3G 
GO: Molecular 
Function 










GO: Biological Process GO:0009790 Embryo development 1,51E-02 15 EPHB2,TBX18,BMP2,FRAS1,PRICKLE1,NRK,SOCS3,RDH
10,GATA2,SOX17,APOA1,ABCG2,FLRT3,MYO18B,ITGA7 




























GO: Biological Process GO:0003308 Negative regulation of 
Wnt signaling pathway 
involved in heart 
development 
1,60E-02 2 BMP2,SOX17 







GO: Biological Process GO:2000725 Regulation of cardiac 
muscle cell 
differentiation 
1,61E-02 3 BMP2,PRICKLE1,PI16 
GO: Biological Process GO:0045669 Positive regulation of 
osteoblast 
differentiation 
1,61E-02 4 BMP2,NPPC,DDR2,ID4 
GO: Biological Process GO:0045667 Regulation of 
osteoblast 
differentiation 
1,61E-02 5 BMP2,NPPC,DDR2,ID1,ID4 
GO: Biological Process GO:0001525 Angiogenesis 1,61E-02 9 EPHB2,PTPRB,NRCAM,KLF5,ANXA3,GATA2,SOX17,ID1,
ESM1 






GO: Biological Process GO:0045995 Regulation of 
embryonic 
development 
1,67E-02 5 TBX18,NRK,GATA2,SOX17,APOA1 
GO: Biological Process GO:0035295 Tube development 1,68E-02 11 TBX18,BMP2,PRICKLE1,KLF5,RDH10,GATA2,SOX17,ID1
,PTHLH,EPHA4,SMAD9 
GO: Biological Process GO:0030178 Negative regulation of 
Wnt signaling pathway 
1,68E-02 6 TBX18,BMP2,PRICKLE1,SOX17,RNF43,DKK2 
GO: Biological Process GO:0048729 Tissue morphogenesis 1,73E-02 11 TBX18,BMP2,FRAS1,PRICKLE1,SOCS3,RDH10,SOX17,ID
4,FLRT3,PTHLH,EPHA4 
GO: Biological Process GO:0051154 Negative regulation of 
striated muscle cell 
differentiation 
1,79E-02 3 BMP2,PRICKLE1,PI16 




Drug D012822 Silicon dioxide 1,93E-02 21 IL11,BMP2,NPPC,FRAS1,PTPRB,PI16,KCNJ8,G0S2,SLITR
K4,SOCS3,XDH,ESM1,DMRTA1,CLEC3B,ABCG2,FLRT3,
SEMA3G,LRRC4C,RGS2,DIRAS3,HAPLN1 
GO: Biological Process GO:0048710 Regulation of astrocyte 
differentiation 
1,94E-02 3 BMP2,ID4,EPHA4 
Table 11. Molecular enrichment associations analysis on DEG performed with Bioconductor tool. Significant annotations with q-value ≤ 0.01 are shown. 
Category ID Name q-value Hit Count Hit in Query List 






































GO: Biological Process GO:0001525 Angiogenesis 1,04E-07 20 CYP1B1,NPPB,PDGFRB,ENPP2,SERPINF1,SOX17,ID1,ES
M1,PTGS2,EDN1,GJA5,HHIP,EPHA2,CD36,PLAU,BMPER,
MMP9,CX3CL1,EPAS1,CDH13 





















Figure 34. Comparative study between under-expressed and over-expressed genes using 
ClusterProfiler method. (A) Comparative analysis based on KEGG. (B) Comparative analysis based on 
Gene Ontology.  GeneRatio corresponds to the number of genes from a specific category. Enrichment 
term is represented by coloured dots (red indicates high enrichment and blue indicates low enrichment). 
Figure 35. Comparative study between under-expressed and overexpressed genes using 
ClusterProfiler method. (A) Comparative analysis based on Reactome. (B) Comparative analysis based 
on Disease Ontology. GeneRatio is the number of genes from a specific category. Enrichment term is 
represented by coloured dots (red indicates high enrichment and blue indicates low enrichment). 
In addition, functional interaction network analysis using several sources of information such as 
protein interaction, genomics, pathways, etc. was performed using the program called 
GeneMANIA (Gene Multiple Association Network Integration Algorithm) [246]. Figure 36 
shows the functional network of genes obtained by GeneMANIA including clusters related with 
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transforming growth factor beta (TFG-β) signalling, axon guidance, cell adhesion molecules and 
activin receptor-like kinase (ALK) 1 signalling. Subsequently, a further network analysis to 
identify a core network from the functional network generated with GeneMANIA was done 
with the method MCODE (Molecular Complex Detection) [247]. MCODE performs a network 
clustering step, which reduces the unconnected nodes in network clusters. Thus, the final cluster 
identified by MCODE was that with higher specificity and showed that the TGF-β, BMP and 
ALK1 signalling pathways arose as a functional process, which distinguish SMCs isolated from 
Sympt or Asympt carotid plaques. Also notable is the identification in this network clustering 
analysis of 3 downregulated genes/isoforms: bone morphogenetic protein 2 (BMP2; DEG: FC 
−1,9; Padj 0,004/DEI: FC-4,27; Padj 0,01), smad family member 9 (SMAD9; DEG: FC −1,51; Padj 
0,05) and inhibitor of DNA binding 1 (ID1; DEG: FC −1,61; Padj 0,03/DEI: FC-1,99; Padj 0,01). 
It was also found inhibitor of DNA binding 4 (ID4; DEG: FC 1,55; Padj 0,09/DEI: FC 1,89; Padj 







Figure 36. GeneMANIA network diagram. Red and green circles are query genes identified as upregulated and downregulated between Sympt and Asympt respectively by 





Figure 37. MCODE network clustering analysis. Illustration of the identified cluster by the network 
clustering algorithm MCODE showing the interaction between ID4, ID1, BMP2, SMAD9, TGF-beta 
signaling, BMP signalling and ALK1 signaling. The circles are genes and the rhomboids are protein 
domains. Green lines represent genetic interactions. Green circles indicate downregulated genes in Sympt 
vs. Asympt and the purple circle indicates upregulated gene in Sympt vs. Asympt. Blue lines represent 
pathways. Grey lines indicate gene-pathway associations. 
4.3.3. Effect of cell culture and passaging on gene expression 
Based on the found DEGs, we have analyzed these gene expressions during passage 0 and 1 
with the aim to verify that these DEGs are not an effect of SMC culture. 
Analysis of gene expression of SMC specific marker MYH11 in SMCs isolated after 3 hours of 
digestion or 16 hours showed no differences (Figure 38A). Furthermore, Figure 38B, C and D 
show no significant differences in gene expression of MYH11, BMP2, ID1 and ID4 genes in 





Figure 38. (A) Differential gene expression analysis of MYH11 in SMCs isolated after 3 and 16 hours of 
collagenase digestion and in SMCs from passage 0 and 1. (B) Differential gene expression of BMP2 in 
passage 0 vs passage 1. (C) Differential gene expression of ID4 in passage 0 vs passage 1. (D) 
Differential gene expression of ID1 in SMCs from passage 0 and passage 1. GAPDH was used as 
housekeeping gene for normalization. Figure shows a representative analysis of gene expression levels in 
two different SMCs samples in each condition with 4 performed replicates to illustrate quality control 
(MYH11). 
4.3.4. Confirmation of RNAseq identified biomarkers by digital PCR 
Forty-one of the identified DEG RNAseq genes were selected for replication in 13 of the 
RNAseq-analysed samples (1 sample was not available) and for further validation in an 
additional cohort of 11 independent samples (4Sympt and 7Asympt) by digital qPCR (dPCR). 
The replication by dPCR showed very similar results to those found by RNAseq (Table 12) with 
similar fold change directions (− or +) for 38 of these genes. Studies comparing RNAseq and 
qPCR data have indeed demonstrated very good correlation (Table 13) [248]. We could not 
detect 3 of the selected genes. In one case (CHODL, chondrolectin) this may have been due to 
very low expression levels seen in the RNAseq data, which were undetectable by digital dPCR. 
In the other two cases (SOCS3, suppressor of cytokine signaling 3 and TNFAIP8L3, TNF-α-
induced protein 8-like 3), where the expected expression levels should not have been low, 
technical issues relating to dPCR amplification and primer specificity may have been at stake. 
Combined analysis of the replication and validation datasets revealed significant fold changes 
coinciding with those of the original RNAseq with the exception of one gene (KCNE4, 
potassium voltage-gated channel subfamily E regulatory subunit 4; FC = 1.01). Thus, validation 
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of 37 out of 38 genes attests to the accuracy of the RNAseq data. In the gene expression analysis 
done with only the 11 additional samples, the majority of genes apart of two (HAPLN1, 
hyaluronan and proteoglycan link protein 1; and TBX18, T-box 18) showed similar fold change 
tendency. From those, 16 genes showed significant fold change differences, 7 genes showed 













 FC Padj FC p-value FC p-value FC p-value 
PTHLH -2,50 <0,0001 -1,32 0,001 -1,12 > 0,1 -1,23 0,006 
ANXA3 -2,23 <0,0001 1,08 0,02 -1,13 0,02 1,08 0,009 
NPPC -1,93 0,0038 -3,75 <0,0001 -10,16 0,0004 -4,54 <0,0001 
ANXA10 -1,93 0,0035 -2,61 <0,0001 -1,63 0,09 -2,06 0,0003 
DIRAS3 -1,93 0,0039 -2,80 0,0003 -1,29 0,08 -2,31 <0.0001 
BMP2 -1,90 0,0049 -2,42 0,005 -3,87 0,08 -3,70 0,0018 
ABCG2 -1,85 0,0104 -1,81 0,0008 -3,44 <0,0001 -2,09 <0,0001 
TMTC2 -1,81 0,0159 -2,04 <0,0001 -1,73 0.03 -2,08 <0,0001 
TMEM35 -1,81 0,0159 -2,37 0,03 -1,59 0,05 -2,13 0,0003 
RGS2 -1,74 0,0188 -2,42 <0,0001 -1,71 0,08 -2,07 0,0006 
ZSCAN31 -1,72 0,0107 -1,90 <0,0001 -1,82 0,03 -1,92 0,0001 
MGST1 -1,72 0,0010 -1,33 0,007 -1,29 0,09 -1,32 <0,007 
ESM1 -1,71 0,0329 -2,03 0,02 -1,99 0,05 -1,90 0,0017 
KLN5 -1,70 0,0031 -1,49 0,0003 -1,39 0,04 -1,51 <0,0001 
DHRS3 -1,70 0,0437 -2,96 <0,0001 -2,57 0,02 -3,14 <0,0001 
FRMD3 -1,70 0,0419 -1,67 0,005 -1,85 0,02 -1,75 0,0005 
ID1 -1,61 0,0368 -1,69 0,05 -5,01 0,009 -4,11 0,0008 
EPHA4 -1,61 0,0470 -1,69 0,0002 -1,39 >0,1 -1,59 0,0003 
HAPLN1 -1,58 0,0997 -2,16 0,0003 1,58 0,0038 -1,14 0,08 
RDH10 -1,57 0,0585 -1,60 0,0002 -1,17 >0,1 -1,50 0,0019 
EPHB2 -1,55 0,0278 -1,91 <0,0001 1,25 >0,1 -1,30 0,017 
IL17RD -1,54 0,0126 -1,28 0,01 -1,04 >0,1 -1,22 0,015 
SMAD9 -1,52 0,0548 -1,68 0,003 -1,20 >0,1 -1,45 0,01 
GULP1 -1,41 0,0471 -1,69 0,0003 -1,30 >0,1 -1,48 0,0032 
DDR2 1,50 0,0219 1,48 0,001 1,01 >0,1 1,32 0,017 
TBX18 1,51 0,0900 1,59 0,0003 -1,39 0,03 1,19 0,05 
ADAMTS7 1,52 0,0224 1,96 <0,0001 1,04 >0,1 1,32 0,0017 
PDK1 1,52 0,0339 1,71 <0,0001 1,17 >0,1 1,40 0,0002 
PFKFB4 1,54 0,0389 1,33 0,003 1,27 >0,1 1,13 0,02 
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ID4 1,55 0,0900 1,73 0,001 1,01 >0,1 1,47 0,0037 
SYNE3 1,60 0,0460 2,00 0,0019 1,01 >0,1 1,79 0,0067 
CA12 1,72 0,0006 1,53 0,001 1,27 0,03 1,47 0,0002 
MOCOS 1,75 0,0011 1,56 0,008 1,92 0,003 1,79 <0,0001 
ITGA7 1,81 0,0051 3,05 <0,0001 1,58 0,09 2,06 <0,0001 
ST6GALNAC5 1,83 0,0096 5,74 <0,0001 2,31 0,04 4,44 <0,0001 
KCNE4 1,87 0,0031 1,33 0,02 1,01 >0,1 1,19 >0,1 
MYO18B 1,70 0,0419 2,71 0,0002 1,06 >0,1 1,95 0,0021 
C10orf10 1,94 0,0006 2,64 <0,0001 1,02 0,06 1,62 0,011 
Table 13. Replication of 38 genes in RNAseq samples and validation in independent cohort. 
4.3.5. Inflammatory pathways in carotid atheroma SMCs 
Based on gene expression profiles disclosed by RNAseq SMCs actively participate in enhancing 
the characteristic inflammation of this disease and in this context, may also be causally involved 
in the rupture of the plaque (Table 9). Extensive purity controls were performed to confirm that 
SMC cultures were devoid of macrophages, lymphocytes and DCs based on the absence of 
CXCL9, CXCL10 and CD5L expression (Figure 13). This was supported post factum by absence 
or very low counts of CD3, CD19, CD57 and CD209 reads, characteristic of professional 
immune cells present in the plaque, in the SMC RNAseq profiles. ECs were also found not to 
contaminate SMC cultures given the absence of their marker PECAM-1 in the SMC cultures 
(Figure 12). 
RNAseq-Identified Highly Expressed Cytokines, Chemokines and TNF Superfamily Members in 
SMCs from Carotid Atherosclerosis Plaques 
Both SMCs from Asympt and Sympt patients expressed overlapping sets of cytokines that may 
promote further inflammation into the atherosclerotic carotid plaque. Among identified genes 
with differences in expression levels between Sympt and Asympt SMCs of carotid 
atherosclerotic plaque, can be found genes associated with immune system (Table 9). 
Enrichment analysis demonstrated that immune response function arose as an enriched category 
(p-value<0.01). 
We have focused in interleukin-mediated signaling (ILs, IL receptors, SOCS, JAK/STAT), 
chemotaxis molecules, leukocyte immunoglobulin-like receptors (LILRs) and TNF, IFN and 
NF-κB family members. The most active pathways relative to immune system appeared to be 
related to positive regulation of lymphocyte activation, especially T lymphocytes, cytokine 
production, cell proliferation, leukocyte and monocyte chemotaxis, apoptosis, TNF-α and NF-
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κβ signaling pathways and calcium ion import. The engagement of these pathways is correlated 
with the expression of molecules such as ILs, IL receptors, CCLs, TNF family members and 
signal transduction factors (Figure 38) that are expressed at high levels in carotid plaque SMCs 
(>1000 reads) and may function to maintain the inflammatory state within the atherosclerotic 
plaque. 
 
Figure 38. The most highly expressed cytokines & inflammation-related genes of human SMCs 
isolated from atherosclerotic plaques. Expressed in logarithmic scale based on the average number of 
reads obtained by RNAseq analysis (from 12 individual samples ± SEM). In the top of each bar in vertical 
appears the average Reads Nº for each gene. 
Interleukin-6 signal transducer (IL-6ST, also called gp130) is the common subunit of the IL-6 
receptor complex and appears to be the most expressed cytokine gene (Figure 38). The IL6-ST 
signaling pathway involves Janus kinase (JAK) 1, signal transducer and activator of 
transcription (STAT) 1 and 3 as well as its ligand IL-6, all of which feature among the highly 
expressed inflammatory SMC genes (Figure 38), while further ligands are less abundantly 
expressed e.g. IL-11 (Table 14), or not (OSM,oncostatin M; IL-27; IL-35) [249]. IL-6 receptor 
(IL-6R), which is a part of IL-6 receptor complex binding to IL-6, appeared also to be expressed 
by SMCs from human carotid atherosclerotic plaques, albeit at lower levels than IL6ST (Reads 
Nº ± SEM: 176 ± 18) (data not shown). IL6-ST/STAT3 signaling attenuation is driven by IL6-
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ST itself recruiting SOCS3 (discussed below) which promotes receptor signaling complex 
degradation [250]. 
In addition to IL-6 [251], TNFRSF12A (Figure 38), TNF receptor superfamily member 12A, is 
the receptor of TNF-like weak inducer of apoptosis (TWEAK) which upon binding is also able 
to induce CCL2 expression [252], which can be found with 2268 number of reads (logarithmic 
scale). 
Osteoprotegerin (OPG) is the protein encoded by the TNF receptor superfamily member 11b 
gene (TNFRSF11B) and, like IL6ST, is highly expressed by carotid plaque SMCs (Figure 38). It 
is a soluble member of the tumor necrosis factor receptor superfamily that regulates 
osteoclastogenesis and has been related to bone and mineral formation [253]. 
OPG can bind to TNF-related apoptosis-inducing ligand (TRAIL or TNFSF10 gene) which is a 
potent activator of apoptosis [254]. It seems that OPG and TRAIL may function to inhibit each 
other, thus, OPG blocks TRAIL-induced apoptosis and this latter one inhibits the OPG-induced 
inhibition of osteoclastogenesis [254]. Although TNFSF10 seems not to be expressed by carotid 
plaque SMCs at appreciable levels, another two receptors for TRAIL named TNFRSF10B 
(DR5: death receptor 5) and TNFRSF10D (DCR2: decoy receptor 2) are found to be among the 
most abundantly expressed inflammation-related genes by SMCs. The first one is able to induce 
apoptosis upon binding to TRAIL, the second, on the contrary, is a decoy receptor that blocks 
TRAIL before its binding to the membrane receptor thus protecting against TRAIL-mediated 
induction of apoptosis [255]. 
CXCL12 or stromal cell-derived factor 1 (SDF-1) is a member of the CXC chemokine family. 
This chemokine consists of various isoforms which are functionally indistinguishable and have 
been found to be involved in platelets aggregation in the initial steps of atherosclerosis 
development. Now, we can involve SMCs in platelets chemoattraction by CXCL12 expression 
(Figure 38) [256]. 
IL1R1 (Figure 38) and IL1RAP (Reads Nº ± SEM: 825 ± 60) are cytokine receptors whose 
ligands IL-1α (Reads Nº ± SEM: 20 ± 7) and IL-1β (Reads Nº ± SEM: 88 ±29) seem not or 
poorly expressed in SMCs. Another member of the IL-1 family, signaling through IL1RAP and 
IL1RL1, IL-33, is abundantly expressed (Figure 38). 
Carotid atherosclerosis SMCs show virtual absence of TNF-α production (Reads Nº ± SEM: 8 ± 
4), but TNFRSF1A, its receptor, appears to be highly expressed (Figure 38). Furthermore, two 
TNF-α-induced proteins (TNFAIP1 and 3) count as well among the highly expressed immune 
genes (Figure 38). These may participate in proteasome-mediated ubiquitin-dependent protein 
catabolic processes [257] or constitute an ubiquitin-editing enzyme containing both ubiquitin 
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ligase and deubiquitinase activities [258], respectively. TNFAIP3 can function as a blocking 
factor for IFN-β and IFN-γ signaling in SMCs through their corresponding receptors IFN alpha 
and beta subunit 1, 2 receptor complex (IFNAR1 and IFNRA2) and interferon gamma receptor 
1, 2 complex (IFNGR1 and IFNGR2), respectively (Figure 38). Both signaling pathways are 
active in atherosclerotic plaque SMCs and work through STAT1, which can be induced by IFN-
β. 
4.3.6. Cytokine and chemokine expression based on patient symptomatology 
A subset of 20 genes of cytokines, chemokines, cytokine receptors and associated factors 
showed significant differences in expression levels between Asympt and Sympt patients. The 
most significant were IL17RD, IL20RB and SOCS3, which retained significance at the 0.05 
level after p-value adjustment, followed by C-C motif chemokine ligand 5 (CCL5), IL11 and 













ENSG00000174564 IL20RB 1,75 0,0001 0,0248** 36 3 103 28 
ENSG00000161570 CCL5 1,65 0,0004 0,0585* 25 2 88 38 
ENSG00000184557 SOCS3 1,61 0,0001 0,0316** 619 95 1163 119 
ENSG00000115604 IL18R1 1,32 0,0519 0,4660 52 5 84 22 
ENSG00000157368 IL34 1,29 0,0757 0,5318 335 110 601 109 
ENSG00000006210 CX3CL1 1,28 0,0592 0,4878 141 23 327 143 
ENSG00000115594 IL1R1 1,28 0,0406 0,4286 3224 236 4466 743 
ENSG00000145779 TNFAIP8 1,27 0,0432 0,4377 382 33 521 84 
ENSG00000163735 CXCL5 1,27 0,0658 0,5091 41 10 97 45 
ENSG00000196083 IL1RAP 1,24 0,0274 0,3756 722 66 929 89 
ENSG00000171150 SOCS5 1,24 0,0388 0,4224 1800 105 2315 251 
ENSG00000027697 IFNGR1 1,19 0,0325 0,3979 1981 140 2389 127 
ENSG00000162434 JAK1 1,18 0,0058 0,2009 5645 219 6722 311 
ENSG00000159128 IFNGR2 1,16 0,0834 0,5513 2092 164 2455 139 
ENSG00000169429 CXCL8 -1,31 0,0374 0,4192 999 323 372 101 
ENSG00000115008 IL1A -1,36 0,0053 0,1917 36 15 5 3 
ENSG00000215788 TNFRSF25 -1,37 0,0264 0,3682 31 4 18 5 
ENSG00000144730 IL17RD -1,54 0,0000 0,0125** 138 5 83 9 
ENSG00000183578 TNFAIP8L3 -1,58 0,0011 0,0998* 368 58 177 32 
ENSG00000095752 IL11 -1,64 0,0005 0,0692* 117 20 46 11 
Table 14.  Differentially expressed immune-relevant genes in SMCs of carotid atherosclerotic 
plaques extracted from Asympt and Sympt patients. The gene expression levels in SMCs from Sympt 
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patients relative to Asympt are expressed by fold change. Only genes with p-value<0.1 have been 
selected. * means p-adjusted value<0.1 while ** is a p-adjusted value<0.05. Num. reads: Average number 
of transcript reads for each gene in Asympt versus Sympt patients (6 each). SEM: standard error of the 
mean. 
IL-17 receptor D (IL-17RD), an orphan receptor with no reported physiological role in IL-17 
signaling [259], arose as the gene with the most highly significant difference between A and S 
(Table 14), and no literature data are available on a putative role in atherosclerosis or vascular 
disease. The second most significant molecule is IL-20 receptor beta subunit (IL-20RB). This 
one functions heterodimerized with IL-20RA for signaling by IL-19, -20 and -24, and can, in 
addition, also pair with IL22-RA1 to bind IL-20 and IL-24 [260]. IL20-RA and IL22-RA1 
appeared not to be, or at very low levels (Reads Nº ± SEM for IL20-RA: 3 ± 0.7; for IL-22RA1: 
4 ± 0.9), expressed in SMCs; however, IL20RB was expressed at significantly higher level in 
SMCs coming from symptomatic atherosclerotic plaques (Table 14). 
SOCS3 is a negative regulator of the Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) signaling pathway that induces the expression of inflammatory genes 
that regulate key atherosclerotic processes, such as leukocyte recruitment, migration and 
proliferation of vascular SMCs, apoptosis and foam cell formation [261]. 
Expression of SOCS3 leads to the inhibition of signaling of a wide range of cytokines, 
hormones and growth factors by blocking the signal transduction through their receptors 
[262,263]. SMCs from atherosclerotic plaques express multiple target receptors for SOCS3 such 
as leukemia inhibitory factor receptor (LIFR), oncostatin M receptor (OSMR), IL-4R, IFNGR-
1/2, IFNAR1/2, insulin-like growth factor 1 receptor (IGF1R), leptin receptor (LEPR), growth 
hormone receptor (GHR), erythropoietin receptor (EPOR) and IL-12 receptor β 2 (IL-12Rβ2). 
All of these are associated to some of the STAT1, 2, 3, 4 and 6 through which they mediate 
signaling. 
IL-11 belongs to the IL-6 cytokine family and is one of the cytokines that signals through the 
common signal transducing subunit IL-6ST [264]. IL11 appeared more abundantly expressed in 
SMCs from Asympt patient carotid atherosclerotic plaques (Table 14). 
Our RNAseq study provide additional support showing that chemokines such as CCL5 are 
expressed in SMCs coming from atherosclerotic plaques, which, moreover, appears to be over-
expressed in Sympt patients compared to Asympt (Table 14). Expression of the chemokine 
CCL5 can be induced by TNF-α, rather than IL-6, through TNFR1 (TNFRSF1A) and posterior 
JAK2 activation and STAT3 phosphorylation, culminating in CCL5 transcription in mice 
vascular SMCs [265]. This CCL5 exerts its function through the receptors C-C motif chemokine 
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receptor (CCR) 1, 3 and 5, of which only CCR1 appeared to be highly expressed by SMCs 
(Reads Nº ± SEM: CCR1: 246 ± 64; CCR3: 0 ± 0; CCR5: 25 ± 9) [265,266]. 
The TIPE (tumor necrosis factor-α-induced protein 8-like, or TNFAIP8L) family comprises 
regulators of immunity and tumorigenesis and is composed of TNFAIP8 (TIPE0), TNFAIP8L1 
(TIPE1), TNFAIP8L2 (TIPE2) and TNFAIP8L3 (TIPE3). This family is involved in signaling 
pathways of chemotaxis, inflammation, tumorigenicity and wound healing [267]. TNFAIP8L3 
showed higher expression in SMCs from Asympt plaques. It is the most recently discovered 
TIPE family member and still awaits functional characterization. 
5. DISCUSSION 
5.1. ATHEROMA PLAQUE SMC CHARACTERIZATION 
SMCs keep their plasticity and can undergo cellular modulation from contractile to synthetic-
state or reverse the phenotype toward the contractile stage in response to changes in local 
environmental cues [173]. Upon injury in atherosclerosis, when remodeling is required, SMCs 
are able to switch between distinct phenotypes with a trend towards increased rates of 
proliferation and migration accompanied by enhanced extracellular matrix component 
production. Also, calcification or release of inflammatory signals is coordinated with a decrease 
in SMC contractile markers [175]. This study has documented the expression patterns of 
relevant genes associated with phenotypic modulation in SMCs by comparing carotid 
atherosclerotic lesions with macroscopically intact regions located within the surgically excised 
carotid artery areas. In addition, the SMCs’ expression pattern was compared between those 
from symptomatic versus asymptomatic to evaluate if any changes were associated with 
symptomatology or plaque rupture. 
The contractile function of SMCs is achieved by expression of a unique repertoire of proteins 
such as ACTA2, MYH11, CALD1, and SM22α/TAGLN [196]. Myocardin binds to the globally 
expressed transcription factor SRF, and this complex regulates the expression of these SMC-
specific markers. SMC contractile specific genes contain a functional CArG box in their 
promoter region, to which the myocardin–SRF complex binds in order to promote SMC gene 
expression. SMCs express MKL2, which is a transcriptional co-factor for SMC-specific genes 
[268].The expression of transcription factor MKL2, and moreover SRF, were decreased in PLQ-
SMCs compared to MIT-SMCs. This result suggests that cells present in damaged areas have 
gone through a phenotypic modulation possibly regulated by the SRF transcriptional pathway 
[199].  Furthermore, KLF4 is a member of a large family of zinc finger-containing DNA-
binding transcription factors and is known to regulate the expression of SMC markers [269] 
since it is a repressor of SRF/myocardin [270]. Krüppel-like factors have been identified as 
105 
 
atheroprotective factors [271] and KFL4, specifically, has been identified as a critical marker 
that regulates SMC phenotypic transition inhibiting expression of contractile genes. Contrary to 
this, it has also been suggested to play a proatherogenic role due to its involvement in inhibiting 
the cell proliferation cycle. KFL4 expression is very low under basal conditions; however, 
injury promotes its expression in vascular tissues [272]. This evidence supports our observation 
that KLF4 is upregulated in PLQ-SMCs, suggesting that de-differentiated SMCs are mainly 
restricted to the area of the lesion, while MIT-SMCs seem to remain predominantly contractile.  
In this study, we found that carotid PLQ-SMCs showed a decreased expression of specific 
contractile phenotype markers MYH11 (protein and mRNA level) and CALD1 (mRNA level) 
compared to MIT-SMCs. MYH11 has been identified as a marker for specific SMC lineage 
[175,273] and is a late marker during development, expressed only in fully differentiated cells 
and showing a high degree of specificity for contractile phenotype SMCs [274]. In addition, 
data obtained from HIASMCs from a healthy donor treated with 7KC, one of the major 
components of oxidized lipoproteins in atheroma plaques, indicates that healthy SMCs under 
these conditions proceed towards a de-differentiation process. Furthermore, decreased levels of 
SMC contractile markers have been reported before in atherosclerosis [175]. Thus, our results 
suggest that PLQ-SMCs might have a decreased contractile capacity. 
We demonstrated that carotid SMCs from PLQ and MIT were positive for MYH11 protein 
staining by immunofluorescence microscopy and that PLQ-SMCs showed a lower volume of 
myofilaments per cell area with lower fluorescence intensity of the protein, in line with the 
results of a previous work in which significantly reduced MYH11 protein staining was observed 
in switched SMCs coming from atherosclerotic carotids [275]. In addition, Song and coworkers 
[276] suggested that myofilament disassembly, especially in the upper cortex, could reflect 
SMC phenotypic  modulation, contractile components degradation, and reorganization of 
contractile and cytoskeletal proteins within the cell [182]. Similarly, our analysis performed by 
z-stack to observe the whole thickness of cells showed that staining of MYH11 was 
predominant in the central region of the cytoplasm in the upper planes of the MIT-SMCs, unlike 
PLQ-SMCs that displayed less prominent myosin staining in the perinuclear area, in which 
myofilaments appeared to be disassembled, such Saltis et al. [277] reported before. Therefore, 
immunofluorescence microscopy shows that MYH11 in MIT-SMCs forms strong myofilament 
bundles, whereas they appear as thin and disassembled fibers in PLQ-SMCs, which is 
characteristic of phenotype modulation in SMCs. 
We have also found increased levels of CD68, LGALS3, and SPP1, together with the reduced 
expression of contractile proteins in PLQ-SMCs compared to SMCs from MIT area, suggesting 
that PLQ-SMCs may have undergone a phenotypic alteration towards a macrophage-like cell to 
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adapt to such changes. This is consistent with results reported before [205,278], demonstrating 
that SMCs have the potential to become macrophage-like cells with a capacity to migrate and to 
display phagocytic behavior to digest excessive material present at the lesion site. In line with 
this notion, we have also analyzed the expression of the autophagy marker MAP1LC3B, which 
is known to be important in the de-differentiation of SMCs through removing contractile 
proteins by autophagy [279] and in carotid plaque stability [280]. Interestingly, PLQ-SMCs 
showed higher expression of MAP1LC3B than MIT-SMCs. HIASMCs treated with 7KC also 
exhibited increased autophagy marker MAP1LC3B expression alongside augmentation of CD68 
and LGALS3. Thus, similarly to what was reported for mouse SMCs and human coronary SMCs 
[281], in our study, HIASMCs loaded with cholesterol may initiate conversion towards foam-
type cells as indicated by their loss of SMC features and their acquisition of macrophage-type 
characteristics. SMC-derived macrophage cells not only make a significant contribution to 
plaque volume and necrotic core formation but also suppress plaque stability and promote 
plaque instability [282]. 
In addition, with the aim to explore any potential correlation between SMC phenotypes and 
patient symptomatology, we have analyzed these contractile markers in SMCs from 
symptomatic and asymptomatic plaques. Interestingly, plaques showed a similar expression 
pattern of PLQ vs. MIT for MYH11 expression, i.e., reduced expression at mRNA and protein 
level in SMCs coming from symptomatic plaques compared to asymptomatic plaques. This 
suggests that SMCs from symptomatic plaques may have suffered a phenotypic modulation, 
while SMCs from asymptomatic plaques retain the contractile capacity associated with MYH11 
expression [175]. 
5.2. SMC TRANSCRIPTOMIC ANALYSIS 
RNAseq technologies have been used as promising means for biomarker identification in 
several diseases lately [283,284]. Since its discovery around 10 years ago, RNAseq has become 
an innovative tool for transcriptomics [285]. Stroke is a heterogeneous disease and the use of 
combination of biomarkers included in panels may enhance sensitivity and specificity of the 
applicability of biomarkers [286]. In this study, RNAseq based transcriptomic data was 
generated from RNA extracted from SMCs isolated from carotid atheroma plaques from 7 
Asympt and 7 Sympt patients with the aim of identifying candidate genes and pathways that 
could discriminate the two groups studied, Sympt and Asympt. We identified genes/transcripts 
candidates for panel/s, which have a potential to classify these two studied groups (Asympt and 
Sympt) (Tables 9 and 10). 
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TGF-β signaling was identified in this study as a crucial pathway in symptomatology of carotid 
atherosclerosis at the vascular smooth muscle cell level. TGF-β signaling emerged initially in 
the functional enrichment analysis performed (Figure 34A) and the subsequent MCODE 
network clustering also identified TFG-β signaling but together with BMP and ALK1 signaling 
with highly interacting nodes (Figure 37). TGF-β superfamily members are involved in several 
processes including cell proliferation, migration, extracellular matrix production, bone 
morphogenesis, etc. and can be classified into two groups: TGF-β/activin/nodal and 
BMP/growth differentiation factors (GDFs) [287]. BMP proteins have multiple functions that 
are associated with growth, differentiation and cell death during embryonic development 
[288]. Some BMPs proteins have osteogenic activity capacity, in fact, BMPs are the active 
proteins responsible for ectopic bone formation [289]; in particular BMP2, which belongs to the 
BMPs that play a role in ossification [290]. It has been reported that BMP2 inhibits SMCs cell 
growth and migration, promoting a contractile phenotype [291], which is observed in normal 
vessels. High levels of BMP2 in blood have been recently associated with plaque progression 
and calcification in coronary atherosclerosis [292]. We found significantly lower levels of 
expression of BMP2 in our symptomatic SMCs compared with asymptomatic, which is 
indicative for a beneficial role of BMP2 in atheroma plaque stability both by contributing to the 
stabilization through bone morphogenesis and by promoting a protective phenotype, which may 
be called an osteogenic phenotype. BMP2 plays a role in ALK1 signaling, in which ALK1 is a 
type I receptor of TGF-β that is regulated by BMP2 expression in vascular cells enhancing 
expression of SMC lineage markers [293]. 
TGF- β pathway can directly transduce extracellular cues from the cell-surface transmembrane 
receptors to the nucleus through intracellular mediators, known as Smads (R-Smad, Co-Smad, I-
Smads). Smads accumulate in the nucleus and elicit transcriptional responses to alter gene 
expression [294]. The subfamily of Smads called R-Smads includes several proteins of which 
some are involved in the BMP signaling branch (i.e. Smad1, Smad5 and Smad9) [295]. 
Particularly, increased transcription of SMAD9 has been found in response to stimulation with 
BMP [288]. Thus, BMP-activated SMAD9 gene [294] has found to be expressed at lower levels 
in Sympt than in Asympt SMCs, as BMP2 (Tables 9 and 10). 
BMP proteins are also related to Id genes (Inhibitors of differentiation: ID1, ID2, ID3 and ID4), 
since they are major downstream transcriptional targets of BMP signaling [296]. In particular, 
ID1, ID2 and ID3 genes have been identified as early response genes in BMP signaling that are 
required for Smad protein binding to DNA [288]. BMPs induce Id gene expression in vascular 
smooth muscle cells. Besides BMPs, growth and differentiation factor 5 (GDF5) and TGF-β 
also regulate the expression of Id proteins [297]. In mammals, four Id proteins partially overlap 
in their profiles of expression and display some functional redundancy in vivo [298]. These 
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proteins have been associated with regulation of several cellular processes such as cell growth, 
senescence, angiogenesis and apoptosis. Interestingly, BMP2 induced the expression of ID1 in 
the mouse myoblast cell line C2C12 [289] and upregulation of the ID1 gene is known to delay 
senescence in endothelial cells [299,300]. Similarly to endothelial cells, our results suggest that 
ID1 expression in SMCs may be exhibiting a role as anti-senescence factor due to high 
expression in Asympt SMCs. Senescence of vascular SMCs involve inhibition of cell cycle, 
then, SMCs in the fibrous cap may contribute significantly to inefficient plaque repair and also 
overexpress genes that directly promote plaque instability including adhesion molecules, 
regulators of haemostasis and MMPs, which may be associated with plaque stability [301]. 
While ID1, 2 and 3 are expressed in multiple tissues, ID4 has been reported to be expressed in 
neuronal tissues and intestinal embryonic epithelium [297,302]. Although ID4 is expressed at a 
much lower level in the vascular wall than the other three Id proteins [302], we found that ID4 
expression levels in all our SMCs samples were not lower but even higher than the other Id 
genes. Also upon comparison of ID4 levels between Sympt and Asympt, we found that ID4 
expression was higher in symptomatic SMC samples. This is also consistent with the 
observation that over-expression of ID4 in astrocyte-derive cell line induces apoptotic cell death 
[303], suggestive for senescence-like phenotype. Thus, based in this hypothesis we can also 
suggest that Sympt cells may also be in a senescence phenotype. 
Other genes identified in our differential expression analysis include those related to bone 
mineralization matter, such as carbonic anhydrase 12 (CA12), parathyroid hormone-like 
hormone (PTHLH) and natriuretic peptide C (NPPC). CA12 showed higher expression in SMCs 
from Sympt vs. Asympt (FC 1,72; Padj = 0,0006) in our study and although during initial phase 
of atherosclerosis bone resorption could be beneficial [304], in later stages, such as in advanced 
plaques from symptomatic patients, bone resorption may affect the plaque destabilization 
process. Conversely, PTHLH was found to be downregulated in SMCs from Sympt vs. Asympt 
(FC −2,5; Padj = 0,0000). PTHLH has been shown to increase bone formation and decrease bone 
resorption [305]. Similarly, NPPC (FC −1,93; Padj = 0,0038) was found to be downregulated in 
Sympt vs. Asympt and is as well considered a positive regulator of bone formation [306]. Thus, 
this finding may reinforce our hypothesis that SMCs from Asympt benefit from bone 
mineralization processes. 
In summary, taken together our gene expression profiling data and combined analysis, SMCs 
isolated from asymptomatic patients may exhibit a calcified/osteogenic-like phenotype, while 
SMCs from symptomatic patients exhibit a senescence-like phenotype. 
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5.3. CYTOKINE PATHWAYS UNEARTHED BY RNASEQ IN CAROTID ATHEROMA 
SMOOTH MUSCLE CELLS 
Although the main producers of cytokines are helper T cells (Th) and macrophages [307], 
activated SMCs were already known to produce many cytokines in atherosclerotic plaques 
[308]. This study adds now new candidates not identified before in this context, and provides 
the genome-wide quantitative expression profiles of cytokine and associated transcripts in 
SMCs coming from atherosclerotic carotid plaques. Both SMCs from Asympt and Sympt 
patients expressed overlapping sets of cytokines that may promote further inflammation into the 
atherosclerotic carotid plaque. 
Based on identified cytokines (Figure 38), the most active pathways identified in SMCs of 
atherosclerotic plaques involves the IL-6ST. IL-6 is considered one of the most highly 
expressed mediators of inflammation and orchestrates chemokine-directed leukocyte trafficking 
and transition from innate to adaptive immunity through regulation of leukocyte activation, 
differentiation and proliferation [309]. It exerts its function through binding to the IL-6ST and 
IL-6R complex, and while IL-6ST displays a more ubiquitous expression, that of IL-6 receptor 
(IL-6R) is highly restricted to hepatocytes, leukocyte subsets and megakaryocytes [310]. 
IL6R appeared to be expressed by SMCs from human carotid atherosclerotic plaques, albeit at 
lower levels than IL6ST (Reads Nº ± SEM: 176 ± 18), which may suggest that SMCs are 
participating in plaque inflammation at least via IL6-IL6R-IL-6ST. Normal human vascular 
SMCs express scant amounts of IL6ST-encoded gp130, however, its high expression by SMCs 
of atherosclerotic plaque may be consequential to activation by “trans-signalling” IL-6/sIL-6R 
(soluble IL-6R) complexes leading to upregulation of IL6ST mRNA and IL-6 secretion. These 
triggering IL-6/sIL-6R complexes are likely to be produced by infiltrating T lymphocytes and 
monocytes. Consequential to these multiple effects of IL-6, a positive regulation of IL-6 
production will be developed by creating an autocrine loop through which SMCs will acquire a 
proinflammatory state [251]. 
Furthermore, among the most expressed inflammatory genes we found many molecules 
associated with IL-6 signaling pathway. For instance, IL-6 signaling through IL6-R/IL-6ST 
induces a massive and rather selective expression of CCL2 in SMCs [251] through STAT3 and 
protein coding IκBζ of NFKB inhibitor zeta (NFKBIZ) gene (Figure 38) [311]. This may result 
in monocyte and T lymphocyte chemotaxis from the circulation to the site of inflammation and 
induces migration of SMCs to the lesion [312]. In addition to IL-6, TNFRSF12A (Figure 38) 
encodes to the TNF receptor superfamily member 12A that is the receptor of TWEAK which 




Besides, CCL2, CXCL12 is also produced by SMC of carotid atherosclerotic plaques (Figure 
38). CXCL12  increases the content of SMC’s collagen and hence, the fibrous cap thickness and 
it, as well, decreases the number of macrophages in advanced lesions of the carotid artery [313]. 
Although it seems to be an antiatherogenic factor it has also the ability to promote rupture-prone 
plaques inducing angiogenesis [314] and platelet aggregation in order to form a thrombus [315] 
after the rupture of atherosclerotic plaque [316]. 
Among the multiple roles of IL-6 in atherosclerotic plaques may also count its participation in 
the increase of OPG protein and the subsequent induction of osteoclast-like cells when it is used 
in combination with the inflammatory cytokine TNF-α [317]. Its expression within 
atherosclerotic plaques has previously been demonstrated and positively associated with the 
presence and severity of carotid atherosclerosis [253], carotid stenosis [159], vulnerable carotid 
plaques [318] and to predict atherosclerotic plaque growth [319]. Although the presence of this 
factor highlights the potential of arterial wall cells to promote calcification and osteogenesis 
under specific conditions, the cellular origin of it remains uncertain [253]. However, our data 
confirm that TNFRSF11B  – OPG encoding gene –  is one of the most highly expressed 
inflammatory genes in SMCs coming from carotid atherosclerotic plaques. 
The fact that carotid atheroma SMCs express high levels of JAK1, STAT1, 2, 3 and 6, as well 
as of the poorly characterized members of SOCS family SOCS4 and 6 (associated with the 
regulation of growth factor receptor signaling [320]), and 5 (IL19, IL4R, IL20RB signaling 
pathways [320,321]) indicates their multi-faceted capacity to regulate cytokine responses 
(Figure 38). SOCS4 and 6, like all SOCS proteins, may be involved in the mechanism of 
accelerating proteasome-mediated destruction of the activated cytokine-receptor complex 
attenuating the signal from the activated cytokine receptor itself and additionally, decreasing 
cell sensitivity to cytokines [322]. However, the activating molecules of these SOCS proteins 
are as yet unknown [323]. 
IL-6ST has been highlighted above as the most active inflammatory pathway found in SMCs 
from human carotid atherosclerotic plaques (Figure 38) and is one of the receptors regulated by 
SOCS3. After IL-6 binding to IL-6ST, JAK/STAT pathway is activated. IL6-ST/STAT3 
signaling attenuation is driven by IL6-ST itself recruiting SOCS3 which promotes receptor 
signaling complex degradation [250]. This signaling pathway needs interaction between JAK 
and SOCS3 to yield inhibition of STAT1 and 3 signaling [324]. A second phosphorylation and 
hence, activation of STAT3 upon inhibition by SOCS3, has been described. This re-
phosphorylation does not require IL-6ST, and instead uses the association of IL-6R and 
epidermal growth factor receptor (EGFR) to accomplish the activation of STAT3 [263]. 
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Both receptor, IL6R and EGFR (Reads Nº ± SEM: 1614 ± 90) are expressed by SMCs of 
atherosclerotic plaques, which leads us to think that SMCs can respond to IL-6 through STAT3 
despite the SOCS3-induced attenuation of its signaling. Moreover, the finding of SOCS3 being 
upregulated in SMCs from symptomatic patients is suggestive for a status of excessive 
inflammation in these plaques and the engagement of SMCs to deal with it. However, SOCS3 is 
involved in several signaling pathways in which it can exert contradictory roles – certainly so in 
T cell regulation, because of the multiple effects of STAT3 on the production of 
antiinflammatory (e.g. IL-10) and proinflammatory (e.g. IL-6) cytokines [325]. 
Th cells are abundantly present in carotid plaques, which can be found Th17 cells expressing 
IL-17A and IL-17F cytokines, as well as IL-21 and -22 which have been found in human 
atherosclerotic plaques [326]. However, the role of Th17 cells is still controversial since they 
have been associated with proatherogenic as well as antiatherogenic effects [327]. SMCs within 
carotid atherosclerotic plaques appear to be sensitive to the IL-17 family cytokines since 
IL17RD, an orphan receptor with no reported physiological role in IL-17 signaling [259], arose 
as the gene with the most highly significant difference between Asympt and Sympt (Table 14). 
No literature data are available on a putative role in atherosclerosis or vascular disease. 
Nevertheless, a recent study shows that IL-17RD deficiency is associated with enhanced 
proinflammatory signaling because of the negative regulation of IL-17A-induced activation of 
NF-κβ by IL-17RD and hence, with increased expression of IL-6 [259]. Additionally, a study by 
Fusch and colleagues indicated that this inactivation of NF-κB could also inhibit IL-1 
expression and TNF signaling [328]. A more recent study shows the ability of IL-17RD to 
inhibit Toll-like receptor (TLR) signaling [329]. Thus, it seems that IL-17RD may play a role in 
controlling exaggerated inflammatory responses [329] and therefore, the finding of higher 
expression in SMCs from Asympt patients may suggest a key role in establishing an 
antiinflammatory status in these plaques. 
Although the direct roles of SOCS3 and IL-17 production in the modulation of vascular 
inflammation and atherosclerotic lesion development remain unknown, T cells deficient in 
SOCS3 have been found to promote polarization of Th17 cells accompanied with reduction of 
infiltrating T cells in murine atherosclerotic plaques [261]. Accordingly, the upregulation of 
IL17RD taken together with downregulation of SOCS3 in asymptomatic SMCs, suggests that 
SMCs in asymptomatic plaques exert a stronger regulatory role toward the stabilization of the 
plaque. 
Besides IL-17RD, another receptor related to cytokines expressed by T cells is IL-20RB. IL-20 
signals through IL-20RA/IL-20RB (Type I receptor) and IL-22RA1/IL-20RB (Type II receptor) 
complexes. The other members of IL-20 subfamily of cytokines, i.e. IL- 19 and IL-24, signal 
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through these receptors complexes too. IL-24 uses the same receptors as IL-20, unlike IL-19 
that only can signal through type II receptor. Both type I and II have been observed only on 
cells of epithelial origin while IL-20 subfamily cytokines are produced by T cells, macrophages 
and DCs, suggesting a role for cross-talk between them [330]. 
IL20RB was expressed at significantly higher level in SMCs coming from symptomatic 
atherosclerotic plaques (Table 14). However, the subunits of complete IL-20 receptor, i.e. 
IL20RA and IL22RA1, appeared not to be, or at very low levels (Reads Nº ± SEM for IL20-RA: 
3 ± 0.7; for IL-22RA1: 4 ± 0.9), expressed in SMCs. Although it is not clear whether IL-20RB 
can bind interleukins and activate a signaling cascade by its own, IL-20RB but not IL-20RA or 
IL-22RA1, have been detected in most immune cells [331,332]. Wahl and colleagues showed 
that IL-19, IL-20, and IL-24 can act on T cells, and that IL-20RB signaling directly influenced 
both in vitro and in an in vivo mouse model responses including downregulating CD8 activation 
and inducing Th1-like immune responses of CD4 T cells [333]. Therefore, they suggested that 
these cytokines acting through IL-20RB have immune regulatory function and might be 
instrumental in the control of excessive immune reactions [333]. Supporting these ideas, it has 
been hypothesized that another receptor chain must pair with IL-20RB to induce IL-20 sub-
family cytokines (IL-19, 20, 24) signaling on immune cells [331]. 
IL-24 is associated with attenuation of vascular calcification, as Lee et al. [334] have 
demonstrated in rat vascular SMCs, whereas IL-19 inhibits oxLDL uptake by and foam cell 
formation of human vascular SMCs [335], as well as, intimal hyperplasia through SOCS5 
activation [321] and hence, reduces inflammatory induction of genes such as IL1β and CXCL8 
[336]. 
Although any functionality of IL-20RB by itself in SMCs has not been described yet, the 
mentioned reports [321,334–336] illustrate the capacity of SMCs to respond to the IL-20 
cytokine family. Therefore, the higher IL20RB expression by SMCs from symptomatic patients 
may have a role in attenuating proinflammatory signaling, as well as in regulating calcification 
of the plaque in response to IL-19 and IL-24. 
The ability of human vascular SMCs to produce IL-11 was described years ago; however, the 
role of IL-11 in vascular wall SMCs within atherosclerotic plaques is not exactly clear [264]. 
IL-11 may be envisaged to exert several positive effects on the atherosclerotic vascular wall; 
protection of ECM, prevention of apoptosis and proinflammatory cytokine production and 
intimal hyperplasia because of its anti-proliferative ability, and importantly, BMP production 
toward a stable calcified plaque [337–339]. TNFAIP8L3, in contrast, showed higher expression 
in SMCs from Asympt plaques. Although its role in atherosclerosis has not been studied yet, a 
limited number of articles focused on cancer and cell tumorigenesis awarded anti-apoptotic, 
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pro-proliferative and pro-migratory roles to TNFAIP8L3 [267,340]. Therefore, pending further 
investigation, TNFAIP8L3 may be of relevance as biomarker of progression of asymptomatic 
atherosclerotic plaque towards a symptomatic and rupture-prone phenotype, based on its 
association with degree of invasion and malignancy in cancer [340]. 
The chemokine/chemokine receptor network is of great importance in the regulation of cell 
recruitment during atherosclerosis, and thus numerous reports document the importance of their 
involvement [341,342]. Many chemokines such as CCL2 or CCL5 are upregulated in vascular 
wall cells (Figura 38 and Table 9) and cooperate in leukocyte recruitment to the injured artery in 
vascular remodeling [343].  Early events surrounding the initiation of the vascular inflammatory 
response program to vascular injury are hallmarked by CCL5 upregulation produced by SMCs, 
as observed in mice [265]. Among the multitudinous effects of CCL5, which generally are 
proinflammatory, T lymphocyte and monocyte chemoattraction are the most characteristic ones 
[344], although it is also involved in angiogenesis, which has been related to plaque instability 
and rupture [36]. Expression of the chemokine CCL5 is colocalized at the site of inflammation 
within atheroma plaques [266] and can be induced by TNF-α, rather than IL-6, through 
TNFRSF1A and posterior JAK2 activation and STAT3 phosphorylation, culminating in CCL5 
transcription in mice vascular SMCs [265]. Moreover, CCL5 was found to be increased in 
patients with unstable angina in the study reported by Kraaijeveld [345] and afterward, Koenen 
& Weber [346] suggested that this chemokine could serve as predictor of cardiovascular risk. 
As aforementioned, BMP2 is involved in bone formation and is found to be highly expressed in 
SMCs from asymptomatic patients, suggesting a calcified phenotype for these cells and stable 
phenotype for these plaques. The resorption of bone is a timed phase of bone destruction and 
implies maturation of multinucleated osteoclasts and initiation of matrix degradation in which 
CCL2 and CCL5 are involved (Figure 38 and Table 9) [347,348]. The effect of acidosis on bone 
has been studied by Mendoza et al. [349], who allude to increased production of IL-6 and CCL5 
by SMCs after acidosis stimulation in vitro, resulting in bone dissolution. Thus, CCL5 may 
serve as an indicator of bone dissolution in atherosclerotic plaques. Therefore, in accordance 
with results from transcriptomic analysis, SMCs from symptomatic plaques displayed more 
CCL5 expression than those from asymptomatic ones that presented a calcified phenotype 
[231]. 
As TGF-β signalling pathway regulates a wide range of cellular processes through diverse 
effects, such as modulation of angiogenesis by affecting cell proliferation, migration and 
differentiation, it has been considered a target for cardiovascular diseases (62). Several 
cardiovascular disorders have been linked to TGF-β signalling pathways: (i) in hemorrhagic 




The exact mechanism involved in plaque destabilization is not known but includes among other 
events SMC differentiation. Our study results contribute to a better understanding of how 
VSMC phenotype affects atheroma plaque development process, which may be valuable for 
future therapeutic approaches in carotid atherosclerosis disease. Furthermore, RNAseq 
transcriptomics has revealed significant differences in gene expression profiles between SMCs 
from Asympt and Sympt carotid plaques and this has provided clues as to the role SMCs may 
play in carotid atheroma plaque destabilization. Osteogenic-like phenotype SMCs may 
positively affect carotid atheroma plaque through participation in plaque stabilization via bone 
formation processes. On the other hand, plaques containing senescence-like phenotype SMCs 
may be more prone to rupture. Our results substantiate an important role of SMCs in carotid 
atheroma plaque disruption. In addition, an improved understanding of the multifaceted roles of 
SMCs in inflammatory processes happening during atherosclerosis would provide the scientific 
community with clues for additional targets for therapeutic intervention. The goal of such 
therapies would be in first place, to stabilize existing plaques so as to minimize the risk to 
develop stroke and to prevent plaque rupture in patients who may present a higher risk to 
develop the disease. 
7. REFERENCES 




[2] I. Tabas, G. García-Cardeña, G.K. Owens, Recent insights into the cellular biology of 
atherosclerosis, J. Cell Biol. 209 (2015) 13–22. doi:10.1083/jcb.201412052. 
[3] A.J. Lusis, Atherosclerosis, Nature. 407 (2000) 233–241. doi:10.1038/35025203. 
[4] C. Hahn, M.A. Schwartz, Mechanotransduction in vascular physiology and atherogenesis, Nat 
Rev Mol Cell Biol. 10 (2009) 53–62. doi:10.1038/nrm2596. 
[5] Organización Mundial de la Salud, Prevención de las enfermedades cardiovasculares. Guía de 
bolsillo para la estimación y el manejo del riesgo cardiovascular, Organ. Mund. La Salud. 1 
(2008) 1–38. 
[6] C. Lahoz, J.M. Mostaza, La aterosclerosis como enfermedad sistémica, Rev. Española Cardiol. 60 
(2007) 184–195. doi:10.1157/13099465. 
[7] World health organization, Cardiovascular diseases, World Hear. Organ. (2017). 
http://www.who.int/mediacentre/factsheets/fs317/en/. 





[9] J. Pelisek, H.-H. Eckstein, A. Zernecke, Pathophysiological Mechanisms of Carotid Plaque 
Vulnerability: Impact on Ischemic Stroke, Arch. Immunol. Ther. Exp. (Warsz). 60 (2012) 431–
442. doi:10.1007/s00005-012-0192-z. 
[10] E.J. Benjamin, M.J. Blaha, S.E. Chiuve, M. Cushman, S.R. Das, R. Deo, S.D. de Ferranti, J. 
Floyd, M. Fornage, C. Gillespie, C.R. Isasi, M.C. Jiménez, L.C. Jordan, S.E. Judd, D. Lackland, 
J.H. Lichtman, L. Lisabeth, S. Liu, C.T. Longenecker, R.H. Mackey, K. Matsushita, D. 
Mozaffarian, M.E. Mussolino, K. Nasir, R.W. Neumar, L. Palaniappan, D.K. Pandey, R.R. 
Thiagarajan, M.J. Reeves, M. Ritchey, C.J. Rodriguez, G.A. Roth, W.D. Rosamond, C. Sasson, 
A. Towfighi, C.W. Tsao, M.B. Turner, S.S. Virani, J.H. Voeks, J.Z. Willey, J.T. Wilkins, J.H.Y. 
Wu, H.M. Alger, S.S. Wong, P. Muntner, Heart disease and stroke statistics—2017 update: a 
report from the american heart association, Circulation. 135 (2017) e146–e603. 
doi:10.1161/CIR.0000000000000485. 
[11] A.R. Naylor, Time is brain!, Surgeon. 5 (2007) 23–30. 
http://www.ncbi.nlm.nih.gov/pubmed/17313125. 
[12] J. Golledge, R.M. Greenhalgh, A.H. Davies, The symptomatic carotid plaque, Stroke. 31 (2000) 
774–781. 
[13] A. Ois, E. Cuadrado-Godia, A. Rodriguez-Campello, J. Jimenez-Conde, J. Roquer, High Risk of 
Early Neurological Recurrence in Symptomatic Carotid Stenosis, Stroke. 40 (2009) 2727–2731. 
doi:10.1161/STROKEAHA.109.548032. 
[14] C.K. Zarins, D.P. Giddens, B.K. Bharadvaj, V.S. Sottiurai, R.F. Mabon, S. Gladov, S. Glagov, 
Carotid bifurcation atherosclerosis: Quantative correlation of plaque localization with flow 
velocity profiles and wall shear stress, Circ. Res. 53 (1983) 502–514. 
doi:10.1161/01.RES.53.4.502. 
[15] C.R. White, J.A. Frangos, The shear stress of it all: the cell membrane and mechanochemical 
transduction, Philos. Trans. R. Soc. B Biol. Sci. 362 (2007) 1459–1467. 
doi:10.1098/rstb.2007.2128. 
[16] P.F. Davies, Flow-mediated endothelial mechanotransduction, Physiol. Rev. 75 (1995) 519–560. 
[17] O. Traub, B.C. Berk, Laminar shear stress: mechanisms by which endothelial cells transduce an 
atheroprotective force, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 677–685. 
[18] S. Glagov, C. Zarins, D.P. Giddens, D.N. Ku, Hemodynamics and atherosclerosis. Insights and 
perspectives gained from studies of human arteries, Arch. Pathol. Lab. Med. 112 (1988) 1018–
1031. http://www.ncbi.nlm.nih.gov/pubmed/3052352. 
[19] A.M. Malek, S.L. Alper, S. Izumo, Hemodynamic shear stress and its role in atherosclerosis., 
JAMA. 282 (1999) 2035–2042. http://www.ncbi.nlm.nih.gov/pubmed/10591386. 
116 
 
[20] A.R. Brooks, P.I. Lelkes, G.M. Rubanyi, Gene Expression Profiling of Vascular Endothelial Cells 
Exposed to Fluid Mechanical Forces: Relevance for Focal Susceptibility to Atherosclerosis, 
Endothelium. 11 (2004) 45–57. doi:10.1080/10623320490432470. 
[21] Y.-S.J. Li, J.H. Haga, S. Chien, Molecular basis of the effects of shear stress on vascular 
endothelial cells, J. Biomech. 38 (2005) 1949–1971. doi:10.1016/j.jbiomech.2004.09.030. 
[22] L.M. Blanco-Colio, J.L. Martín-Ventura, F. Vivanco, J.B. Michel, O. Meilhac, J. Egido, Biology 
of atherosclerotic plaques: What we are learning from proteomic analysis, Cardiovasc. Res. 72 
(2006) 18–29. doi:10.1016/j.cardiores.2006.05.017. 
[23] J. Dunn, H. Qiu, S. Kim, D. Jjingo, R. Hoffman, C.W. Kim, I. Jang, D.J. Son, D. Kim, C. Pan, Y. 
Fan, I.K. Jordan, H. Jo, Flow-dependent epigenetic DNA methylation regulates endothelial gene 
expression and atherosclerosis, J. Clin. Invest. 124 (2014) 3187–3199. doi:10.1172/JCI74792. 
[24] P.A. Murphy, R.O. Hynes, Alternative Splicing of Endothelial Fibronectin Is Induced by 
Disturbed Hemodynamics and Protects Against Hemorrhage of the Vessel Wall, Arterioscler. 
Thromb. Vasc. Biol. 34 (2014) 2042–2050. doi:10.1161/ATVBAHA.114.303879. 
[25] E. Adiguzel, P.J. Ahmad, C. Franco, M.P. Bendeck, Collagens in the progression and 
complications of atherosclerosis, Vasc. Med. 14 (2009) 73–89. doi:10.1177/1358863X08094801. 
[26] H.C. Stary, Natural history and histological classification of atherosclerotic lesions : an update, 
Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1177–1178. doi:10.1161/01.ATV.20.5.1177. 
[27] R. Ross, Inflammation or Atherogenesis, N. Engl. J. Med. 340 (1999) 115–126. 
doi:10.1056/NEJM199901143400207. 
[28] D.C. Chappell, S.E. Varner, R.M. Nerem, R.M. Medford, R.W. Alexander, Oscillatory Shear 
Stress Stimulates Adhesion Molecule Expression in Cultured Human Endothelium, Circ. Res. 82 
(1998) 532–539. doi:10.1161/01.RES.82.5.532. 
[29] G.C. Fernández, F.M. Tardáguila, C. Trinidad, L. María, V. Pilar, S. Miguel, A. De, 
Fisiopatología de la placa de ateroma y sus implicaciones en la imagen atherosclerotic plaque 
and, 45 (2003) 107–114. 
[30] J. Martínez-González, V. Llorente-Cortés, L. Badimon, Biología celular y molecular de las 
lesiones ateroscleróticas, Rev. Española Cardiol. 54 (2001) 218–231. doi:10.1016/S0300-
8932(01)76294-X. 
[31] W. Insull, The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to 
Medical Treatment, Am. J. Med. 122 (2009) S3–S14. doi:10.1016/j.amjmed.2008.10.013. 
[32] L. Badimón, G. Vilahur, T. Padró, L. Badimón, Lipoproteins, Platelets, and Atherothrombosis, 
Rev Esp Cardiol. Cardiovasc. Transl. Med. 62 (2009) 1161–78. 
[33] T. Inaba, T. Gotoda, H. Shimano, M. Shimada, K. Harada, K. Kozaki, Y. Watanabe, E. Hoh, K. 
Motoyoshi, Y. Yazaki, Platelet-derived growth factor induces c-fms and scavenger receptor genes 
in vascular smooth muscle cells, J Biol Chem. 267 (1992) 13107–13112. 
117 
 
[34] P. Vijayagopal, D.L. Glancy, Macrophages stimulate cholesteryl ester accumulation in cocultured 
smooth muscle cells incubated with lipoprotein-proteoglycan complex, Arterioscler. Thromb. 
Vasc. Biol. 16 (1996) 1112–1121. http://www.ncbi.nlm.nih.gov/pubmed/8792764. 
[35] F.D. Kolodgie, A.P. Burke, G. Nakazawa, R. Virmani, Is pathologic intimal thickening the key to 
understanding early plaque progression in human atherosclerotic disease?, Arterioscler. Vasc. 
Biol. 27 (2007) 986–989. doi:10.1161/01.ATV.0000258865.44774.41. 
[36] R. Di Stefano, F. Felice, A. Balbarini, Angiogenesis as risk factor for plaque vulnerability, Curr. 
Pharm. Des. 15 (2009) 1095–106. doi:10.2174/138161209787846892. 
[37] B. Ho-Tin-Noé, J.B. Michel, Initiation of angiogenesis in atherosclerosis: smooth muscle cells as 
mediators of the angiogenic response to atheroma formation, Trends Cardiovasc. Med. 21 (2011) 
183–187. doi:10.1016/j.tcm.2012.05.007. 
[38] C. Camaré, M. Pucelle, A. Nègre-Salvayre, R. Salvayre, Angiogenesis in the atherosclerotic 
plaque, Redox Biol. 12 (2017) 18–34. doi:10.1016/j.redox.2017.01.007. 
[39] P.K. Shah, Z.S. Galis, Matrix Metalloproteinase Hypothesis of Plaque Rupture: Players Keep 
Piling Up But Questions Remain, Circulation. 104 (2001) 1878–1880. 
[40] J.L. Johnson, Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic 
plaque stability, Expert Rev. Cardiovasc. Ther. 5 (2007) 265–282. doi:10.1586/14779072.5.2.265. 
[41] A. Müller, S.D. Krämer, R. Meletta, K. Beck, S. V. Selivanova, Z. Rancic, P.A. Kaufmann, B. 
Vos, J. Meding, T. Stellfeld, T.K. Heinrich, M. Bauser, J. Hütter, L.M. Dinkelborg, R. Schibli, 
S.M. Ametamey, Gene expression levels of matrix metalloproteinases in human atherosclerotic 
plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability, 
Nucl. Med. Biol. 41 (2014) 562–569. doi:10.1016/j.nucmedbio.2014.04.085. 
[42] J.L. Johnson, N.P. Jenkins, W.-C. Huang, K. Di Gregoli, G.B. Sala-Newby, V.P.W. Scholtes, F.L. 
Moll, G. Pasterkamp, A.C. Newby, Relationship of MMP-14 and TIMP-3 Expression with 
Macrophage Activation and Human Atherosclerotic Plaque Vulnerability, Mediators Inflamm. 
2014 (2014) 1–17. doi:10.1155/2014/276457. 
[43] P.K. Shah, Biomarkers of Plaque Instability, Curr. Cardiol. Rep. 16 (2014) 547. 
doi:10.1007/s11886-014-0547-7. 
[44] L. Badimon, G. Vilahur, Thrombosis formation on atherosclerotic lesions and plaque rupture, J. 
Intern. Med. 276 (2014) 618–632. doi:10.1111/joim.12296. 
[45] S.A. Steitz, M.Y. Speer, G. Curinga, H.-Y. Yang, P. Haynes, R. Aebersold, T. Schinke, G. 
Karsenty, C.M. Giachelli, Smooth Muscle Cell Phenotypic Transition Associated With 
Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers, 
Circ. Res. 89 (2001) 1147–1154. doi:10.1161/hh2401.101070. 
[46] M. Slevin, A.B. Elasbali, M. Miguel Turu, J. Krupinski, L. Badimon, J. Gaffney, Identification of 
Differential Protein Expression Associated with Development of Unstable Human Carotid 
118 
 
Plaques, Am. J. Pathol. 168 (2006) 1004–1021. doi:10.2353/ajpath.2006.050471. 
[47] J.M. Seeger, E. Barratt, G.A. Lawson, N. Klingman, The relationship between carotid plaque 
composition, plaque morphology, and neurologic symptoms., J. Surg. Res. 58 (1995) 330–336. 
[48] M. de Weerd, J.P. Greving, B. Hedblad, M.W. Lorenz, E.B. Mathiesen, D.H. O’Leary, M. 
Rosvall, M. Sitzer, E. Buskens, M.L. Bots, Prevalence of Asymptomatic Carotid Artery Stenosis 
in the General Population: An Individual Participant Data Meta-Analysis, Stroke. 41 (2010) 
1294–1297. doi:10.1161/STROKEAHA.110.581058. 
[49] D. Inzitari, M. Eliasziw, P. Gates, B.L. Sharpe, R.K. Chan, H.E. Meldrum, H.J. Barnett, The 
causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis, N. Engl. 
J. Med. 342 (2000) 1693–1700. 
[50] A.L. Abbott, B.R. Chambers, J.L. Stork, C.R. Levi, C.F. Bladin, G.A. Donnan, Embolic Signals 
And Prediction of Ipsilateral Stroke or Transient Ischemic Attack in Asymptomatic Carotid 
Stenosis: A Multicenter Prospective Cohort Study, Stroke. 36 (2005) 1128–1133. 
doi:10.1161/01.STR.0000166059.30464.0a. 
[51] Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the 
MRC European Carotid Surgery Trial (ECST), Lancet (London, England). 351 (1998) 1379–
1387. http://www.ncbi.nlm.nih.gov/pubmed/9593407. 
[52] K. Skagen, M. Skjelland, M. Zamani, D. Russell, Unstable carotid artery plaque: new insights and 
controversies in diagnostics and treatment, Croat. Med. J. 57 (2016) 311–320. 
doi:10.3325/cmj.2016.57.311. 
[53] G.W. van Lammeren, A.G. den Hartog, G. Pasterkamp, A. Vink, J.-P.P.M. de Vries, F.L. Moll, 
G.J. de Borst, Asymptomatic Carotid Artery Stenosis: Identification of Subgroups with Different 
Underlying Plaque Characteristics, Eur. J. Vasc. Endovasc. Surg. 43 (2012) 632–636. 
doi:10.1016/j.ejvs.2012.03.011. 
[54] A. van der Wal, A.E. Becker, Atherosclerotic plaque rupture – pathologic basis of plaque stability 
and instability, Cardiovasc. Res. 41 (1999) 334–344. doi:10.1016/S0008-6363(98)00276-4. 
[55] L. Perisic, S. Aldi, Y. Sun, L. Folkersen, A. Razuvaev, J. Roy, M. Lengquist, S. Åkesson, C.E. 
Wheelock, L. Maegdefessel, A. Gabrielsen, J. Odeberg, G.K. Hansson, G. Paulsson-Berne, U. 
Hedin, Gene expression signatures, pathways and networks in carotid atherosclerosis, J. Intern. 
Med. 279 (2016) 293–308. doi:10.1111/joim.12448. 
[56] S. Carr, A. Farb, W.H. Pearce, R. Virmani, J.S.T. Yao, Atherosclerotic plaque rupture in 
symptomatic carotid artery stenosis, J. Vasc. Surg. 23 (1996) 755–766. doi:10.1016/S0741-
5214(96)70237-9. 
[57] L. Hermus, G.M. van Dam, C.J. Zeebregts, Advanced Carotid Plaque Imaging, Eur. J. Vasc. 
Endovasc. Surg. 39 (2010) 125–133. doi:10.1016/j.ejvs.2009.11.020. 
[58] M.T. Dirksen, A.C. Van Der Wal, F.M. Van Den Berg, C.M. Van Der Loos, A.E. Becker, 
119 
 
Distribution of inflammatory cells in atherosclerotic plaques relates to the direction of flow, 
Circulation. 98 (1998) 2000–2003. doi:10.1161/01.CIR.98.19.2000. 
[59] B. Fagerberg, M. Ryndel, J. Kjelldahl, L.M. Akyürek, L. Rosengren, L. Karlström, G. Bergström, 
F.J. Olson, Differences in Lesion Severity and Cellular Composition between in vivo Assessed 
Upstream and Downstream Sides of Human Symptomatic Carotid Atherosclerotic Plaques, J. 
Vasc. Res. 47 (2010) 221–230. doi:10.1159/000255965. 
[60] L. Baroncini, A. Filho, S. Ramos, A. Martins, L. Murta, Histological composition and progression 
of carotid plaque, Thromb. J. 5 (2007) 4. doi:10.1186/1477-9560-5-4. 
[61] A.J. Lepedda, A. Cigliano, G.M. Cherchi, R. Spirito, M. Maggioni, F. Carta, F. Turrini, C. 
Edelstein, A.M. Scanu, M. Formato, A proteomic approach to differentiate histologically 
classified stable and unstable plaques from human carotid arteries, Atherosclerosis. 203 (2009) 
112–118. doi:10.1016/j.atherosclerosis.2008.07.001. 
[62] B. Verhoeven, W.E. Hellings, F.L. Moll, J.P. de Vries, D.P.V. de Kleijn, P. de Bruin, E. Busser, 
A.H. Schoneveld, G. Pasterkamp, Carotid atherosclerotic plaques in patients with transient 
ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic 
and amaurosis fugax patients, J. Vasc. Surg. 42 (2005) 1075–1081. 
doi:10.1016/j.jvs.2005.08.009. 
[63] A.E. Park, W.J. McCarthy, W.H. Pearce, J.S. Matsumura, J.S.T. Yao, Carotid plaque morphology 
correlates with presenting symptomatology, J. Vasc. Surg. 27 (1998) 872–879. 
doi:10.1016/S0741-5214(98)70267-8. 
[64] J.-B. Michel, R. Virmani, E. Arbustini, G. Pasterkamp, Intraplaque haemorrhages as the trigger of 
plaque vulnerability, Eur. Heart J. 32 (2011) 1977–1985. doi:10.1093/eurheartj/ehr054. 
[65] Y.-C. Chen, A.L. Huang, T.S. Kyaw, A. Bobik, K. Peter, Atherosclerotic Plaque Rupture, 
Arterioscler. Thromb. Vasc. Biol. 36 (2016) e63–e72. doi:10.1161/ATVBAHA.116.307993. 
[66] H. Van Damme, M. Vivario, J. Boniver, R. Limet, Histologic characterization of carotid plaques, 
Cardiovasc. Pathol. 3 (1994) 9–17. doi:10.1016/1054-8807(94)90003-5. 
[67] C.D. Liapis, E.D. Avgerinos, N.P. Kadoglou, J.D. Kakisis, What a vascular surgeon should know 
and do about atherosclerotic risk factors, J. Vasc. Surg. 49 (2009) 1348–1354. 
doi:10.1016/j.jvs.2008.12.046. 
[68] R. Stocker, J.F. Keaney, Role of Oxidative Modifications in Atherosclerosis, Physiol. Rev. 84 
(2004) 1381–1478. doi:10.1152/physrev.00047.2003. 
[69] F.R. Maxfield, I. Tabas, Role of cholesterol and lipid organization in disease, Nature. 438 (2005) 
612–621. doi:10.1038/nature04399. 
[70] J.F. Bentzon, F. Otsuka, R. Virmani, E. Falk, Mechanisms of Plaque Formation and Rupture, 
Circ. Res. 114 (2014) 1852–1866. doi:10.1161/CIRCRESAHA.114.302721. 
[71] R.J. Doonan, A. Hafiane, C. Lai, J.P. Veinot, J. Genest, S.S. Daskalopoulou, Cholesterol Efflux 
120 
 
Capacity, Carotid Atherosclerosis, and Cerebrovascular Symptomatology, Arterioscler. Thromb. 
Vasc. Biol. 34 (2014) 921–926. doi:10.1161/ATVBAHA.113.302590. 
[72] P. Sobieszczyk, J. Beckman, Carotid Artery Disease, Circulation. 114 (2006) e244–e247. 
doi:10.1161/CIRCULATIONAHA.105.542860. 
[73] S. LEHOUX, Y. CASTIER, A. TEDGUI, Molecular mechanisms of the vascular responses to 
haemodynamic forces, J. Intern. Med. 259 (2006) 381–392. doi:10.1111/j.1365-
2796.2006.01624.x. 
[74] P. Jankowski, G. Bilo, K. Kawecka‐Jaszcz, The pulsatile component of blood pressure – Its role 
in the pathogenesis of atherosclerosis, Blood Press. 16 (2007) 238–245. 
doi:10.1080/08037050701428166. 
[75] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins, Age-specific relevance of usual blood 
pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 
prospective studies.Age-specific relevance of usual blood pressure to vascular mortality: a meta-
analysis of individual d, Lancet. 360 (2002) 1903–13. 
http://www.ncbi.nlm.nih.gov/pubmed/12493255. 
[76] J.R. Romero, J. Morris, A. Pikula, Stroke prevention: modifying risk factors, Ther. Adv. 
Cardiovasc. Dis. 2 (2008) 287–303. doi:10.1177/1753944708093847. 
[77] M.K. Gaba, S. Gaba, L.T. Clark, Cardiovascular disease in patients with diabetes: clinical 
considerations, J. Assoc. Acad. Minor. Phys. 10 (1999) 15–22. 
http://www.ncbi.nlm.nih.gov/pubmed/10826004. 
[78] A. Bruno, S.R. Levine, M.R. Frankel, T.G. Brott, Y. Lin, B.C. Tilley, P.D. Lyden, J.P. Broderick, 
T.G. Kwiatkowski, S.E. Fineberg, Admission glucose level and clinical outcomes in the NINDS 
rt-PA Stroke Trial, Neurology. 59 (2002) 669–674. doi:10.1212/WNL.59.5.669. 
[79] M.W. Parsons, P.A. Barber, P.M. Desmond, T.A. Baird, D.G. Darby, G. Byrnes, B.M. Tress, 
S.M. Davis, Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance 
imaging and spectroscopy study, Ann. Neurol. 52 (2002) 20–28. doi:10.1002/ana.10241. 
[80] C.A. Kawamura M, Heinecke JW, Pathophysiological concentrations of glucose promote 
oxidative modification of low density lipoprotein by a superoxide- dependent pathway., J Clin 
Invest. 94 (1994) 771–778. 
[81] J.W. Stephens, M.P. Khanolkar, S.C. Bain, The biological relevance and measurement of plasma 
markers of oxidative stress in diabetes and cardiovascular disease, Atherosclerosis. 202 (2009) 
321–329. doi:10.1016/j.atherosclerosis.2008.06.006. 
[82] R.S. Shah, J.W. Cole, Smoking and stroke: the more you smoke the more you stroke, Expert Rev. 
Cardiovasc. Ther. 8 (2010) 917–932. doi:10.1586/erc.10.56. 
[83] A.D. Gepner, M.E. Piper, H.M. Johnson, M.C. Fiore, T.B. Baker, J.H. Stein, Effects of smoking 
and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial, Am. 
121 
 
Heart J. 161 (2011) 145–151. doi:10.1016/j.ahj.2010.09.023. 
[84] S.Y. Woo, J.H. Joh, S.-A. Han, H.-C. Park, Prevalence and risk factors for atherosclerotic carotid 
stenosis and plaque, Medicine (Baltimore). 96 (2017) e5999. 
doi:10.1097/MD.0000000000005999. 
[85] T. Truelsen, S. Begg, C. Mathers, The global burden of cerebrovascular disease, World Heal. 
Organ. (2006) 1–67. 
[86] R.L. Sacco, R. Adams, G. Albers, M.J. Alberts, O. Benavente, K. Furie, L.B. Goldstein, P. 
Gorelick, J. Halperin, R. Harbaugh, S.C. Johnston, I. Katzan, M. Kelly-Hayes, E.J. Kenton, M. 
Marks, L.H. Schwamm, T. Tomsick, Guidelines for Prevention of Stroke in Patients With 
Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From 
the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored 
by the Council on C, Stroke. 37 (2006) 577–617. doi:10.1161/01.STR.0000199147.30016.74. 
[87] S.-H. Suk, R.L. Sacco, B. Boden-Albala, J.F. Cheun, J.G. Pittman, M.S. Elkind, M.C. Paik, 
Abdominal Obesity and Risk of Ischemic Stroke: The Northern Manhattan Stroke Study, Stroke. 
34 (2003) 1586–1592. doi:10.1161/01.STR.0000075294.98582.2F. 
[88] S.N. Blair, J.B. Kampert, H.W. Kohl, C.E. Barlow, C.A. Macera, R.S. Paffenbarger, L.W. 
Gibbons, E. Bouchard C, Shephard RJ, Stephens T, W.P. Stefanick ML, P.M. Kriska AM, Blair 
SN, A.C. of S. Medicine, B. SN, H.C. Paffenbarger RS Jr, Hyde RT, Wing AL, B.E. Morris JN, 
Clayton DG, Everitt MG, Semmence AM, G.L. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark 
DG, Cooper KH, K.J. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee I, Jung DL, M.C. Blair SN, 
Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, P.M. Peters RK, Cady LD Jr, 
Bischoff DP, Bernstein L, P.R.J. Helmrich SP, Ragland DR, Leung RW, W.R. Balke B,  et al 
Pollock ML, Bohannon RL, Cooper KH, W.A. Pollock ML, Foster C, Schmidt D, Hellman C, 
Linnerud AC, A.C. of S. Medicine, C. DR, T.C. Fagard RH, Influences of Cardiorespiratory 
Fitness and Other Precursors on Cardiovascular Disease and All-Cause Mortality in Men and 
Women, JAMA J. Am. Med. Assoc. 276 (1996) 205–210. 
doi:10.1001/jama.1996.03540030039029. 
[89] M.B. Britten, A.M. Zeiher, V. Schächinger, Clinical importance of coronary endothelial 
vasodilator dysfunction and therapeutic options, J. Intern. Med. 245 (1999) 315–327. 
doi:10.1046/j.1365-2796.1999.00449.x. 
[90] R.L. Sacco, R. Gan, B. Boden-Albala, I.F. Lin, D.E. Kargman, W.A. Hauser, S. Shea, M.C. Paik, 
Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study., 
Stroke A J. Cereb. Circ. 29 (1998) 380–387. http://www.ncbi.nlm.nih.gov/pubmed/9472878. 
[91] C. Do Lee, A.R. Folsom, S.N. Blair, Physical Activity and Stroke Risk: A Meta-Analysis, Stroke. 
34 (2003) 2475–2482. doi:10.1161/01.STR.0000091843.02517.9D. 
[92] G. Wendel-Vos, A. Schuit, H. Boshuizen, W. Verschuren, W. Saris, D. Kromhout, Physical 




[93] M. Endres, K. Gertz, U. Lindauer, J. Katchanov, J. Schultze, H. Schrok, G. Nickenig, W. 
Kuschinsky, U. Dirnagl, U. Laufs, Mechanisms of stroke prevention by physical activity, Ann. 
Neurol. 54 (2003) 582–590. 
[94] Y.-H. Ding, C.N. Young, X. Luan, J. Li, J.A. Rafols, J.C. Clark, J.P. McAllister, Y. Ding, 
Exercise preconditioning ameliorates inflammatory injury in ischemic rats during reperfusion, 
Acta Neuropathol. 109 (2005) 237–246. doi:10.1007/s00401-004-0943-y. 
[95] P. Rothwell, M. Eliasziw, S. Gutnikov, C. Warlow, H. Barnett, Endarterectomy for symptomatic 
carotid stenosis in relation to clinical subgroups and timing of surgery, Lancet. 363 (2004) 915–
924. doi:10.1016/S0140-6736(04)15785-1. 
[96] K. Cheng, D. Mikhailidis, G. Hamilton, A. Seifalian, A review of the carotid and femoral intima-
media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular 
risk factors, Cardiovasc. Res. 54 (2002) 528–538. doi:10.1016/S0008-6363(01)00551-X. 
[97] O. Joakimsen, K.H. Bonna, E. Stensland-bugge, B.K. Jacobsen, Age and Sex Differences in the 
Distribution and Ultrasound Morphology of Carotid Atherosclerosis The Tromsø Study, 
Arterioscler. Thromb. Vasc. Biol. 19 (1999) 3007–3013. 
[98] A.L. Abbott, G.A. Donnan, Does the ‘High Risk’ Patient with Asymptomatic Carotid Stenosis 
Really Exist?, Eur. J. Vasc. Endovasc. Surg. 35 (2008) 524–533. doi:10.1016/j.ejvs.2008.01.017. 
[99] G. Sangiorgi, S. Roversi, G. Biondi Zoccai, M.G. Modena, F. Servadei, A. Ippoliti, A. Mauriello, 
Sex-related differences in carotid plaque features and inflammation, J. Vasc. Surg. 57 (2013) 
338–344. doi:10.1016/j.jvs.2012.07.052. 
[100] A.J. Comerota, S.X. Salles-Cunha, Y. Daoud, L. Jones, H.G. Beebe, Gender differences in blood 
velocities across carotid stenoses, J. Vasc. Surg. 40 (2004) 939–944. 
doi:10.1016/j.jvs.2004.08.030. 
[101] B.D. MacNeill, I.-K. Jang, B.E. Bouma, N. Iftimia, M. Takano, H. Yabushita, M. Shishkov, C.R. 
Kauffman, S.L. Houser, H.T. Aretz, D. DeJoseph, E.F. Halpern, G.J. Tearney, Focal and multi-
focal plaque macrophage distributions in patients with acute and stable presentations of coronary 
artery disease, J. Am. Coll. Cardiol. 44 (2004) 972–979. doi:10.1016/j.jacc.2004.05.066. 
[102] F. Iemolo, Sex Differences in Carotid Plaque and Stenosis, Stroke. 35 (2004) 477–481. 
doi:10.1161/01.STR.0000110981.96204.64. 
[103] E. Marulanda-Londoño, S. Chaturvedi, Carotid stenosis in women: time for a reappraisal, BMJ. 1 
(2016) 192–196. doi:10.1136/svn-2016-000043. 
[104] O. van Oostrom, E. Velema, A.H. Schoneveld, J.P.P.M. de Vries, P. de Bruin, C.A. Seldenrijk, 
D.P.V. de Kleijn, E. Busser, F.L. Moll, J.H. Verheijen, R. Virmani, G. Pasterkamp, Age-related 




[105] S. Homma, N. Hirose, H. Ishida, T. Ishii, G. Araki, J.H. Halsey, Carotid Plaque and Intima-Media 
Thickness Assessed by B-Mode Ultrasonography in Subjects Ranging From Young Adults to 
Centenarians, Stroke. 32 (2001) 830–835. doi:10.1161/01.STR.32.4.830. 
[106] G. Gennaro, C. Ménard, E. Giasson, S.-É. Michaud, M. Palasis, S. Meloche, A. Rivard, Role of 
p44/p42 MAP Kinase in the Age-Dependent Increase in Vascular Smooth Muscle Cell 
Proliferation and Neointimal Formation, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 204–210. 
doi:10.1161/01.ATV.0000053182.58636.BE. 
[107] G. Milio, E. Corrado, D. Sorrentino, I. Muratori, S. La Carrubba, G. Mazzola, R. Tantillo, G. 
Vitale, S. Mansueto, S. Novo, Asymptomatic Carotid Lesions and Aging: Role of Hypertension 
and Other Traditional and Emerging Risk Factors, Arch. Med. Res. 37 (2006) 342–347. 
doi:10.1016/j.arcmed.2005.06.012. 
[108] E. Ammirati, F. Fogacci, Clinical relevance of biomarkers for the identification of patients with 
carotid atherosclerotic plaque: Potential role and limitations of cysteine protease legumain, 
Atherosclerosis. 257 (2017) 248–249. doi:10.1016/j.atherosclerosis.2017.01.003. 
[109] T. Benedek, P. Maurovich-Horváth, P. Ferdinandy, B. Merkely, The Use of Biomarkers for the 
Early Detection of Vulnerable Atherosclerotic Plaques and Vulnerable Patients. A Review, J. 
Cardiovasc. Emergencies. 2 (2016) 106–113. doi:10.1515/jce-2016-0017. 
[110] B. Lindahl, Are there really biomarkers of vulnerable plaque?, Clin. Chem. 58 (2012) 151–153. 
doi:10.1373/clinchem.2011.165811. 
[111] S.Z.H. Rittersma, A.C. van der Wal, K.T. Koch, J.J. Piek, J.P.S. Henriques, K.J. Mulder, 
J.P.H.M. Ploegmakers, M. Meesterman, R.J. de Winter, Plaque Instability Frequently Occurs 
Days or Weeks Before Occlusive Coronary Thrombosis: A Pathological Thrombectomy Study in 
Primary Percutaneous Coronary Intervention, Circulation. 111 (2005) 1160–1165. 
doi:10.1161/01.CIR.0000157141.00778.AC. 
[112] P. Libby, P.M. Ridker, G.K. Hansson, Progress and challenges in translating the biology of 
atherosclerosis, Nature. 473 (2011) 317–325. doi:10.1038/nature10146. 
[113] V.R. Taqueti, M.F. Di Carli, M. Jerosch-Herold, G.K. Sukhova, V.L. Murthy, E.J. Folco, R.Y. 
Kwong, C.K. Ozaki, M. Belkin, M. Nahrendorf, R. Weissleder, P. Libby, Increased 
Microvascularization and Vessel Permeability Associate With Active Inflammation in Human 
Atheromata, Circ. Cardiovasc. Imaging. 7 (2014) 920–929. 
doi:10.1161/CIRCIMAGING.114.002113. 
[114] M.-L.M. Grønholdt, B.G. Nordestgaard, J. Bentzon, B.M. Wiebe, J. Zhou, E. Falk, H. Sillesen, 
Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode 
imaging, and elevated plasma lipid levels, J. Vasc. Surg. 35 (2002) 137–145. 
doi:10.1067/mva.2002.119042. 
[115] P. Poredos, A. Spirkoska, L. Lezaic, M.B. Mijovski, M.K. Jezovnik, Patients with an Inflamed 
Atherosclerotic Plaque have Increased Levels of Circulating Inflammatory Markers, J. 
124 
 
Atheroscler. Thromb. 24 (2017) 39–46. doi:10.5551/jat.34884. 
[116] R. Blackburn, P. Giral, E. Bruckert, J.-M. André, S. Gonbert, M. Bernard, M.J. Chapman, G. 
Turpin, Elevated C-Reactive Protein Constitutes an Independent Predictor of Advanced Carotid 
Plaques in Dyslipidemic Subjects, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1962–1968. 
doi:10.1161/hq1201.099433. 
[117] S.K. Singh, M. V. Suresh, B. Voleti, A. Agrawal, The connection between C‐reactive protein 
and atherosclerosis, Ann. Med. 40 (2008) 110–120. doi:10.1080/07853890701749225. 
[118] M. Di Napoli, F. Papa, V. Bocola, Prognostic influence of increased C-reactive protein and 
fibrinogen levels in ischemic stroke, Stroke. 32 (2001) 133–138. doi:10.1161/01.STR.32.1.133. 
[119] H. Grufman, I. Gonçalves, A. Edsfeldt, M. Nitulescu, A. Persson, M. Nilsson, J. Nilsson, Plasma 
levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid 
atherosclerotic plaques, J. Intern. Med. 275 (2014) 127–133. doi:10.1111/joim.12133. 
[120] O. Yousuf, B.D. Mohanty, S.S. Martin, P.H. Joshi, M.J. Blaha, K. Nasir, R.S. Blumenthal, M.J. 
Budoff, High-Sensitivity C-Reactive Protein and Cardiovascular Disease, J. Am. Coll. Cardiol. 62 
(2013) 397–408. doi:10.1016/j.jacc.2013.05.016. 
[121] A. Edsfeldt, H. Grufman, G. Asciutto, M. Nitulescu, A. Persson, M. Nilsson, J. Nilsson, I. 
Gonçalves, Circulating cytokines reflect the expression of pro-inflammatory cytokines in 
atherosclerotic plaques, Atherosclerosis. 241 (2015) 443–449. 
doi:10.1016/j.atherosclerosis.2015.05.019. 
[122] W. Peeters, W.E. Hellings, D.P.V. de Kleijn, J.P.P.M. de Vries, F.L. Moll, A. Vink, G. 
Pasterkamp, Carotid Atherosclerotic Plaques Stabilize After Stroke: Insights Into the Natural 
Process of Atherosclerotic Plaque Stabilization, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 128–
133. doi:10.1161/ATVBAHA.108.173658. 
[123] Y. Seino, U. Ikeda, M. Ikeda, K. Yamamoto, Y. Misawa, T. Hasegawa, S. Kano, K. Shimada, 
Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions, Cytokine. 6 (1994) 
87–91. doi:1043-4666(94)90013-2 [pii]. 
[124] O. Reikerås, P. Borgen, Activation of Markers of Inflammation, Coagulation and Fibrinolysis in 
Musculoskeletal Trauma, PLoS One. 9 (2014) e107881. doi:10.1371/journal.pone.0107881. 
[125] B. Schieffer, Impact of Interleukin-6 on Plaque Development and Morphology in Experimental 
Atherosclerosis, Circulation. 110 (2004) 3493–3500. doi:10.1161/01.CIR.0000148135.08582.97. 
[126] X. Shi, W.-L. Xie, W.-W. Kong, D. Chen, P. Qu, Expression of the NLRP3 Inflammasome in 
Carotid Atherosclerosis, J. Stroke Cerebrovasc. Dis. 24 (2015) 2455–2466. 
doi:10.1016/j.jstrokecerebrovasdis.2015.03.024. 
[127] Z. Mallat, A. Corbaz, A. Scoazec, S. Besnard, G. Lesèche, Y. Chvatchko, A. Tedgui, Expression 
of Interleukin-18 in human atherosclerotic plaques and relation to plaque instability, Circulation. 
104 (2001) 1598–1603. 
125 
 
[128] M.K. Salem, H.Z. Butt, E. Choke, D. Moore, K. West, T.G. Robinson, R.D. Sayers, A.R. Naylor, 
M.J. Bown, Gene and Protein Expression of Chemokine (C-C-Motif) Ligand 19 is Upregulated in 
Unstable Carotid Atherosclerotic Plaques, Eur. J. Vasc. Endovasc. Surg. 52 (2016) 427–436. 
doi:10.1016/j.ejvs.2016.05.018. 
[129] C. Erbel, T. Dengler, S. Wangler, F. Lasitschka, F. Bea, N. Wambsganss, M. Hakimi, D. Böckler, 
H. Katus, C. Gleissner, Expression of IL-17A in human atherosclerotic lesions is associated with 
increased inflammation and plaque vulnerability, Basic Res. Cardiol. 106 (2011) 125–134. 
doi:10.1007/s00395-010-0135-y. 
[130] A.E. Michelsen, C.N. Rathcke, M. Skjelland, S. Holm, T. Ranheim, K. Krohg-Sørensen, M.F. 
Klingvall, F. Brosstad, E. Oie, H. Vestergaard, P. Aukrust, B. Halvorsen, Increased YKL-40 
expression in patients with carotid atherosclerosis, Atherosclerosis. 211 (2010) 589–595. 
doi:10.1016/j.atherosclerosis.2010.02.035. 
[131] Y.-N. Qian, Y.-T. Luo, H.-X. Duan, L.-Q. Feng, Q. Bi, Y.-J. Wang, X.-Y. Yan, Adhesion 
Molecule CD146 and its Soluble Form Correlate Well with Carotid Atherosclerosis and Plaque 
Instability, CNS Neurosci. Ther. 20 (2014) 438–445. doi:10.1111/cns.12234. 
[132] A. Edsfeldt, M. Nitulescu, H. Grufman, C. Gronberg, A. Persson, M. Nilsson, M. Persson, H. 
Bjorkbacka, I. Goncalves, Soluble Urokinase Plasminogen Activator Receptor is Associated With 
Inflammation in the Vulnerable Human Atherosclerotic Plaque, Stroke. 43 (2012) 3305–3312. 
doi:10.1161/STROKEAHA.112.664094. 
[133] A. Abbas, I. Gregersen, S. Holm, I. Daissormont, V. Bjerkeli, K. Krohg-Sørensen, K.R. Skagen, 
T.B. Dahl, D. Russell, T. Almås, D. Bundgaard, L.H. Alteheld, A. Rashidi, C.P. Dahl, A.E. 
Michelsen, E.A. Biessen, P. Aukrust, B. Halvorsen, M. Skjelland, Interleukin 23 levels are 
increased in carotid atherosclerosis. Possible role for the interleukin 23/interleukin 17 axis, 
Stroke. 46 (2015) 793–799. doi:10.1161/STROKEAHA.114.006516. 
[134] T.B. Dahl, A. Yndestad, M. Skjelland, E. Oie, A. Dahl, A. Michelsen, J.K. Damas, S.H. Tunheim, 
T. Ueland, C. Smith, B. Bendz, S. Tonstad, L. Gullestad, S.S. Froland, K. Krohg-Sorensen, D. 
Russell, P. Aukrust, B. Halvorsen, Increased Expression of Visfatin in Macrophages of Human 
Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque 
Destabilization, Circulation. 115 (2007) 972–980. 
doi:10.1161/CIRCULATIONAHA.106.665893. 
[135] W.-J. Kim, H. Kim, K. Suk, W.-H. Lee, Macrophages express granzyme B in the lesion areas of 
atherosclerosis and rheumatoid arthritis, Immunol. Lett. 111 (2007) 57–65. 
doi:10.1016/j.imlet.2007.05.004. 
[136] A. Abbas, P. Aukrust, T.B. Dahl, V. Bjerkeli, E.B.L. Sagen, A. Michelsen, D. Russell, K. Krohg-
Sorensen, S. Holm, M. Skjelland, B. Halvorsen, High Levels of S100A12 Are Associated With 




[137] D. Rodríguez, C.J. Morrison, C.M. Overall, Matrix metalloproteinases: What do they not do? 
New substrates and biological roles identified by murine models and proteomics, Biochim. 
Biophys. Acta - Mol. Cell Res. 1803 (2010) 39–54. doi:10.1016/j.bbamcr.2009.09.015. 
[138] Z.S. Galis, G.K. Sukhova, M.W. Lark, P. Libby, Increased expression of matrix 
metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic 
plaques., J. Clin. Invest. 94 (1994) 2493–2503. doi:10.1172/JCI117619. 
[139] J.L. Johnson, Metalloproteinases in atherosclerosis, Eur. J. Pharmacol. 816 (2017) 93–106. 
doi:10.1016/j.ejphar.2017.09.007. 
[140] I.M. Loftus, A.R. Naylor, S. Goodall, M. Crowther, L. Jones, P.R.F. Bell, M.M. Thompson, 
Increased Matrix Metalloproteinase-9 Activity in Unstable Carotid Plaques, Stroke. 31 (2000) 
40–47. 
[141] K.J. Molloy, M.M. Thompson, J.L. Jones, E.C. Schwalbe, P.R.F. Bell, A.R. Naylor, I.M. Loftus, 
Unstable Carotid Plaques Exhibit Raised Matrix Metalloproteinase-8 Activity, Circulation. 110 
(2004) 337–343. doi:10.1161/01.CIR.0000135588.65188.14. 
[142] A. Abbas, P. Aukrust, D. Russell, K. Krohg-Sørensen, T. Almås, D. Bundgaard, V. Bjerkeli, E.L. 
Sagen, A.E. Michelsen, T.B. Dahl, S. Holm, T. Ueland, M. Skjelland, B. Halvorsen, Matrix 
Metalloproteinase 7 Is Associated with Symptomatic Lesions and Adverse Events in Patients with 
Carotid Atherosclerosis, PLoS One. 9 (2014) e84935. doi:10.1371/journal.pone.0084935. 
[143] H. Williams, J.L. Johnson, C.L. Jackson, S.J. White, S.J. George, MMP-7 mediates cleavage of 
N-cadherin and promotes smooth muscle cell apoptosis, Cardiovasc. Res. 87 (2010) 137–146. 
doi:10.1093/cvr/cvq042. 
[144] J.P.G. Sluijter, W.P.C. Pulskens, A.H. Schoneveld, E. Velema, C.F. Strijder, F. Moll, J.-P. de 
Vries, J. Verheijen, R. Hanemaaijer, D.P.V. de Kleijn, G. Pasterkamp, Matrix Metalloproteinase 2 
Is Associated With Stable and Matrix Metalloproteinases 8 and 9 With Vulnerable Carotid 
Atherosclerotic Lesions: A Study in Human Endarterectomy Specimen Pointing to a Role for 
Different Extracellular Matrix Metalloproteinase In, Stroke. 37 (2006) 235–239. 
doi:10.1161/01.STR.0000196986.50059.e0. 
[145] N. Eldrup, M.-L.M. Gronholdt, H. Sillesen, B.G. Nordestgaard, Elevated Matrix 
Metalloproteinase-9 Associated With Stroke or Cardiovascular Death in Patients With Carotid 
Stenosis, Circulation. 114 (2006) 1847–1854. doi:10.1161/CIRCULATIONAHA.105.593483. 
[146] N. Oksala, M. Levula, N. Airla, M. Pelto-Huikko, R.M. Ortiz, O. Järvinen, J. Salenius, B. Ozsait, 
E. Komurcu-Bayrak, N. Erginel-Unaltuna, A.J. Huovila, L. Kytömäki, J.T. Soini, M. Kähönen, 
P.J. Karhunen, R. Laaksonen, T. Lehtimäki, ADAM-9, ADAM-15, and ADAM-17 are 
upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and 
femoral arteries—Tampere vascular study, Ann. Med. 41 (2009) 279–290. 
doi:10.1080/07853890802649738. 
[147] C. Lipp, F. Lohoefer, C. Reeps, M. Rudelius, M. Baummann, U. Heemann, H.-H. Eckstein, J. 
127 
 
Pelisek, Expression of a Disintegrin and Metalloprotease in Human Abdominal Aortic 
Aneurysms, J. Vasc. Res. 49 (2012) 198–206. doi:10.1159/000332959. 
[148] G. Musumeci, R. Coleman, R. Imbesi, G. Magro, R. Parenti, M.A. Szychlinska, R. Scuderi, C.S. 
Cinà, S. Castorina, P. Castrogiovanni, ADAM-10 could mediate cleavage of N-cadherin 
promoting apoptosis in human atherosclerotic lesions leading to vulnerable plaque: A 
morphological and immunohistochemical study, Acta Histochem. 116 (2014) 1148–1158. 
doi:10.1016/j.acthis.2014.06.002. 
[149] D. Wågsäter, H. Björk, C. Zhu, J. Björkegren, G. Valen, A. Hamsten, P. Eriksson, ADAMTS-4 
and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human 
atherosclerotic plaques, Atherosclerosis. 196 (2008) 514–522. 
doi:10.1016/j.atherosclerosis.2007.05.018. 
[150] E. Bengtsson, K. Hultman, P. Dunér, G. Asciutto, P. Almgren, M. Orho-Melander, O. Melander, 
J. Nilsson, A. Hultgårdh-Nilsson, I. Gonçalves, ADAMTS-7 is associated with a high-risk plaque 
phenotype in human atherosclerosis, Sci. Rep. 7 (2017) 3753. doi:10.1038/s41598-017-03573-4. 
[151] A.-C. Jönsson Rylander, A. Lindgren, J. Deinum, G.M.L. Bergström, G. Böttcher, I. Kalies, K. 
Wåhlander, Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and 
TAFI in advanced carotid plaque, J. Thromb. Haemost. 15 (2017) 758–769. 
doi:10.1111/jth.13641. 
[152] S. Ding, M. Zhang, Y. Zhao, W. Chen, G. Yao, C. Zhang, P. Zhang, Y. Zhang, The role of carotid 
plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke, Am. J. Med. 
Sci. 336 (2008) 27–31. doi:10.1097/MAJ.0b013e31815b60a1. 
[153] P. Musialek, W. Tracz, L. Tekieli, P. Pieniazek, A. Kablak-Ziembicka, T. Przewlocki, E. Stepien, 
P. Kapusta, R. Motyl, J. Stepniewski, A. Undas, P. Podolec, Multimarker Approach in 
Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery 
Stenosis, J. Clin. Neurol. 9 (2013) 165–175. doi:10.3988/jcn.2013.9.3.165. 
[154] R.P. Fabunmi, G.K. Sukhova, S. Sugiyama, P. Libby, Expression of tissue inhibitor of 
metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential 
protective mechanism in plaque stability., Circ. Res. 83 (1998) 270–278. 
http://circres.ahajournals.org/cgi/content/abstract/83/3/270. 
[155] I. Koskivirta, O. Rahkonen, M. Mäyränpää, S. Pakkanen, M. Husheem, A. Sainio, H. Hakovirta, 
J. Laine, E. Jokinen, E. Vuorio, P. Kovanen, H. Järveläinen, Tissue inhibitor of 
metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular 
pathology, Histochem. Cell Biol. 126 (2006) 335–342. doi:10.1007/s00418-006-0163-8. 
[156] P. Heider, N. Pfäffle, J. Pelisek, M. Wildgruber, H. Poppert, M. Rudelius, H.-H. Eckstein, Is 
Serum Pregnancy-Associated Plasma Protein A Really a Potential Marker of Atherosclerotic 




[157] G. Sangiorgi, A. Mauriello, E. Bonanno, C. Oxvig, C.A. Conover, M. Christiansen, S. Trimarchi, 
V. Rampoldi, D.R. Holmes, R.S. Schwartz, L.G. Spagnoli, Pregnancy-Associated Plasma Protein-
A Is Markedly Expressed by Monocyte-Macrophage Cells in Vulnerable and Ruptured Carotid 
Atherosclerotic Plaques, J. Am. Coll. Cardiol. 47 (2006) 2201–2211. 
doi:10.1016/j.jacc.2005.11.086. 
[158] A. Mauriello, G. Sangiorgi, G. Palmieri, R. Virmani, D.R. Holmes, R.S. Schwartz, R. Pistolese, 
A. Ippoliti, L.G. Spagnoli, Hyperfibrinogenemia is associated with specific histocytological 
composition and complications of atherosclerotic carotid plaques in patients affected by transient 
ischemic attacks, Circulation. 101 (2000) 744–50. 
http://www.ncbi.nlm.nih.gov/pubmed/10683347. 
[159] J. Golledge, M. McCann, S. Mangan, A. Lam, M. Karan, Osteoprotegerin and osteopontin are 
expressed at high concentrations within symptomatic carotid atherosclerosis, Stroke. 35 (2004) 
1636–1641. doi:10.1161/01.STR.0000129790.00318.a3. 
[160] D.P. V. de Kleijn, F.L. Moll, W.E. Hellings, G. Ozsarlak-Sozer, P. de Bruin, P.A. Doevendans, 
A. Vink, L.M. Catanzariti, A.H. Schoneveld, A. Algra, M.J. Daemen, E.A. Biessen, W. de Jager, 
H. Zhang, J.-P. de Vries, E. Falk, S.K. Lim, P.J. van der Spek, S.K. Sze, G. Pasterkamp, Local 
Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular 
Events, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 612–619. 
doi:10.1161/ATVBAHA.109.194944. 
[161] S. Rocchiccioli, G. Pelosi, S. Rosini, M. Marconi, F. Viglione, L. Citti, M. Ferrari, M. Trivella, A. 
Cecchettini, Secreted proteins from carotid endarterectomy: an untargeted approach to disclose 
molecular clues of plaque progression, J. Transl. Med. 11 (2013) 260. doi:10.1186/1479-5876-11-
260. 
[162] X.-D. Xiong, W.-D. Xiong, S.-S. Xiong, G.-H. Chen, Research Progress on the Risk Factors and 
Outcomes of Human Carotid Atherosclerotic Plaques, Chin. Med. J. (Engl). 130 (2017) 722. 
doi:10.4103/0366-6999.201598. 
[163] Z. Chen, M. Ichetovkin, M. Kurtz, E. Zycband, D. Kawka, J. Woods, X. He, A.S. Plump, E. 
Hailman, Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and 
plaque vulnerability, Lipids Health Dis. 9 (2010) 61. doi:10.1186/1476-511X-9-61. 
[164] K. Nishi, H. Itabe, M. Uno, K.T. Kitazato, H. Horiguchi, K. Shinno, N. Shinji, Oxidized LDL in 
Carotid Plaques and Plasma Associates With Plaque Instability, Arterioscler. Thromb. Vasc. Biol. 
22 (2002) 1649–1654. doi:10.1161/01.ATV.0000033829.14012.18. 
[165] E. Verhoye, M.R. Langlois, Circulating oxidized low-density lipoprotein: a biomarker of 
atherosclerosis and cardiovascular risk?, Clin. Chem. Lab. Med. 47 (2009) 128–137. 
doi:10.1515/CCLM.2009.037. 
[166] D. Alkazemi, G. Egeland, J. Vaya, S. Meltzer, S. Kubow, Oxysterol as a Marker of Atherogenic 




[167] V.M. Olkkonen, M. Lehto, Oxysterols and oxysterol binding proteins: role in lipid metabolism 
and atherosclerosis, Ann. Med. 36 (2004) 562–572. doi:10.1080/07853890410018907. 
[168] A. Daugherty, J.L. Dunn, D.L. Rateri, J.W. Heinecke, Myeloperoxidase, a catalyst for lipoprotein 
oxidation, is expressed in human atherosclerotic lesions., J. Clin. Invest. 94 (1994) 437–444. 
doi:10.1172/JCI117342. 
[169] M. Exner, E. Minar, W. Mlekusch, S. Sabeti, J. Amighi, W. Lalouschek, G. Maurer, C. 
Bieglmayer, H. Kieweg, O. Wagner, M. Schillinger, Myeloperoxidase Predicts Progression of 
Carotid Stenosis in States of Low High-Density Lipoprotein Cholesterol, J. Am. Coll. Cardiol. 47 
(2006) 2212–2218. doi:10.1016/j.jacc.2006.01.067. 
[170] L. Zheng, M. Settle, G. Brubaker, D. Schmitt, S.L. Hazen, J.D. Smith, M. Kinter, Localization of 
Nitration and Chlorination Sites on Apolipoprotein A-I Catalyzed by Myeloperoxidase in Human 
Atheroma and Associated Oxidative Impairment in ABCA1-dependent Cholesterol Efflux from 
Macrophages, J. Biol. Chem. 280 (2005) 38–47. doi:10.1074/jbc.M407019200. 
[171] P. Maitrias, V. Metzinger-Le Meuth, Z.A. Massy, E. M’Baya-Moutoula, T. Reix, T. Caus, L. 
Metzinger, MicroRNA deregulation in symptomatic carotid plaque, J. Vasc. Surg. 62 (2015) 
1245–1250.e1. doi:10.1016/j.jvs.2015.06.136. 
[172] S. Dolz, D. Górriz, J.I. Tembl, D. Sánchez, G. Fortea, V. Parkhutik, A. Lago, Circulating 
MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis, 
Stroke. 48 (2017) 10–16. doi:10.1161/STROKEAHA.116.013650. 
[173] E.M. Rzucidlo, K.A. Martin, R.J. Powell, Regulation of vascular smooth muscle cell 
differentiation, J. Vasc. Surg. 45 (2007) A25–A32. doi:10.1016/j.jvs.2007.03.001. 
[174] J.E. Hungerford, C.D. Little, Developmental biology of the vascular smooth muscle cell: Building 
a multilayered vessel wall, J. Vasc. Res. 36 (1999) 2–27. doi:10.1159/000025622. 
[175] D. Gomez, G.K. Owens, Smooth muscle cell phenotypic switching in atherosclerosis, Cardiovasc. 
Res. 95 (2012) 156–164. doi:10.1093/cvr/cvs115. 
[176] L.A. Martinez-Lemus, X. Wu, E. Wilson, M.A. Hill, G.E. Davis, M.J. Davis, G.A. Meininger, 
Integrins as Unique Receptors for Vascular Control, J. Vasc. Res. 40 (2003) 211–233. 
doi:10.1159/000071886. 
[177] W.B. Campbell, J.R. Falck, Arachidonic acid metabolites as endothelium-derived hyperpolarizing 
factors, Hypertension. 49 (2007) 590–596. doi:10.1161/01.HYP.0000255173.50317.fc. 
[178] F.J. Haddy, P.M. Vanhoutte, M. Feletou, Role of potassium in regulating blood flow and blood 
pressure, Am. J. Physiol. Integr. Comp. Physiol. 290 (2006) R546–R552. 
doi:10.1152/ajpregu.00491.2005. 
[179] K.G. Birukov, N. Bardy, S. Lehoux, R. Merval, V.P. Shirinsky, A. Tedgui, Intraluminal pressure 
is essential for the maintenance of smooth muscle caldesmon and filamin content in aortic organ 
130 
 
culture, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 922–927. doi:10.1161/01.ATV.18.6.922. 
[180] G.K. Owens, M.S. Kumar, B.R. Wamhoff, Molecular regulation of vascular smooth muscle cell 
differentiation in development and disease., Physiol. Rev. 84 (2004) 767–801. 
doi:10.1152/physrev.00041.2003. 
[181] S.S.M. Rensen, P.A.F.M. Doevendans, G.J.J.M. van Eys, Regulation and characteristics of 
vascular smooth muscle cell phenotypic diversity., Neth. Heart J. 15 (2007) 100–108. 
http://www.ncbi.nlm.nih.gov/pubmed/17612668. 
[182] J. Chamley-Campbell, G.R. Campbell, R. Ross, The smooth muscle cell in culture., Physiol. Rev. 
59 (1979) 1–61. http://physrev.physiology.org/content/59/1/1.full.pdf. 
[183] M.R. Bennett, S. Sinha, G.K. Owens, Vascular Smooth Muscle Cells in Atherosclerosis, Circ. 
Res. 118 (2016) 692–702. doi:10.1161/CIRCRESAHA.115.306361. 
[184] H. Shen, K. Eguchi, N. Kono, K. Fujiu, S. Matsumoto, M. Shibata, Y. Oishi-Tanaka, I. Komuro, 
H. Arai, R. Nagai, I. Manabe, Saturated Fatty Acid Palmitate Aggravates Neointima Formation 
by Promoting Smooth Muscle Phenotypic Modulation, Arterioscler. Thromb. Vasc. Biol. 33 
(2013) 2596–2607. doi:10.1161/ATVBAHA.113.302099. 
[185] R.A. Deaton, Q. Gan, G.K. Owens, Sp1-dependent activation of KLF4 is required for PDGF-BB-
induced phenotypic modulation of smooth muscle, Am. J. Physiol. Circ. Physiol. 296 (2009) 
H1027–H1037. doi:10.1152/ajpheart.01230.2008. 
[186] S. Li, D.-Z. Wang, Z. Wang, J.A. Richardson, E.N. Olson, The serum response factor coactivator 
myocardin is required for vascular smooth muscle development, Proc. Natl. Acad. Sci. 100 
(2003) 9366–9370. doi:10.1073/pnas.1233635100. 
[187] J.M. Miano, X. Long, K. Fujiwara, Serum response factor: master regulator of the actin 
cytoskeleton and contractile apparatus, Am. J. Physiol. Physiol. 292 (2007) C70–C81. 
doi:10.1152/ajpcell.00386.2006. 
[188] S. Shinohara, S. Shinohara, T. Kihara, J. Miyake, Regulation of Differentiated Phenotypes of 
Vascular Smooth Muscle Cells, in: Curr. Basic Pathol. Approaches to Funct. Muscle Cells 
Tissues - From Mol. to Humans, InTech, 2012: pp. 331–344. doi:10.5772/48573. 
[189] P. Lacolley, V. Regnault, A. Nicoletti, Z. Li, J.B. Michel, The vascular smooth muscle cell in 
arterial pathology: A cell that can take on multiple roles, Cardiovasc. Res. 95 (2012) 194–204. 
doi:10.1093/cvr/cvs135. 
[190] J. Thyberg, K. Blomgren, J. Roy, P.K. Tran, U. Hedin, Phenotypic modulation of smooth muscle 
cells after arterial injury is associated with changes in the distribution of laminin and fibronectin, 
J Histochem Cytochem. 45 (1997) 837–846. doi:10.1177/002215549704500608. 
[191] J.L. Johnson, Emerging regulators of vascular smooth muscle cell function in the development 




[192] Y. Vengrenyuk, H. Nishi, X. Long, M. Ouimet, N. Savji, F.O. Martinez, C.P. Cassella, K.J. 
Moore, S.A. Ramsey, J.M. Miano, E.A. Fisher, Cholesterol loading reprograms the microRNA-
143/145-Myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-
like phenotype, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 535–546. 
doi:10.1161/ATVBAHA.114.304029. 
[193] T. Yoshida, M. Yamashita, M. Hayashi, Krüppel-like Factor 4 Contributes to High Phosphate-
induced Phenotypic Switching of Vascular Smooth Muscle Cells into Osteogenic Cells, J. Biol. 
Chem. 287 (2012) 25706–25714. doi:10.1074/jbc.M112.361360. 
[194] J.A. Leopold, Vascular calcification: Mechanisms of vascular smooth muscle cell calcification, 
Trends Cardiovasc. Med. 25 (2015) 267–274. doi:10.1016/j.tcm.2014.10.021. 
[195] M.R. Alexander, G.K. Owens, Epigenetic Control of Smooth Muscle Cell Differentiation and 
Phenotypic Switching in Vascular Development and Disease, Annu. Rev. Physiol. 74 (2012) 13–
40. doi:10.1146/annurev-physiol-012110-142315. 
[196] C. Chaabane, M. Coen, M.-L. Bochaton-Piallat, Smooth muscle cell phenotypic switch: 
implication for foam cell formation, Curr. Opin. Lipidol. 25 (2014) 374–379. 
doi:10.1097/MOL.0000000000000113. 
[197] D.A. Chistiakov, A.N. Orekhov, Y. V. Bobryshev, Vascular smooth muscle cell in 
atherosclerosis, Acta Physiol. 214 (2015) 33–50. doi:10.1111/apha.12466. 
[198] N.A. Pidkovka, O.A. Cherepanova, T. Yoshida, M.R. Alexander, R.A. Deaton, J.A. Thomas, N. 
Leitinger, G.K. Owens, Oxidized Phospholipids Induce Phenotypic Switching of Vascular 
Smooth Muscle Cells In Vivo and In Vitro, Circ. Res. 101 (2007) 792–801. 
doi:10.1161/CIRCRESAHA.107.152736. 
[199] L.S. Shankman, D. Gomez, O.A. Cherepanova, M. Salmon, G.F. Alencar, R.M. Haskins, P. 
Swiatlowska, A.A.C. Newman, E.S. Greene, A.C. Straub, B. Isakson, G.J. Randolph, G.K. 
Owens, KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in 
atherosclerotic plaque pathogenesis, Nat. Med. 21 (2015) 628–637. doi:10.1038/nm.3866. 
[200] D.M. Schrijvers, Phagocytosis of Apoptotic Cells by Macrophages Is Impaired in Atherosclerosis, 
Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1256–1261. 
doi:10.1161/01.ATV.0000166517.18801.a7. 
[201] L.L. Demer, Y. Tintut, Inflammatory, Metabolic, and Genetic Mechanisms of Vascular 
Calcification, Arterioscler. Thromb. Vasc. Biol. 34 (2014) 715–723. 
doi:10.1161/ATVBAHA.113.302070. 
[202] V.J. Dzau, R.C. Braun-Dullaeus, D.G. Sedding, Vascular proliferation and atherosclerosis: new 
perspectives and therapeutic strategies, Nat. Med. 8 (2002) 1249–1256. doi:10.1038/nm1102-
1249. 
[203] J.A. Beamish, P. He, K. Kottke-Marchant, R.E. Marchant, Molecular Regulation of Contractile 
Smooth Muscle Cell Phenotype: Implications for Vascular Tissue Engineering, Tissue Eng. Part 
132 
 
B Rev. 16 (2010) 467–491. doi:10.1089/ten.TEB.2009.0630. 
[204] C.L. Papke, J. Cao, C.S. Kwartler, C. Villamizar, K.L. Byanova, S.-M. Lim, H. Sreenivasappa, G. 
Fischer, J. Pham, M. Rees, M. Wang, C. Chaponnier, G. Gabbiani, A.Y. Khakoo, J. Chandra, A. 
Trache, W. Zimmer, D.M. Milewicz, Smooth muscle hyperplasia due to loss of smooth muscle α-
actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels 
of platelet-derived growth factor receptor-β, Hum. Mol. Genet. 22 (2013) 3123–3137. 
doi:10.1093/hmg/ddt167. 
[205] M.E. Sandison, J. Dempster, J.G. Mccarron, The Transition of Smooth Muscle Cells from a 
Contractile to a Migratory , Phagocytic Phenotype : Direct Demonstration of Phenotypic 
Modulation, J. Physiol. epub befor (2016) 6189–6209. doi:10.1113/JP272729.This. 
[206] L.H. Dong, J.K. Wen, G. Liu, M.A. McNutt, S.B. Miao, R. Gao, B. Zheng, H. Zhang, M. Han, 
Blockade of the Ras-Extracellular Signal-Regulated Kinase 1/2 Pathway Is Involved in Smooth 
Muscle 22 -Mediated Suppression of Vascular Smooth Muscle Cell Proliferation and Neointima 
Hyperplasia, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 683–691. 
doi:10.1161/ATVBAHA.109.200501. 
[207] M. Han, L.-H. Dong, B. Zheng, J.-H. Shi, J.-K. Wen, Y. Cheng, Smooth muscle 22 alpha 
maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous 
actin bundling, Life Sci. 84 (2009) 394–401. doi:10.1016/j.lfs.2008.11.017. 
[208] S. Feil, F. Hofmann, R. Feil, SM22 Modulates Vascular Smooth Muscle Cell Phenotype During 
Atherogenesis, Circ. Res. 94 (2004) 863–865. doi:10.1161/01.RES.0000126417.38728.F6. 
[209] S. a Fisher, Vascular smooth muscle phenotypic diversity and function, Physiol. Genomics. 42A 
(2010) 169–187. doi:10.1152/physiolgenomics.00111.2010. 
[210] K. Hayashi, Y. Fujio, I. Kato, K. Sobue, Structural and functional relationships between h- and l-
Caldesmons, J. Biol. Chem. 266 (1991) 355–361. 
[211] M. Gimona, I. Kaverina, G.P. Resch, E. Vignal, G. Burgstaller, Calponin repeats regulate actin 
filament stability and formation of podosomes in smooth muscle cells, Mol. Biol. Cell. 14 (2003) 
2482–2491. doi:10.1091/mbc.E02-11-0743. 
[212] R. Liu, J.-P. Jin, Calponin isoforms CNN 1, CNN 2 and CNN 3: Regulators for actin cytoskeleton 
functions in smooth muscle and non-muscle cells, Gene. 585 (2016) 143–153. 
doi:10.1016/j.gene.2016.02.040. 
[213] G.J. van Eys, P.M. Niessen, S.S. Rensen, Smoothelin in Vascular Smooth Muscle Cells, Trends 
Cardiovasc. Med. 17 (2007) 26–30. doi:10.1016/j.tcm.2006.11.001. 
[214] D. PAULIN, Z. LI, Desmin: a major intermediate filament protein essential for the structural 
integrity and function of muscle, Exp. Cell Res. 301 (2004) 1–7. 
doi:10.1016/j.yexcr.2004.08.004. 
[215] I. Vukovic, N. Arsenijevic, V. Lackovic, V. Todorovic, The origin and differentiation potential of 
133 
 
smooth muscle cells in coronary atherosclerosis., Exp. Clin. Cardiol. 11 (2006) 123–128. 
http://www.ncbi.nlm.nih.gov/pubmed/18651048. 
[216] S. Sakurai, T. Fukasawa, J.M. Chong, A. Tanaka, M. Fukayama, Embryonic form of smooth 
muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial 
cells of Cajal, Am. J. Pathol. 154 (1999) 23–28. doi:10.1016/S0002-9440(10)65246-7. 
[217] J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, F. Speleman, 
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of 
multiple internal control genes, Genome Biol. 3 (2002) research0034.1. doi:10.1186/gb-2002-3-7-
research0034. 
[218] T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative CT method, Nat. 
Protoc. 3 (2008) 1101–1108. doi:10.1038/nprot.2008.73. 
[219] R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. 
Aggarwal, S.Y. Ahn, M.A. AlMazroa, M. Alvarado, H.R. Anderson, L.M. Anderson, K.G. 
Andrews, C. Atkinson, L.M. Baddour, S. Barker-Collo, D.H. Bartels, M.L. Bell, E.J. Benjamin, 
D. Bennett, K. Bhalla, B. Bikbov, A. Bin Abdulhak, G. Birbeck, F. Blyth, I. Bolliger, S. Boufous, 
C. Bucello, M. Burch, P. Burney, J. Carapetis, H. Chen, D. Chou, S.S. Chugh, L.E. Coffeng, S.D. 
Colan, S. Colquhoun, K.E. Colson, J. Condon, M.D. Connor, L.T. Cooper, M. Corriere, M. 
Cortinovis, K. Courville De Vaccaro, W. Couser, B.C. Cowie, M.H. Criqui, M. Cross, K.C. 
Dabhadkar, N. Dahodwala, D. De Leo, L. Degenhardt, A. Delossantos, J. Denenberg, D.C. Des 
Jarlais, S.D. Dharmaratne, E.R. Dorsey, T. Driscoll, H. Duber, B. Ebel, P.J. Erwin, P. Espindola, 
M. Ezzati, V. Feigin, A.D. Flaxman, M.H. Forouzanfar, F.G.R. Fowkes, R. Franklin, M. Fransen, 
M.K. Freeman, S.E. Gabriel, E. Gakidou, F. Gaspari, R.F. Gillum, D. Gonzalez-Medina, Y.A. 
Halasa, D. Haring, J.E. Harrison, R. Havmoeller, R.J. Hay, B. Hoen, P.J. Hotez, D. Hoy, K.H. 
Jacobsen, S.L. James, R. Jasrasaria, S. Jayaraman, N. Johns, G. Karthikeyan, N. Kassebaum, A. 
Keren, J.P. Khoo, L.M. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, M. Lipnick, 
S.E. Lipshultz, S. Lockett Ohno, J. Mabweijano, M.F. MacIntyre, L. Mallinger, L. March, G.B. 
Marks, R. Marks, A. Matsumori, R. Matzopoulos, B.M. Mayosi, J.H. McAnulty, M.M. 
McDermott, J. McGrath, Z.A. Memish, G.A. Mensah, T.R. Merriman, C. Michaud, M. Miller, 
T.R. Miller, C. Mock, A.O. Mocumbi, A.A. Mokdad, A. Moran, K. Mulholland, M.N. Nair, L. 
Naldi, K.M.V. Narayan, K. Nasseri, P. Norman, M. O’Donnell, S.B. Omer, K. Ortblad, R. 
Osborne, D. Ozgediz, B. Pahari, J.D. Pandian, A. Panozo Rivero, R. Perez Padilla, F. Perez-Ruiz, 
N. Perico, D. Phillips, K. Pierce, C.A. Pope, E. Porrini, F. Pourmalek, M. Raju, D. Ranganathan, 
J.T. Rehm, D.B. Rein, G. Remuzzi, F.P. Rivara, T. Roberts, F. Rodriguez De León, L.C. 
Rosenfeld, L. Rushton, R.L. Sacco, J.A. Salomon, U. Sampson, E. Sanman, D.C. Schwebel, M. 
Segui-Gomez, D.S. Shepard, D. Singh, J. Singleton, K. Sliwa, E. Smith, A. Steer, J.A. Taylor, B. 
Thomas, I.M. Tleyjeh, J.A. Towbin, T. Truelsen, E.A. Undurraga, N. Venketasubramanian, L. 
Vijayakumar, T. Vos, G.R. Wagner, M. Wang, W. Wang, K. Watt, M.A. Weinstock, R. 
Weintraub, J.D. Wilkinson, A.D. Woolf, S. Wulf, P.H. Yeh, P. Yip, A. Zabetian, Z.J. Zheng, 
A.D. Lopez, C.J.L. Murray, Global and regional mortality from 235 causes of death for 20 age 
134 
 
groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010, 
Lancet. 380 (2012) 2095–2128. doi:10.1016/S0140-6736(12)61728-0. 
[220] D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, S.L. Salzberg, TopHat2: accurate 
alignment of transcriptomes in the presence of insertions, deletions and gene fusions, Genome 
Biol. 14 (2013) R36. doi:10.1186/gb-2013-14-4-r36. 
[221] C. Trapnell, B. a Williams, G. Pertea, A. Mortazavi, G. Kwan, M.J. van Baren, S.L. Salzberg, 
B.J. Wold, L. Pachter, Transcript assembly and quantification by RNA-Seq reveals unannotated 
transcripts and isoform switching during cell differentiation, Nat. Biotechnol. 28 (2010) 511–515. 
doi:10.1038/nbt.1621. 
[222] M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-
seq data with DESeq2, Genome Biol. 15 (2014) 550. doi:10.1186/s13059-014-0550-8. 
[223] Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: a practical and powerful 
approach to multiple testing, J. R. Stat. Soc. Ser. B. 57 (1995) 289–300. doi:10.2307/2346101. 
[224] G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: an R Package for Comparing Biological 
Themes Among Gene Clusters, Omi. A J. Integr. Biol. 16 (2012) 284–287. 
doi:10.1089/omi.2011.0118. 
[225] C. V Remillard, A. Makino, J.X. Yuan, Textbook of Pulmonary Vascular Disease, Springer US, 
Boston, MA, 2011. doi:10.1007/978-0-387-87429-6. 
[226] A.T. Churchman, R.C.M. Siow, Isolation, Culture and Characterisation of Vascular Smooth 
Muscle Cells, in: Angiogenes. Protoc., 2009: pp. 127–138. doi:10.1007/978-1-59745-241-0_7. 
[227] GeneCards, CXCL9, GeneCards - Hum. Gene Database. (2014). http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CXCL9&keywords=cxcl9. 
[228] GeneCards, CXCL10, GeneCards - Hum. Gene Database. (2010). http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CXCL10&keywords=cxcl10. 
[229] GeneCards, CD5L, GeneCards - Hum. Gene Database. (n.d.). http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CD5L&keywords=cd5L. 
[230] S. Arai, J.M. Shelton, M. Chen, M.N. Bradley, A. Castrillo, A.L. Bookout, P.A. Mak, P.A. 
Edwards, D.J. Mangelsdorf, P. Tontonoz, T. Miyazaki, A role for the apoptosis inhibitory factor 
AIM/Spα/Api6 in atherosclerosis development, Cell Metab. 1 (2005) 201–213. 
doi:10.1016/j.cmet.2005.02.002. 
[231] I. Alloza, H. Goikuria, J.L. Idro, J.C. Triviño, J.M. Fernández Velasco, E. Elizagaray, M. García-
Barcina, G. Montoya-Murillo, E. Sarasola, R. Vega Manrique, M. del M. Freijo, K. 
Vandenbroeck, RNAseq based transcriptomics study of SMCs from carotid atherosclerotic 
plaque: BMP2 and IDs proteins are crucial regulators of plaque stability, Sci. Rep. 7 (2017) 3470. 
doi:10.1038/s41598-017-03687-9. 
[232] S. Feil, B. Fehrenbacher, R. Lukowski, F. Essmann, K. Schulze-Osthoff, M. Schaller, R. Feil, 
135 
 
Transdifferentiation of Vascular Smooth Muscle Cells to Macrophage-Like Cells During 
Atherogenesis, Circ. Res. 115 (2014) 662–667. doi:10.1161/CIRCRESAHA.115.304634. 
[233] J. Song, N.F. Worth, B.E. Rolfe, G.R. Campbell, J.H. Campbell, Heterogeneous distribution of 
isoactins in cultured vascular smooth muscle cells does not reflect segregation of contractile and 
cytoskeletal domains, J. Histochem. Cytochem. 48 (2000) 1441–1452. 
doi:10.1177/002215540004801101. 
[234] D. Sims, I. Sudbery, N.E. Ilott, A. Heger, C.P. Ponting, Sequencing depth and coverage: key 
considerations in genomic analyses, Nat. Rev. Genet. 15 (2014) 121–132. doi:10.1038/nrg3642. 
[235] Y. Liu, J. Zhou, K.P. White, RNA-seq differential expression studies: more sequence or more 
replication?, Bioinformatics. 30 (2014) 301–304. doi:10.1093/bioinformatics/btt688. 
[236] D. Risso, K. Schwartz, G. Sherlock, S. Dudoit, GC-Content Normalization for RNA-Seq Data, 
BMC Bioinformatics. 12 (2011) 480. doi:10.1186/1471-2105-12-480. 
[237] K.D. Hansen, R.A. Irizarry, Z. WU, Removing technical variability in RNA-seq data using 
conditional quantile normalization, Biostatistics. 13 (2012) 204–216. 
doi:10.1093/biostatistics/kxr054. 
[238] R.C. Team, R: A language and environment for statistical computing, (2013). http://www.r-
project.org/. 
[239] W. Stacklies, H. Redestig, M. Scholz, D. Walther, J. Selbig, pcaMethods a bioconductor package 
providing PCA methods for incomplete data, Bioinformatics. 23 (2007) 1164–1167. 
doi:10.1093/bioinformatics/btm069. 
[240] S. Anders, W. Huber, Differential expression analysis for sequence count data, Genome Biol. 11 
(2010) R106. doi:10.1186/gb-2010-11-10-r106. 
[241] C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. Salzberg, J.L. 
Rinn, L. Pachter, Differential gene and transcript expression analysis of RNA-seq experiments 
with TopHat and Cufflinks, Nat. Protoc. 7 (2012) 562–578. doi:10.1038/nprot.2012.016. 
[242] J.A. Blake, K.R. Christie, M.E. Dolan, H.J. Drabkin, D.P. Hill, L. Ni, D. Sitnikov, S. Burgess, T. 
Buza, C. Gresham, F. McCarthy, L. Pillai, H. Wang, S. Carbon, H. Dietze, S.E. Lewis, C.J. 
Mungall, M.C. Munoz-Torres, M. Feuermann, P. Gaudet, S. Basu, R.L. Chisholm, R.J. Dodson, 
P. Fey, H. Mi, P.D. Thomas, A. Muruganujan, S. Poudel, J.C. Hu, S.A. Aleksander, B.K. 
McIntosh, D.P. Renfro, D.A. Siegele, H. Attrill, N.H. Brown, S. Tweedie, J. Lomax, D. Osumi-
Sutherland, H. Parkinson, P. Roncaglia, R.C. Lovering, P.J. Talmud, S.E. Humphries, P. Denny, 
N.H. Campbell, R.E. Foulger, M.C. Chibucos, M.G. Giglio, H.Y. Chang, R. Finn, M. Fraser, A. 
Mitchell, G. Nuka, S. Pesseat, A. Sangrador, M. Scheremetjew, S.Y. Young, R. Stephan, M.A. 
Harris, S.G. Oliver, K. Rutherford, V. Wood, J. Bahler, A. Lock, P.J. Kersey, M.D. McDowall, 
D.M. Staines, M. Dwinell, M. Shimoyama, S. Laulederkind, G.T. Hayman, S.J. Wang, V. Petri, 
P. D’Eustachio, L. Matthews, R. Balakrishnan, G. Binkley, J.M. Cherry, M.C. Costanzo, J. 
Demeter, S.S. Dwight, S.R. Engel, B.C. Hitz, D.O. Inglis, P. Lloyd, S.R. Miyasato, K. Paskov, G. 
136 
 
Roe, M. Simison, R.S. Nash, M.S. Skrzypek, S. Weng, E.D. Wong, T.Z. Berardini, D. Li, E. 
Huala, J. Argasinska, C. Arighi, A. Auchincloss, K. Axelsen, G. Argoud-Puy, A. Bateman, B. 
Bely, M.C. Blatter, C. Bonilla, L. Bougueleret, E. Boutet, L. Breuza, A. Bridge, R. Britto, C. 
Casals, E. Cibrian-Uhalte, E. Coudert, I. Cusin, P. Duek-Roggli, A. Estreicher, L. Famiglietti, P. 
Gane, P. Garmiri, A. Gos, N. Gruaz-Gumowski, E. Hatton-Ellis, U. Hinz, C. Hulo, R. Huntley, F. 
Jungo, G. Keller, K. Laiho, P. Lemercier, D. Lieberherr, A. Macdougall, M. Magrane, M. Martin, 
P. Masson, P. Mutowo, C. O’Donovan, I. Pedruzzi, K. Pichler, D. Poggioli, S. Poux, C. Rivoire, 
B. Roechert, T. Sawford, M. Schneider, A. Shypitsyna, A. Stutz, S. Sundaram, M. Tognolli, C. 
Wu, I. Xenarios, J. Chan, R. Kishore, P.W. Sternberg, K. Van Auken, H.M. Muller, J. Done, Y. 
Li, D. Howe, M. Westerfeld, Gene Ontology Consortium: going forward, Nucleic Acids Res. 43 
(2015) D1049–D1056. doi:10.1093/nar/gku1179. 
[243] M. Kanehisa, S. Goto, KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res. 
28 (2000) 27–30. doi:10.1093/nar/28.1.27. 
[244] A. Fabregat, K. Sidiropoulos, P. Garapati, M. Gillespie, K. Hausmann, R. Haw, B. Jassal, S. Jupe, 
F. Korninger, S. McKay, L. Matthews, B. May, M. Milacic, K. Rothfels, V. Shamovsky, M. 
Webber, J. Weiser, M. Williams, G. Wu, L. Stein, H. Hermjakob, P. D’Eustachio, The Reactome 
pathway Knowledgebase, Nucleic Acids Res. 44 (2016) D481–D487. doi:10.1093/nar/gkv1351. 
[245] G. Yu, L.-G. Wang, G.-R. Yan, Q.-Y. He, DOSE: an R/Bioconductor package for disease 
ontology semantic and enrichment analysis, Bioinformatics. 31 (2015) 608–609. 
doi:10.1093/bioinformatics/btu684. 
[246] J. Montojo, K. Zuberi, H. Rodriguez, G.D. Bader, Q. Morris, GeneMANIA: Fast gene network 
construction and function prediction for Cytoscape, F1000Research. 153 (2014) 1–7. 
doi:10.12688/f1000research.4572.1. 
[247] R. Saito, M.E. Smoot, K. Ono, J. Ruscheinski, P.-L. Wang, S. Lotia, A.R. Pico, G.D. Bader, T. 
Ideker, A travel guide to Cytoscape plugins, Nat. Methods. 9 (2012) 1069–1076. 
doi:10.1038/nmeth.2212. 
[248] A.R. Wu, N.F. Neff, T. Kalisky, P. Dalerba, B. Treutlein, M.E. Rothenberg, F.M. Mburu, G.L. 
Mantalas, S. Sim, M.F. Clarke, S.R. Quake, Quantitative assessment of single-cell RNA-
sequencing methods, Nat. Methods. 11 (2014) 41–46. doi:10.1038/nmeth.2694. 
[249] P.C. HEINRICH, I. BEHRMANN, S. HAAN, H.M. HERMANNS, G. MÜLLER-NEWEN, F. 
SCHAPER, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem. 
J. 374 (2003) 1–20. doi:10.1042/bj20030407. 
[250] G.W. Jones, L. McLeod, C.L. Kennedy, S. Bozinovski, M. Najdovska, B.J. Jenkins, Imbalanced 
gp130 signalling in ApoE-deficient mice protects against atherosclerosis, Atherosclerosis. 238 
(2015) 321–328. doi:10.1016/j.atherosclerosis.2014.12.037. 
[251] M. Klouche, S. Bhakdi, M. Hemmes, S. Rose-John, Novel path to activation of vascular smooth 
muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble 
137 
 
receptor., J. Immunol. 163 (1999) 4583–4589. 
[252] V.L. King, Atherosclerosis: should we stop TWEAKing it?, Arterioscler. Thromb. Vasc. Biol. 29 
(2009) 1982–1983. doi:10.1161/ATVBAHA.109.197228. 
[253] G. Straface, F. Biscetti, D. Pitocco, G. Bertoletti, M. Misuraca, C. Vincenzoni, F. Snider, V. 
Arena, E. Stigliano, F. Angelini, L. Iuliano, S. Boccia, C. De Waure, F. Giacchi, G. Ghirlanda, A. 
Flex, Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, 
TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability, Stroke. 42 (2011) 
3022–3028. doi:10.1161/STROKEAHA.111.619288. 
[254] J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. 
Appelbaum, C. Eichman, R. DiPrinzio, R.A. Dodds, I.E. James, M. Rosenberg, J.C. Lee, P.R. 
Young, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J. Biol. Chem. 273 (1998) 
14363–14367. doi:10.1074/jbc.273.23.14363. 
[255] L. O’Leary,  a M. van der Sloot, C.R. Reis, S. Deegan,  a E. Ryan, S.P.S. Dhami, L.S. Murillo, 
R.H. Cool, P.C. de Sampaio, K. Thompson, G. Murphy, W.J. Quax, L. Serrano, A. Samali, E. 
Szegezdi, Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal 
cells in controlling tumour TRAIL sensitivity, Oncogene. 35 (2016) 1261–1270. 
doi:10.1038/onc.2015.180. 
[256] E.P.C. van der Vorst, Y. Döring, C. Weber, Chemokines and their receptors in atherosclerosis, J. 
Mol. Med. 93 (2015) 963–971. doi:10.1007/s00109-015-1317-8. 
[257] Genecards - Human Genes. Gene Database. Gene Search., (1980). http://www.genecards.org/cgi-
bin/carddisp.pl?gene=TNFAIP1&keywords=TNFAIP1 (accessed July 28, 2017). 
[258] I.E. Wertz, K.M. O’Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, P. Wu, C. Wiesmann, R. 
Baker, D.L. Boone, A. Ma, E. V Koonin, V.M. Dixit, De-ubiquitination and ubiquitin ligase 
domains of A20 downregulate NF-kB signalling, Nature. 430 (2004) 694–699. 
doi:10.1038/nature02794. 
[259] M. Mellett, P. Atzei, A. Horgan, E. Hams, T. Floss, W. Wurst, P.G. Fallon, P.N. Moynagh, 
Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia, Nat. 
Commun. 3 (2012) 1119. doi:10.1038/ncomms2127. 
[260] C.C. Wei, Y.H. Hsu, H.H. Li, Y.C. Wang, M.Y. Hsieh, W.Y. Chen, C.H. Hsing, M.S. Chang, IL-
20: biological functions and clinical implications, J. Biomed. Sci. 13 (2006) 601–612. 
doi:10.1007/s11373-006-9087-5. 
[261] T. Tamiya, I. Kashiwagi, R. Takahashi, H. Yasukawa, A. Yoshimura, Suppressors of cytokine 
signaling (SOCS) proteins and JAK/STAT pathways: Regulation of T-cell inflammation by 
SOCS1 and SOCS3, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 980–985. 
doi:10.1161/ATVBAHA.110.207464. 
[262] O.J. de Boer, J.J. van der Meer, P. Teeling, C.M. van der Loos, M.M. Idu, F. Van Maldegem, J. 
Aten, A.C. van der Wal, Differential expression of interleukin-17 family cytokines in intact and 
138 
 
complicated human atherosclerotic plaques, J. Pathol. 220 (2010) 499–508. 
doi:10.1002/path.2667. 
[263] B. Carow, M.E. Rottenberg, SOCS3, a major regulator of infection and inflammation, Front. 
Immunol. 5 (2014) 1–13. doi:10.3389/fimmu.2014.00058. 
[264] H. Taki, T. Sakai, E. Sugiyama, T. Mino, A. Kuroda, K. Taki, T. Hamazaki, H. Koizumi, M. 
Kobayashi, Monokine stimulation of interleukin-11 production by human vascular smooth muscle 
cells in vitro, Atheroscler. 144 (1999) 375–380. 
[265] J.C. Kovacic, R. Gupta, A.C. Lee, M. Ma, F. Fang, C.N. Tolbert, A.D. Walts, L.E. Beltran, H. 
San, G. Chen, C.S. Hilaire, M. Boehm, Stat3-dependent acute Rantes production in vascular 
smooth muscle cells modulates inflammation following arterial injury in mice, J. Clin. Invest. 120 
(2010) 303–314. doi:10.1172/JCI40364. 
[266] N.R. Veillard, B. Kwak, G. Pelli, F. Mulhaupt, R.W. James, A.E.I. Proudfoot, F. Mach, 
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice, Circ. Res. 
94 (2004) 253–261. doi:10.1161/01.RES.0000109793.17591.4E. 
[267] J.R. Goldsmith, Y.H. Chen, Regulation of inflammation and tumorigenesis by the TIPE family of 
phospholipid transfer proteins, Cell. Mol. Immunol. 14 (2017) 482–487. doi:10.1038/cmi.2017.4. 
[268] G.C.T. Pipes, E.E. Creemers, E.N. Olson, The myocardin family of transcriptional coactivators: 
versatile regulators of cell growth, migration, and myogenesis., Genes Dev. 20 (2006) 1545–56. 
doi:10.1101/gad.1428006. 
[269] R. Ross, J.A. Glomset, Atherosclerosis and the arterial smooth muscle cell: Proliferation of 
smooth muscle is a key event in the genesis of the lesions of atherosclerosis, Science (80-. ). 180 
(1973) 1332–1339. doi:10.1172/JCI200215686.9. 
[270] Y. Liu, S. Sinha, O.G. McDonald, Y. Shang, M.H. Hoofnagle, G.K. Owens, Kruppel-like Factor 
4 Abrogates Myocardin-induced Activation of Smooth Muscle Gene Expression, J. Biol. Chem. 
280 (2005) 9719–9727. doi:10.1074/jbc.M412862200. 
[271] E.K. Arkenbout, R.J. Dekker, C.J.M. de Vries, A.J.G. Horrevoets, H. Pannekoek, Focusing on 
transcription factor families in atherogenesis: the function of LKLF and TR3., Thromb. Haemost. 
89 (2003) 522–529. doi:10.1055/s-0037-1613383. 
[272] B. Zheng, M. Han, J.-K. Wen, Role of Krüppel-like factor 4 in phenotypic switching and 
proliferation of vascular smooth muscle cells, IUBMB Life. 62 (2010) 132–139. 
doi:10.1002/iub.298. 
[273] H. Iwata, I. Manabe, K. Fujiu, T. Yamamoto, N. Takeda, K. Eguchi, A. Furuya, M. Kuro-o, M. 
Sata, R. Nagai, Bone marrow-derived cells contribute to vascular inflammation but do not 
differentiate into smooth muscle cell lineages, Circulation. 122 (2010) 2048–2057. 
doi:10.1161/CIRCULATIONAHA.110.965202. 
[274] Y. Liu, B. Deng, Y. Zhao, S. Xie, R. Nie, Differentiated markers in undifferentiated cells: 
139 
 
Expression of smooth muscle contractile proteins in multipotent bone marrow mesenchymal stem 
cells, Dev. Growth Differ. 55 (2013) 591–605. doi:10.1111/dgd.12052. 
[275] N.F. Worth, B.E. Rolfe, J. Song, G.R. Campbell, Vascular smooth muscle cell phenotypic 
modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins, 
Cell Motil. Cytoskeleton. 49 (2001) 130–145. doi:10.1002/cm.1027. 
[276] J. Song, B.E. Rolfe, J.H. Campbell, G.R. Campbell, Changes in three-dimensional architecture of 
microfilaments in cultured vascular smooth muscle cells during phenotypic modulation, Tissue 
Cell. 30 (1998) 324–333. doi:10.1016/S0040-8166(98)80045-1. 
[277] J. Saltis, A.C. Thomasb, A. Agrotis, J.H. Campbellb, G.R. Campbellb, A. Bobik, Expression of 
growth factor receptors on arterial smooth muscle cells . Dependency on cell phenotype and 
serum factors, Methods. 118 (1995) 77–87. 
[278] S. Allahverdian, A.C. Chehroudi, B.M. McManus, T. Abraham, G.A. Francis, Contribution of 
intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human 
atherosclerosis, Circulation. 129 (2014) 1551–1559. 
doi:10.1161/CIRCULATIONAHA.113.005015. 
[279] J.K. Salabei, B.G. Hill, Autophagic regulation of smooth muscle cell biology, Redox Biol. 
(2015). doi:10.1016/j.redox.2014.12.007. 
[280] B. Swaminathan, H. Goikuria, R. Vega, A. Rodríguez-Antigüedad, A. López Medina, M. Del 
Mar Freijo, K. Vandenbroeck, I. Alloza, Autophagic marker MAP1LC3B expression levels are 
associated with carotid atherosclerosis symptomatology, PLoS One. 9 (2014). 
doi:10.1371/journal.pone.0115176. 
[281] Y. Vengrenyuk, H. Nishi, X. Long, M. Ouimet, N. Savji, F.O. Martinez, C.P. Cassella, K.J. 
Moore, S.A. Ramsey, J.M. Miano, E.A. Fisher, Cholesterol Loading Reprograms the MicroRNA-
143/145–Myocardin Axis to Convert Aortic Smooth Muscle Cells to a Dysfunctional 
Macrophage-Like Phenotype, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 535–546. 
doi:10.1161/ATVBAHA.114.304029. 
[282] M.W. Huff, J.G. Pickering, Can a vascular smooth muscle-derived foam-cell really change its 
spots?, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 492–495. 
doi:10.1161/ATVBAHA.115.305225. 
[283] S. Shukla, X. Zhang, Y.S. Niknafs, L. Xiao, R. Mehra, M. Cieślik, A. Ross, E. Schaeffer, B. 
Malik, S. Guo, S.M. Freier, H.-H. Bui, J. Siddiqui, X. Jing, X. Cao, S.M. Dhanasekaran, F.Y. 
Feng, A.M. Chinnaiyan, R. Malik, Identification and Validation of PCAT14 as Prognostic 
Biomarker in Prostate Cancer, Neoplasia. 18 (2016) 489–499. doi:10.1016/j.neo.2016.07.001. 
[284] R. Miao, H. Luo, H. Zhou, G. Li, D. Bu, X. Yang, X. Zhao, H. Zhang, S. Liu, Y. Zhong, Z. Zou, 
Y. Zhao, K. Yu, L. He, X. Sang, S. Zhong, J. Huang, Y. Wu, R.A. Miksad, S.C. Robson, C. Jiang, 
Y. Zhao, H. Zhao, Identification of prognostic biomarkers in hepatitis B virus-related 
hepatocellular carcinoma and stratification by integrative multi-omics analysis, J. Hepatol. 61 
140 
 
(2014) 840–849. doi:10.1016/j.jhep.2014.05.025. 
[285] S. Goodwin, J.D. McPherson, W.R. McCombie, Coming of age: ten years of next-generation 
sequencing technologies, Nat. Rev. Genet. 17 (2016) 333–351. doi:10.1038/nrg.2016.49. 
[286] G.C. Jickling, F.R. Sharp, Biomarker Panels in Ischemic Stroke, Stroke. 46 (2015) 915–920. 
doi:10.1161/STROKEAHA.114.005604. 
[287] K. Miyazono, K. Kusanagi, H. Inoue, Divergence and convergence of TGF-beta/BMP signaling., 
J. Cell. Physiol. 187 (2001) 265–276. doi:10.1002/jcp.1080. 
[288] S. Tsukamoto, T. Mizuta, M. Fujimoto, S. Ohte, K. Osawa, A. Miyamoto, K. Yoneyama, E. 
Murata, A. Machiya, E. Jimi, S. Kokabu, T. Katagiri, Smad9 is a new type of transcriptional 
regulator in bone morphogenetic protein signaling, Sci. Rep. 4 (2014) 7596. 
doi:10.1038/srep07596. 
[289] T. Katagiri, M. Imada, T. Yanai, T. Suda, N. Takahashi, R. Kamijo, Identification of a BMP-
responsive element in Id1, the gene for inhibition of myogenesis, Genes to Cells. 7 (2002) 949–
960. doi:10.1046/j.1365-2443.2002.00573.x. 
[290] N.W. Morrell, D.B. Bloch, P. ten Dijke, M.-J.T.H. Goumans, A. Hata, J. Smith, P.B. Yu, K.D. 
Bloch, Targeting BMP signalling in cardiovascular disease and anaemia, Nat. Rev. Cardiol. 13 
(2016) 106–120. doi:10.1038/nrcardio.2015.156. 
[291] A.Y. Simões Sato, G.L. Bub, A.H. Campos, BMP-2 and -4 produced by vascular smooth muscle 
cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation, 
Atherosclerosis. 235 (2014) 45–55. doi:10.1016/j.atherosclerosis.2014.03.030. 
[292] M. Zhang, J. Sara, F. Wang, L.-P. Liu, L.-X. Su, J. Zhe, X. Wu, J. Liu, Increased plasma BMP-2 
levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic 
patients, Cardiovasc. Diabetol. 14 (2015) 64. doi:10.1186/s12933-015-0214-3. 
[293] Y. YAO, A. ZEBBOUDJ, A. TORRES, E. SHAO, K. BOSTROM, Activin-like kinase receptor 1 
(ALK1) in atherosclerotic lesions and vascular mesenchymal cells, Cardiovasc. Res. 74 (2007) 
279–289. doi:10.1016/j.cardiores.2006.09.014. 
[294] A. Weiss, L. Attisano, The TGFbeta Superfamily Signaling Pathway, Wiley Interdiscip. Rev. 
Dev. Biol. 2 (2013) 47–63. doi:10.1002/wdev.86. 
[295] R.N. Wang, J. Green, Z. Wang, Y. Deng, M. Qiao, M. Peabody, Q. Zhang, J. Ye, Z. Yan, S. 
Denduluri, O. Idowu, M. Li, C. Shen, A. Hu, R.C. Haydon, R. Kang, J. Mok, M.J. Lee, H.L. Luu, 
L.L. Shi, Bone Morphogenetic Protein (BMP) signaling in development and human diseases, 
Genes Dis. 1 (2014) 87–105. doi:10.1016/j.gendis.2014.07.005. 
[296] J. Yang, X. Li, Y. Li, M. Southwood, L. Ye, L. Long, R.S. Al-Lamki, N.W. Morrell, Id proteins 
are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle 




[297] J. Yang, X. Li, N.W. Morrell, Id proteins in the vasculature: from molecular biology to 
cardiopulmonary medicine, Cardiovasc. Res. 104 (2014) 388–398. doi:10.1093/cvr/cvu215. 
[298] K. Miyazono, K. Miyazawa, Id: A Target of BMP Signaling, Sci. Signal. 2002 (2002) pe40-pe40. 
doi:10.1126/stke.2002.151.pe40. 
[299] K. Nishiyama, Id1 Gene Transfer Confers Angiogenic Property on Fully Differentiated 
Endothelial Cells and Contributes to Therapeutic Angiogenesis, Circulation. 112 (2005) 2840–
2850. doi:10.1161/CIRCULATIONAHA.104.516898. 
[300] F. Kyei, D.-B. Asante, J. Edekor, E. Sarpong, E. Gavor, D. Konja, Down-regulation of Id1 and 
Id3 genes affects growth and survival of Human Umbilical Vein Endothelial Cells (HUVECs), J. 
Appl. Biol. Biotechnol. 4 (2016) 023–029. doi:10.7324/JABB.2016.40204. 
[301] I. Gorenne, M. Kavurma, S. Scott, M. Bennett, Vascular smooth muscle cell senescence in 
atherosclerosis., Cardiovasc. Res. 72 (2006) 9–17. doi:10.1016/j.cardiores.2006.06.004. 
[302] Y. Jen, K. Manova, R. Benezra, Expression patterns of Id1, Id2, and Id3 are highly related but 
distinct from that of Id4 during mouse embryogenesis, Dev. Dyn. 207 (1996) 235–252. 
doi:10.1002/(SICI)1097-0177(199611)207:3<235::AID-AJA1>3.0.CO;2-I. 
[303] P.J. Andres-Barquin, M.-C. Hernandez, M. a Israel, Id4 Expression Induces Apoptosis in 
Astrocytic Cultures and Is Down-regulated by Activation of the cAMP-Dependent Signal 
Transduction Pathway, Exp. Cell Res. 247 (1999) 347–355. doi:10.1006/excr.1998.4360. 
[304] R. Bouchareb, N. Côté, Marie-Chloé-Boulanger, K. Le Quang, D. El Husseini, J. Asselin, F. 
Hadji, D. Lachance, E.E. Shayhidin, A. Mahmut, P. Pibarot, Y. Bossé, Y. Messaddeq, D. 
Boudreau, A. Marette, P. Mathieu, Carbonic anhydrase XII in valve interstitial cells promotes the 
regression of calcific aortic valve stenosis, J. Mol. Cell. Cardiol. 82 (2015) 104–15. 
doi:10.1016/j.yjmcc.2015.03.002. 
[305] L.F. de Castro, D. Lozano, S. Portal-Núñez, M. Maycas, M. De la Fuente, J.R. Caeiro, P. Esbrit, 
Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP 
(107-139) to ovariectomized mice, J. Cell. Physiol. 227 (2012) 1752–1760. 
doi:10.1002/jcp.22902. 
[306] P. Hu, B.Y. Huang, X. Xia, Q. Xuan, B. Hu, Y.H. Qin, Therapeutic effect of CNP on renal 
osteodystrophy by antagonizing the FGF-23/MAPK pathway, J. Recept. Signal Transduct. 36 
(2016) 213–219. doi:10.3109/10799893.2015.1075041. 
[307] J.-M. Zhang, J. An, Cytokines, inflammation and pain, Int Anesth. Clin. 45 (2007) 27–37. 
doi:10.1097/AIA.0b013e318034194e. 
[308] J.-I. Koga, M. Aikawa, Crosstalk between macrophages and smooth muscle cells in 
atherosclerotic vascular diseases, Vascul. Pharmacol. 57 (2012) 24–28. 
doi:10.1016/j.vph.2012.02.011. 
[309] S.A. Jones, Directing transition from innate to acquired immunity: defining a role for IL-6, J. 
142 
 
Immunol. 175 (2005) 3463–3468. doi:10.4049/jimmunol.175.6.3463. 
[310] T. Kishimoto, IL-6: from its discovery to clinical applications, Int. Immunol. 22 (2010) 347–352. 
doi:10.1093/intimm/dxq030. 
[311] D.G. Hildebrand, E. Alexander, S. Horber, S. Lehle, K. Obermayer, N.-A. Munck, O. Rothfuss, 
J.-S. Frick, M. Morimatsu, I. Schmitz, J. Roth, J.M. Ehrchen, F. Essmann, K. Schulze-Osthoff, 
IκBζ is a transcriptional key regulator of CCL2/MCP-1, J. Immunol. 190 (2013) 4812–4820. 
doi:10.4049/jimmunol.1300089. 
[312] S. Watanabe, W. Mu, A. Kahn, N. Jing, J.H. Li, H.Y. Lan, T. Nakagawa, R. Ohashi, R.J. 
Johnson, Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells, 
Am. J. Nephrol. 24 (2004) 387–392. doi:10.1159/000079706. 
[313] S. Akhtar, F. Gremse, F. Kiessling, C. Weber, A. Schober, CXCL12 promotes the stabilization of 
atherosclerotic lesions mediated by smooth muscle progenitor cells in apoe-deficient mice, 
Arterioscler. Thromb. Vasc. Biol. 33 (2013) 679–686. doi:10.1161/ATVBAHA.112.301162. 
[314] F. Guo, Y. Wang, J. Liu, S. Mok, F. Xue, W. Zhang, CXCL12/CXCR4: a symbiotic bridge 
linking cancer cells and their stromal neighbors in oncogenic communication networks, 
Oncogene. 35 (2015) 816–826. doi:10.1038/onc.2015.139. 
[315] S. Abi-Younes, A. Sauty, F. Mach, G.K. Sukhova, P. Libby, A.D. Luster, The stromal cell-
derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic 
plaques, Circ. Res. 86 (2000) 131–138. doi:10.1161/01.RES.86.2.131. 
[316] C. Weber, Platelets and Chemokines in Atherosclerosis: Partners in Crime, Circ. Res. 96 (2005) 
612–616. doi:10.1161/01.RES.0000160077.17427.57. 
[317] K. Yokota, K. Sato, T. Miyazaki, H. Kitaura, H. Kayama, F. Miyoshi, Y. Araki, Y. Akiyama, K. 
Takeda, T. Mimura, Combination of tumor necrosis factor α and interleukin-6 induces mouse 
osteoclast-like cells with bone resorption activity both in vitro and in vivo, Arthritis Rheumatol. 
66 (2014) 121–129. doi:10.1002/art.38218. 
[318] N.P.E. Kadoglou, T. Gerasimidis, S. Golemati, A. Kapelouzou, P.E. Karayannacos, C.D. Liapis, 
The relationship between serum levels of vascular calcification inhibitors and carotid plaque 
vulnerability, J. Vasc. Surg. 47 (2008) 55–62. doi:http://dx.doi.org/10.1016/j.jvs.2007.09.058. 
[319] S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, 
W. Poewe, J. Willeit, Osteoprotegerin is a risk factor for progressive atherosclerosis and 
cardiovascular disease, Circulation. 109 (2004) 2175–2180. 
doi:10.1161/01.CIR.0000127957.43874.BB. 
[320] Y. Feng, A.J. Sanders, F. Ruge, C.A. Morris, K.G. Harding, W.G. Jiang, Expression of the SOCS 
family in human chronic wound tissues: Potential implications for SOCS in chronic wound 
healing, Int. J. Mol. Med. 38 (2016) 1349–1358. doi:10.3892/ijmm.2016.2733. 
[321] Y. Tian, L.J. Sommerville, A. Cuneo, S.E. Kelemen, M. V Autieri, Expression and suppressive 
143 
 
effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of 
intimal hyperplasia, Am. J. Pathol. 173 (2008) 901–909. doi:10.2353/ajpath.2008.080163. 
[322] M.C. Trengove, A.C. Ward, SOCS proteins in development and disease, Am. J. Clin. Exp. 
Immunol. 2 (2013) 1–29. 
[323] M. Fujimoto, T. Naka, Regulation of cytokine signaling by SOCS family molecules, Trends 
Immunol. 24 (2003) 659–666. doi:10.1016/j.it.2003.10.008. 
[324] J.J. Babon, L.N. Varghese, N.A. Nicola, Inhibition of IL-6 family cytokines by SOCS3, Semin. 
Immunol. 26 (2014) 13–19. doi:10.1016/j.smim.2013.12.004. 
[325] F. Seif, M. Khoshmirsafa, H. Aazami, M. Mohsenzadegan, G. Sedighi, M. Bahar, The role of 
JAK-STAT signaling pathway and its regulators in the fate of T helper cells, Cell Commun. 
Signal. 15 (2017) 23. doi:10.1186/s12964-017-0177-y. 
[326] S. Taleb, A. Tedgui, Z. Mallat, IL-17 and Th17 cells in atherosclerosis: Subtle and contextual 
roles, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 258–264. 
doi:10.1161/ATVBAHA.114.303567. 
[327] F. Ilhan, S.T. Kalkanli, Atherosclerosis and the role of immune cells, World J. Clin. Cases. 3 
(2015) 345–352. doi:10.12998/wjcc.v3.i4.345. 
[328] Y. Fuchs, M. Brunwasser, S. Haif, J. Haddad, B. Shneyer, O. Goldshmidt-Tran, L. Korsensky, M. 
Abed, S. Zisman-Rozen, L. Koren, Y. Carmi, R. Apte, R.B. Yang, A. Orian, J. Bejar, D. Ron, Sef 
is an inhibitor of proinflammatory cytokine signaling, acting by cytoplasmic sequestration of NF-
κB, Dev. Cell. 23 (2012) 611–623. doi:10.1016/j.devcel.2012.07.013. 
[329] M. Mellett, P. Atzei, R. Bergin, A. Horgan, T. Floss, W. Wurst, J.J. Callanan, P.N. Moynagh, 
Orphan receptor IL-17RD regulates Toll-like receptor signalling via SEFIR/TIR interactions, Nat. 
Commun. 6 (2015) 6669. doi:10.1038/ncomms7669. 
[330] Y. Hsu, W. Chen, C. Chan, C. Wu, Z. Sun, M. Chang, Anti – IL-20 monoclonal antibody inhibits 
the differentiation of osteoclasts and protects against osteoporotic bone loss, J. Exp. Med. 208 
(2011) 1849–1861. doi:10.1084/jem.20102234. 
[331] N.J. Logsdon, A. Deshpande, B.D. Harris, K.R. Rajashankar, M.R. Walter, Structural basis for 
receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines, Proc. 
Natl. Acad. Sci. 109 (2012) 12704–12709. doi:10.1073/pnas.1117551109. 
[332] A. Sahoo, S.-H. Im, Molecular mechanisms governing IL-24 gene expression, Immune Netw. 12 
(2012) 1–7. doi:10.4110/in.2012.12.1.1. 
[333] C. Wahl, W. Müller, F. Leithäuser, G. Adler, F. Oswald, J. Reimann, R. Schirmbeck, A. Seier, 
J.M. Weiss, B. Prochnow, U.M. Wegenka, IL-20 receptor 2 signaling down-regulates antigen-
specific T cell responses, J. Immunol. 182 (2009) 802–810. doi:10.4049/jimmunol.182.2.802. 
[334] K.-M. Lee, H.-A. Kang, M. Park, H.-Y. Lee, M.-J. Song, K. Ko, J.-W. Oh, H.-S. Kang, 
Interleukin-24 suppresses the growth of vascular smooth muscle cells by inhibiting H(2)O(2)-
144 
 
induced reactive oxygen species production, Pharmacology. 90 (2012) 332–41. 
doi:10.1159/000343242. 
[335] K. Gabunia, A.B. Herman, M. Ray, S.E. Kelemen, R.N. England, R.D. La Cadena, W.J. Foster, 
K.J. Elliott, S. Eguchi, M. V. Autieri, Induction of MiR133a expression by IL-19 targets 
LDLRAP1 and reduces oxLDL uptake in VSMC, J. Mol. Cell. Cardiol. 105 (2017) 38–48. 
doi:10.1016/j.yjmcc.2017.02.005. 
[336] A.A. Cuneo, D. Herrick, M. V. Autieri, Il-19 reduces VSMC activation by regulation of mRNA 
regulatory factor HuR and reduction of mRNA stability, J. Mol. Cell. Cardiol. 49 (2010) 647–
654. doi:10.1016/j.yjmcc.2010.04.016. 
[337] R. Maier, V. Ganu, M. Lotz, Interleukin-11, an inducible cytokine in human articular 
chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of 
metalloproteinases, J. Biol. Chem. 268 (1993) 21527–21532. 
[338] M. Abdelnaseer, N. Elfayomi, E.H. Esmail, M.M. Kamal, A. Hamdy, R.M.A. Samie, E. Elsawy, 
Relationship between matrix metalloproteinase-9 and common carotid artery intima media 
thickness, Neurol. Sci. 37 (2016) 117–122. doi:10.1007/s10072-015-2358-z. 
[339] Y. Takeuchi, S. Watanabe, G. Ishii, S. Takeda, K. Nakayama, S. Fukumoto, Y. Kaneta, D. Inoue, 
T. Matsumoto, K. Harigaya, T. Fujita, Interleukin-11 as a stimulatory factor for bone formation 
prevents bone loss with advancing age in mice, J. Biol. Chem. 277 (2002) 49011–49018. 
doi:10.1074/jbc.M207804200. 
[340] K. Lian, C. Ma, C. Hao, Y. Li, N. Zhang, Y.H. Chen, S. Liu, TIPE3 protein promotes breast 
cancer metastasis through activating AKT and NF-κB signaling pathways, Oncotarget. 8 (2017) 
48889–48904. doi:10.18632/oncotarget.16522. 
[341] A.O. Kraaijeveld, S.C.A. de Jager, T.J.C. van Berkel, E.A.L. Biessen, J.W. Jukema, Chemokines 
and atherosclerotic plaque progression: towards therapeutic targeting?, Curr. Pharm. Des. 13 
(2007) 1039–52. doi:10.2174/138161207780487584. 
[342] E. Galkina, K. Ley, Immune and inflammatory mechanisms of atherosclerosis, Annu. Rev. 
Immunol. 27 (2009) 165–197. doi:10.1146/annurev.immunol.021908.132620. 
[343] A. Schober, Chemokines in vascular dysfunction and remodeling, Arterioscler. Thromb. Vasc. 
Biol. 28 (2008) 1950–1959. doi:10.1161/ATVBAHA.107.161224. 
[344] T.J. Schall, K. Bacon, K.J. Toy, D. V Goeddel, Selective attraction of monocytes and T 
lymphocytes of the memory phenotype by cytokine RANTES, Nature. 347 (1990) 669–671. 
doi:10.1038/347669a0. 
[345] A.O. Kraaijeveld, S.C.A. De Jager, W.J. De Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. 
Putter, T.J.C. Van Berkel, L. Nagelkerken, J.W. Jukema, E.A.L. Biessen, CC chemokine ligand-5 
(CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of 
refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms, 
Circulation. 116 (2007) 1931–1941. doi:10.1161/CIRCULATIONAHA.107.706986. 
145 
[346] R.R. Koenen, C. Weber, Therapeutic targeting of chemokine interactions in atherosclerosis, Nat. 
Rev. Drug Discov. 9 (2010) 141–153. doi:10.1038/nrd3048. 
[347] X. Yu, Y. Huang, P. Collin-Osdoby, P. Osdoby, CCR1 chemokines promote the chemotactic 
recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory 
cytokines in osteoblasts, J Bone Min. Res. 19 (2004) 2065–2077. doi:10.1359/JBMR.040910. 
[348] B. Peruzzi, A. Teti, The physiology and pathophysiology of the osteoclast, Clin. Rev. Bone 
Miner. Metab. 10 (2012) 71–97. doi:10.1007/s12018-011-9086-6. 
[349] F.J. Mendoza, I. Lopez, A.M. De Oca, J. Perez, M. Rodriguez, E. Aguilera-Tejero, Metabolic 
acidosis inhibits soft tissue calcification in uremic rats, Kidney Int. 73 (2008) 407–414. 
doi:10.1038/sj.ki.5002646. 
